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ABSTRACT 
 
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, 
posing a serious demographic and economic burden worldwide. In the UK, CRC affects one in 
every twenty people and it is often detected once well-established and after it has spread beyond the 
bowel (Stage IIA-C and Stage IIIA-C). A diagnosis at such advanced stages is associated with poor 
treatment response and survival. However, studies have identified two sub-groups of post-treatment 
CRC patients – those with good outcome (reactive disease) and those with poor outcome (non-
reactive disease).  
Evidence indicates the presence of an effective immune response differentiates between those 
patients who respond well to treatment and those who do not. To investigate these underlying 
mechanisms we used the serological analysis of cDNA recombinant libraries (SEREX) technique to 
determine which antigens are recognised by patients in each group. Immunoscreening a healthy 
donor testes cDNA library with sera from three patients with Duke’s B reactive disease led to the 
identification of five antigens. These were (1) the immunoglobulin heavy constant gamma 3 (G3m 
marker), IGHG3 gene, located on chromosome 14 at 14q32.33, which encodes IgG3, and was 
recognised by sera from patients CC005 and CC014; (2) the immunoglobulin heavy constant 
gamma 2, IGHG2 gene, located on chromosome 14 at 14q32.33 and recognised by CC014 sera; 
while (3) CYB5R3, (4) RPL37A and (5) SLC34A2 were recognised by CC005, CC014 and CC014 
sera respectively. CYB5R3 is a NADH-cytochrome b5 reductase 3 protein which has been shown to 
be upregulated in lung tissue with a RAS mutation in mice.  Ribosomal protein L37a (RPL37A) has 
previously been shown to be upregulated in astrocytomas and to have a general association with 
lifetime glioblastoma survival and overall glioblastoma survival. Solute carrier family 34 member 2 
(SLC34A2) encodes a protein which acts as a pH-sensitive sodium-dependent phosphate 
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transporter. SLC34A2 has been shown to be upregulated in breast and ovarian cancers and it is 
suggested that SLC34A2 is involved in the process of carcinogenesis, making it an attractive target 
in therapeutic strategies and also as a diagnostic biomarker. Although other antigens were found, 
and their sequences identified, all were unknown and not found in the databases. 
RT-PCR analysis of the Duke’s B colon cancer cell line SW480 showed consistent expression of 
BCP-20. Although, expression of SSX2, NY-ESO-1, TSP50, HAGE and RAGE were detected, the 
data was not easily reproductible. Further optimisation of the PCR conditions and primer pairs 
would be necessary to confirm these findings.  
We hope in the future we can disern the role of these antigens in the inflammatory immune 
responses associated with reactive Dukes’ B colon cancer which would help us better understand 
the mechanisms which underlie effective anti-tumour responses post-surgery. It may also be that 
RPL37A is a biomarker for patient survival in colorectal cancer and this would be worthy of further 
investigation.  
IV 
 
DEDICATIONS 
 
 
In memory of my beloved grandmother who always believed in me and inspired me to 
pursue my dreams no matter how impossible they seemed. 
 
To Dr Barbara Guinn who is a true inspiration as a scientist, a role model and a friend. 
With a never-ending enthusiasm, positive energy and support she turned this research 
project into an unforgettable journey. Thank you for every moment. 
 
To my best friends and colleagues Emma and Kay who stood by me at all times. 
Thank you for always encouraging me to keep going when science and faith would 
fail.  
 
To Simon who reminded me that it is possible to have it all. 
 
To all my friends and colleagues from the University of Bedfordshire. Thank you for 
your support and friendship throughout my research degree. 
V 
 
QUOTE 
 
 
“Around here, however, we don’t look backwards for very long. We keep moving 
forward, opening up new doors and doing new things… and curiosity keeps 
leading us down new paths.”  
 
- Walt Disney
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CHAPTER 1   Introduction   
1.1 The Global Challenge 
‘You have cancer’ – the diagnosis that millions of people around the world hear every year and also 
the second leading cause of death worldwide. The number of new cancer cases each year is 
gradually increasing and the mortality rate is expected to rise from 7.6 million in 2008 to over 17 
million in 2030 (Ferlay et al, 2010, Bray et al, 2012). On average, one of every three people is 
expected to experience some type of cancer in the course of their lifetime and this frequency is 
expected to increase (Quaglia et al, 2005) as the population ages. The World Health Organization 
(WHO) reports that an increasing percentage of all newly diagnosed cancer cases annually occurs in 
low- and middle-income countries and this is attributed to a wide range of behavioural, genetic and 
environmental risk factors (Thun et al, 2010). Nevertheless, the increase in the average life 
expectancy and the adoption of an unhealthy lifestyle (such as smoking, physical inactivity and 
poor diet) worldwide have also contributed to the rise of a new trend in the cancer demography. 
Newly-diagnosed cancers from the low- and middle-income countries today account for more than 
51% of the total number and their share in the global burden is expected to continue to increase 
with the growth and aging of the population (Thun et al, 2010). In addition, the lack of resources for 
early cancer detection and effective treatments in the developing world contributes to an increase in 
cancer-related deaths.  
Today, some of the most commonly diagnosed cancers both in economically developing and 
developed countries include prostate, breast, lung and CRC - “the big four” - accounting for nearly 
50% of the total cases diagnosed (Jemal et al, 2010). Cancer is a global challenge, opposing a 
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serious demographic and economic burden with worldwide economic costs estimated to be as high 
as £572 billion per year. These alarming statistics resulted in the development of national strategies 
and action plans for cancer control including prevention, early detection and effective treatment 
(WHO Library Cataloguing-in-Publication data, 2008-2013). However, the demand for the 
development of new approaches to cancer screening and therapy is recognized globally and brings 
the research attention on these aims sharply into focus. 
 
1.2 Colorectal Cancer (CRC) 
CRC is one of the most commonly diagnosed cancers worldwide. It affects the bowel and the 
rectum and is rare in people under 40, with almost 85 per cent of cases being diagnosed in persons 
over 65 years of age (WHO Library Cataloguing-in-Publication data, 2008-2013). Statistics show 
that men and women are affected equally, while it is the third most common type of cancer in men 
(after prostate and lung cancer) and the second most common cancer in women (after breast cancer)
 
(WHO Library Cataloguing-in-Publication data, 2008-2013). One in every twenty people in the UK 
develops CRC with only half of them surviving beyond five years, mainly because it is often 
detected once well-established and after it has spread beyond the bowel. The disease stage at the 
time of diagnosis governs both the choice of treatment and the prognosis. CRC is staged to reflect 
how far the cancer has spread and whether or not it has reached nearby structures such as lymph 
nodes or distant organs. The most commonly used staging system for CRC is that of the American 
Joint Committee on Cancer (AJCC), also known as TNM system (Edge et al, 2010). It describes 
three key pieces of information: ‘T’ – how far has the primary Tumour grown; ‘N’ – the extent of 
spread to nearby lymph Nodes; and ‘M’ – describes whether the cancer has Metastasized. The 
15 
 
information from the T, N and M is combined to determine the cancer stage grouping from Stage I 
(the least advanced) to Stage IV (the most advanced). Two of the older staging systems include 
Duke’s (Dukes, 1932) and Astler-Coller (Astler & Coller, 1954) but these are very rarely used 
today. 
Stage I (A-C) (Duke’s A-C) CRC is reported to be an asymptomatic malignancy, developing slowly 
by the progressive accumulation of genetic mutations within precancerous bowel lesions and 
polyps. Diagnosis at this stage reduces the risk of death from CRC, giving 90% chance of survival 
beyond five years (Mayer, 2005; O’Connell et al, 2004) and significantly low levels of disease 
recurrence. However, most cases of CRC are detected once the cancerous cells have moved beyond 
the middle layers of the colon (Figure 1.1). This is classified as stage IIB (Duke’s B) and is one of 
the most commonly diagnosed forms of CRC. Currently, the course of treatment for CRC patients is 
fairly similar regardless of the significant differences in the biological features of each CRC case. 
Usually, the most effective approach is tumour resection, followed by chemo- or radiotherapy for 
stage III and sometimes for stage II CRC patients. However, recent studies suggest that not all stage 
III patients benefit from these therapies and that 25% of stage II cases are under treated (Marshall et 
al, 2007; Zaniboni et al, 2004). Furthermore, a number of non-aggressive tumours are frequently 
over-treated, leading to the patient experience of unnecessary and severe side effects. Methods such 
as, faecal occult blood test, sigmoidoscopy, colonoscopy, virtual colonoscopy and double contrast 
barium enema offer improvements in the detection rates of CRCs (Strul & Arber, 2007). However, 
their diagnostic value is limited with regards to costs, risks, lack of sensitivity especially in early 
stages and inconvenience to the patient (National Cancer Institute Factsheets). Therefore, the focus 
remains on developing efficient methods for the early detection of CRC such as the identification of 
early disease biomarkers which could be used in non-invasive (urine and blood serum) tests. Such 
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molecular biosensors for CRC would enable widespread screening alongside general health 
examinations and may further reduce the mortality rate associated with late stage detection of CRC 
(Kim et al, 2008).  
 
Figure 1.1 Diagrammatic representation of a malignant primary tumour that has moved beyond the 
middle layers of the colon. In this scenario the tumour cells have also metastasized to a nearby lymph node. 
This image indicates are stages of Duke’s IIB to stage IV.  
 
Murphy et al, 2000 suggested that there are two sub-groups of patients with Stage IIB CRC – those 
with good treatment outcome (reactive disease) and those with poor treatment outcomes (non-
reactive disease). Whether the difference between these two groups of patients can be determined 
by differences in humoral responses warrants further investigation and provides the basis of our 
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own current studies. Tumour biomarkers offer an opportunity to translate unique CRC biological 
features into diagnostically pertinent information and would enable personalized treatments which 
could inform conventional and immunotherapeutic interventions. This would enable discerning 
treatment strategies for aggressive and non-aggressive cancers and the clear “up front” distinction 
of reactive from non-reactive disease. 
In part, to address this need, researchers are investigating immune responses in cancer patients to 
identify new immunotherapy targets and biomarkers. They are hoping to identify and evaluate 
tumour-associated antigens (TAAs) and CTAs that could prove to be efficient diagnostic, 
prognostic or immunotherapeutic targets in CRC (Schlom et al, 2007). Recent developments in the 
fields of genomics and proteomics have greatly contributed to these studies, enabling the 
identification of multiple potential antigens within a single experiment (Wollscheid et al, 2004). 
Techniques, such as DNA microarray analysis, protein microarrays, peptide (pMHC) tetramers, 
SErological identification of antigens by Recombinant EXpression cloning (SEREX), SERological 
Proteome Analysis (SERPA) and peptide elution from MHC for mass spectrometry analysis are 
now commonly used to evaluate the expression profiles of genes and proteins as well as antigen 
recognition within different types, sub-types and stages of cancer. Their application in a number of 
studies conducted on myeloid leukemia (AML) (Guinn et al, 2005; Knights et al, 2006), diffuse 
large B-cell lymphoma (Liggins et al, 2004), lung cancer (Hanafusa et al, 2011) and osteosarcoma 
(Zou et al, 2012) have already proven successful and have led to the discovery of a large panel of 
antigens with prognostic and immunotherapeutic relevance. It has also provided an insight into the 
biological complexity and individuality of each cancer case, demonstrating considerable 
heterogenicity among patients and within tumour types. Therefore, genomics, proteomics or a 
combination of multiple methods could aid the discovery of novel biomarkers specific for CRC and 
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contribute to the development of personalized therapies which would maximize efficiency and 
minimize side effects for the patient.   
 
1.3 The Search for Tumour Antigens Specific for CRC  
The desire to identify TAAs has inspired and attracted researchers for more than four decades. Most 
efforts were driven by the aim to uncover specific epitopes on cancer cells which could elicit 
immune responses in the autologous host (Qiu & Hanash, 2009; Fratta et al, 2011). In the 1970s a 
method known as ‘autologous typing’ was used successfully to identify a number of antigens 
including alpha fetoprotein (in hepatoma and germ cell tumours), carcinoembryonic antigen (CEA) 
(in gastrointestinal cancers), prostate-specific antigen (in prostate cancer), CA125 (in ovarian 
cancer), and AU (in melanomas) (Old, 1981; Thomas & Sweep, 2001). This novel serological 
technique offered a substantial improvement over existing methods as it enabled the analysis of the 
cellular (T-cell defined) anti-tumour human immune responses in an autologous manner where only 
tumour-specific antigens could be recognized (Old, 1981). However, autologous typing did not 
completely fulfill the original hopes for its success due to several limitations. The major 
disadvantage arose from its reliance on cultured tumour cell lines and not all tumour types could be 
propagated ex vivo to allow autologous typing to be performed. Furthermore, only a small fraction 
of the total number of patients was found to have demonstrable levels of autologous antibody with 
specificity for cell surface antigens on their tumour (Qiu & Hanash, 2009; Fratta et al, 2011). In the 
cases when the technique was successful and a tumour antigen was identified, the low titer of 
antibodies that were often detected made any further biochemical or molecular characterization of 
the antigens almost impossible. However, the method of autologous typing contributed to the 
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identification of a number of human tumour antigens which were categorized into four classes: 
Differentiation antigens – e.g. gp-100; Mutational antigens – e.g. abnormal forms of p53; 
Retroviral antigens – Epstein Barr Virus (EBV) and Human Papilloma Virus (HPV); and CT 
antigens (Fratta et al, 2011).  
1.3.1 CT Antigens 
CTAs were classified as a type of TAAs with restricted expression in testis, placenta and various 
types of cancer (Fratta et al, 2011). In the field of cancer serology they were quickly identified as 
the ideal targets for tumour-specific immunotherapeutic approaches (Simpson et al, 2005; Lim et al, 
2012; Caballero et al, 2009; Scanlan et al, 2002; Cheng et al, 2011).  
The selective expression pattern of CTAs is considered to be a consequence of gene activation by 
DNA demethylation (De Smet et al, 1995; Ogawa et al, 2005) and histone post-translational 
modifications (Karpf, 2006) both occurring constitutively in the testis, but also in tumour cells 
(Ogawa et al, 2005). Some CTAs have been found to be expressed in healthy tissues such as liver, 
pancreas and spleen but at a significantly lower level (<1%) when compared to their expression in 
testis (Caballero & Chen, 2009). Around 70 families of CTAs have been identified to date and 
further classified as X-CTAs and non-X-CTAs depending on the chromosomal location to which 
the genes are mapped (Old, 2001). The genes for distinct X-CTAs have been previously reported to 
encode for different antigenic peptides that are presented with HLA class I or HLA class II allo-
specificities, eliciting both cell-mediated and humoral immune responses (Traversari, 1999). The 
blood-testis barrier and the lack of HLA class I expression on the surface of germ cells prevents the 
cells of the immune system from interacting with the CTAs expressed there (Medin, 2010). It has 
been suggested that as the B and T cells have not been previously challenged by CTAs the  immune 
20 
 
response should be able to recognize CTAs as non-self structures when expressed on cancer cells 
(Medin, 2010) circumventing the need to break tolerance. These findings suggest that CTAs can be 
viewed as promising molecular targets for the development of immunotherapeutic interventions for 
specific cancer types without the possibility of triggering autoimmune responses. The identification 
of CTAs specific for a particular type of cancer is a promising approach for the development of 
peptide or recombinant full-length protein anti-cancer vaccines and for antigen-specific adoptive T-
cell transfer as part of cancer therapy (Slingluff, 2011). In that respect, NY-ESO-1 (a CTA with 
strong immunogenicity still detectable at sera dilutions of 1 in 40,000 (Jager et al, 1998)) has been 
of interest in relation to the development of cancer vaccine trials. Several ongoing trials have been 
based on this antigen alone or its use in combination with an immune enhancer are currently 
ongoing (Roswell Park Cancer Institute, 2012; Cancer Research Institute, 2009). However, the 
expression of other CTAs within various types of cancer and at different disease stages appears to 
be heterogeneous and further investigation is required for the identification of effective 
immunotherapeutic targets.  
Although, CTA expression is generally correlated with tumour progression and immunogenicity in 
various types of cancer, little is known about this in relation to CRC. In addition, CTAs were often 
found to be poorly expressed (low level, heterogeneous expression) in CRC (Marits et al, 2009) 
highlighting the need for the identification of further immunogenic CTAs involved in CRC 
development. Such proteins would be candidates for cancer-specific therapy trials and may provide 
effective biomarkers for diagnosis, prognosis and monitoring of CRC disease progression. 
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1.3.2 SEREX 
The limited success of autologous typing demonstrated the need for a more comprehensive 
experimental approach for the identification of TAAs. It was not until the mid-1990s when a new 
autologous immunoscreening technique was shown to circumvent some of the limitations of 
autologous typing. This method was called SEREX (Sahin et al, 1995). It allowed the identification 
of numerous TAAs based on their recognition by antibodies in diluted pre-cleared autologous 
patient sera and in a small number of experiments. The advantages of SEREX were quickly 
recognized and a substantial pool of data encompassing serologically relevant antigens within 
cancer began to collect. SEREX was capable of identifying immunoglobulin G (IgG) antibody 
responses to both highly (NY-ESO-1) and weakly immunogenic TAAs (Chen et al, 1997; Old & 
Chen, 1998). Approximately one-third of these antigens were novel and referred to as SEREX-
defined antigens. In addition, sera was shown to be able to detect CD8
+
 T-cell recognized TAAs 
including NY-ESO-1 (Jager et al, 1998), MAGE-1 and tyrosinase (Jager et al, 1998; Sahin et al, 
1995; Tureci et al, 1997) as well as TAAs recognized by IgG antibodies which are also known to 
require CD4
+
 T-cell help (NY-ESO-1) (Sahin et al, 1995; Chen et al, 1997; Tureci et al, 1997; Zeng 
et al, 2001; Nakatsura et al, 2001; Nishikawa et al, 2001). These findings demonstrate that the 
cellular and humoral immune system work in concert and are both stimulated by TAAs in the case 
of cancer. Furthermore, several antigens (NY-ESO-1, MAGE-1 and hMena) (Modugno et al, 2004) 
that elicit humoral as well as cell mediated immune responses have also been successfully identified 
through SEREX. Studies have investigated CD8
+
 and CD4
+
 T-cell recognition of SEREX-defined 
antigens and the data showed that co-immunization with such proteins in combination with a 
cytotoxic T lymphocyte (CTL) epitope enhanced CD8
+
 induction in a CD4
+
 T cell–dependent 
manner (Nishikawa et al, 2005; Neumann et al, 2005). 
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The continuously increasing number of SEREX antigens led to the creation of a Cancer Immunome 
Database, a free repository for the antigens identified by this serological approach (Cancer 
Immunome Database). The success of SEREX lies in its reliance on the construction of a cDNA 
library from human tissues (cell lines, primary tumour or normal donor testes) and their expression 
in a prokaryotic system (Sahin et al, 1995). Immunoscreening with SEREX permits quick and 
effective extraction, processing, sequencing and subsequent molecular analysis of the protein of 
interest as both the TAA and its coding cDNA are present in the same plaque. However, the use of 
SEREX has several limitations. It has been previously reported that SEREX-defined antigens are 
predominantly nuclear proteins which are often transcription factors (Jager et al, 1998) and/or 
ubiquitously expressed (Cancer Immunome Database; Hartmann et al, 2005). As such, they rarely 
show evidence of mutations or other structural abnormalities and are often weakly immunogenic, 
incapable of eliciting and sustaining strong humoral immune responses (Qiu & Hanash, 2009). In 
addition phage can only express proteins in their primary structure which may cause the failure to 
detect antigenic sequences consequent to eukaryotic post-translational modifications (Mischo et al, 
2003). Regardless of the limitations, SEREX-defined antigens are already being investigated as 
diagnostic markers including Testis-Specific Protease (TSP50) in ovarian and CRCs (Shan et al, 
2002)) and as immunotherapeutic targets such as OVA66 in ovarian cancer (Jin et al, 2008), 
KIF20A in pancreatic cancer (Imai et al, 2011). 
1.3.3 SERPA 
SERPA is a powerful tool used for the identification and validation of immunogenic TAAs. Similar 
to SEREX, it uses the antibody repertoire contained within the sera of a cancer patient to 
successfully identify TAAs (Klein-Scory et al, 2012). In comparison to SEREX, SERPA does not 
require the use of a cDNA library, making this method less time consuming and less labour 
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intensive. Furthermore, SERPA is better suited for the detection of possible post translational 
modification and protein isoforms as it relies on the separation of complex mixtures of proteins 
extracted from cell cultures or tumours. The separation is performed via the use of a two 
dimensional gel electrophoresis (2-DE) (Forgber et al, 2009a). A number of TAAs have been 
identified to date using SERPA in various types of cancer including lymphoma (Forgber et al, 
2009b), renal cell carcinoma (Klade et al, 2001), ovarian cancer (Gagnon et al, 2008) and CRC (He 
et al, 2007). These studies have established the specificity of SERPA and its great potential in 
uncovering immunogenic TAAs and identifying tumour markers. However, similar to SEREX, 
most of the antigens identified by SERPA are predominantly weakly immunogenic intracellular 
proteins and very rarely membrane-associated ones (Suzuki et al, 2010; Chen, 2004). This and the 
finding that a number of antigens found by T cell cloning have also been found by SEREX suggests 
that most antigens induce B and T cell responses (Jager & Knuth, 2004), although not necessarily to 
the same epitope(s). In addition, SERPA has demonstrated a drawback associated with the use of 2-
DE: low abundance (such as regulatory and signal transduction proteins and receptors (Chevalier, 
2010)), hydrophobic or insoluble proteins (such as membrane proteins (Chevalier, 2010)) are 
inherently difficult to detect (Suzuki et al, 2010).   
SEREX and SERPA are two methodologies that seem complementary to each other as they identify 
two different sets of antigens (SEREX for the identification of antigens with altered expression; 
SERPA for the identification of antigenic proteins resulting from post-translational modifications). 
Therefore, the identification and validation of CRC-related CTAs using SERPA and SEREX 
independently or as a combined approach is worthy of further consideration. 
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1.3.4 RAYS 
RAYS is another serological strategy applied to the process of discovering immunogenic CTAs. 
RAYS permits the expression of immunogenic proteins on the surface of yeast allowing for a more 
natural folding of the protein and partial glycosylation (by virtue of it being a eukaryotic system) 
(Mischo et al, 2003). This permits the analysis of proteins in their natural conformation when 
compared to the prokaryotic expression utilized by SEREX. This method has demonstrated 
specificity and sensitivity for the detection of an antibody response to a conformation-dependent 
epitope - the colorectal cancer antigen A33. Therefore, the CTAs that have escaped detection due to 
the fact that they elicit immune responses only after undergoing the appropriate post-translational 
modifications could potentially be identified via RAYS. To date, RAYS has allowed the 
confirmation of antigen immunogenicity through screening of eukaryotic cDNA expression 
libraries derived from pancreatic cancer (Wadle et al, 2006) and prostate cancer (Jung et al, 2010). 
RAYS offers a less time-consuming analysis of the serological autoreactivity in cancer patients and 
it has provided an effective anticancer vaccine platform (recognizing NY-ESO-1) in prostate cancer 
patients (Jung et al, 2010). However, its further development is required to allow the detection of 
novel target antigens (such as is achieved with SEREX or SERPA) and its application in CRC 
requires further analysis.   
1.3.5 SADA 
To evaluate the seroreactivity of a number (or a panel) of SEREX-defined antigens in a particular 
type of cancer, a spot immunoassay, known as SADA, has been successfully developed and utilised 
(Scanlan et al, 2002). Although, several antigens have been evaluated in cases of colon cancer 
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(MAGEA3, SSX2, and NY-ESO-1 (Scanlan et al, 2002)), additional improvements in the 
sensitivity of SADA are still required. 
1.3.6 Protein microarrays  
Protein microarrays allow the rapid and easy detection of tumour antigens using patient sera 
(Stempfer et al, 2010; Gunawardana & Diamandis, 2007). Recent studies have demonstrated the 
efficiency of the technique in the rapid identification of immunogenic membrane-based TAAs with 
high reproducibility of the experimental analyses of lung and brain (Stempfer et al, 2010) and 
ovarian (Gunawardana & Diamandis, 2008) cancers. In this context, protein microarrays has a great 
advantage as this methodology allows the construction and simultaneous analysis of a large panel of 
candidate tumour biomarkers (approximately 9,000). However it should be noted that although 
protein microarrays have vast screening potential they are limited to defined proteins from a limited 
albeit not insubstantive pool.  
Understanding the molecular interactions between T cell receptors on cytotoxic T lymphocytes 
(CTL) and peptide/MHC class I complexes on tumour cells is an essential tool for the development 
of immunogenic vaccines (Tsukahara et al, 2008). Several such vaccines have already been 
designed based on TAA epitopes and have been implemented in phase I and II clinical trials for 
different types of cancer (HPV (Muderpach et al, 2000), WT1 (Oka et al, 2004), human telomerase 
reverse transcriptase (Bolonaki et al, 2007) and HLA-A24
+
HRPC (Noguchi et al, 2005) peptide 
vaccinations). The strength of vaccine-mediated immunological responses generally need to be 
enhanced and this will be much more feasible in patients in subsequent (Phase III) clinical trials 
who are likely to have less advanced disease. However the results obtained from clinical trials to 
date warrants further investigation. 
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1.4  Tumour profiling in patients with CRC 
A number of studies have been conducted over the last decade aiming to identify novel biomarkers 
that would prove to be efficient in CRC profiling as prognostic, predictive or therapeutic 
biomarkers. The recent improvements in proteomics and genomics methods have greatly aided this 
aim and have led to the identification of a number of CTAs and TAAs relevant to CRC. However, 
the clinical significance of only a small fraction of these potential markers in CRC has been 
evaluated to date: 
1.4.1 CTAs in CRC  
NY-ESO-1 has been recently studied in relation to CRC. It was demonstrated that some CTAs are 
capable of eliciting strong humoral and cell-mediated immune responses in some patients with CRC 
(Stockert et al, 1998). However, its expression in CRC is often highly heterogeneous, when present, 
which poses an obstacle in the development of a generalized immunotherapy. As discussed earlier 
in this review, NY-ESO-1 has also been targeted in several vaccine clinical trials worldwide 
involving CRC patients. Recently, a new Phase I trial of a fusion protein vaccine is being organized 
targeting solid tumours expressing NY-ESO-1 and this investigation includes Stage I – IV CRC 
(U.S. National Institute of Health, 2012). In addition, NY-ESO-1 expression was shown to correlate 
with CRC stages and local lymph node metastasis (Li et al, 2005) making it a potential prognostic 
biomarker for CRC. 
TSP50 was originally identified as abnormally expressed in breast cancer cells (Yuan et al, 1999) 
and has recently been studied for the first time in CRC patient samples. The expression of TSP50 
was found to correlate with the clinicopathological characteristics and disease-specific survival for 
CRC patients (Zheng et al, 2011). Furthermore, the study demonstrated that TSP50 expression is 
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highly specific for CRC as compared to colorectal adenomas and normal tissues, allowing the easy 
differentiation between them. TSP50 is an attractive predictive biomarker for poor survival in 
patients with early stages CRC (Stage I and II), but not in patients with advanced stage disease. As 
such, it is the only effective predictive biomarker reported to date for patients with early stage 
CRCs (Zheng et al, 2011).  
CABYR is a calcium-binding tyrosine phosphorylation-regulated fibrous sheath protein and its 
expression was first identified in human spermatozoa (Naaby-Hanen et al, 2002; reviewed in 
Chiriva-Internati et al, 2008). Subsequent detection of CABYR in lung carcinoma and its absence 
in healthy tissues, led it to be considered as a novel CTA, which has been shown to have some 
immunogenic properties that could serve as a basis for the development of immunotherapy for 
cancer patients (Luo et al, 2007). Additional studies on CABYR expression in brain (Hsu et al, 
2005), hepatocellular (Li et al, 2012) and other carcinomas (Tseng et al, 2011) have shown that 
there are at least five different isoforms of this protein which could play unique roles in the process 
of carcinogenesis. Following these discoveries a recent study has reported a frequent 
overexpression of CABYR a/b and c isoforms in CRC tumours when compared to adjacent normal 
tissues (Shantha Kumara et al, 2012). However, a more comprehensive investigation is required to 
determine whether CABYR expression correlates with tumour stages and is a suitable therapeutic 
vaccine candidate in CRC. 
SPAG9 is another antigen found to be exclusively expressed in testis (Jagadish et al, 2005) that is a 
particularly attractive target for immunotherapy in epithelial ovarian cancer (Garg et al, 2007), 
thyroid cancer (Garg et al, 2009) and in CML (Kanojia et al, 2010). A recent study has investigated 
the expression of SPAG9 in CRC patients aiming to explore its possible role in colon cancer 
tumorigenesis and its effectiveness in eliciting a humoral immune response (Kanojia et al, 2011). 
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Interestingly, the study has reported a close relationship between SPAG9 expression and early 
stages of CRC development suggesting that it could serve as an early diagnostic biomarker for CRC 
patients. The investigation had also demonstrated that SPAG9 could play a key role in the tumour 
development and could also serve as a target for the development of immunotherapeutic methods. 
Other CTAs, found to exhibit a strong correlation with CRC presentation are listed in Table 1.1. 
1.4.2 TAAs in CRC 
CD133 is a cell surface protein marker found on undifferentiated cancer cells that exhibit stem-like 
properties. These cells account for the propagation, growth and recurrence of AML (Lapidot et al, 
1994; Krivtsov et al, 2006) and CRC (Wang et al, 2012; Ricci-Vitiani et al, 2007) and for the 
resistance of these cancers to current therapies. The functional importance of CD133 expression has 
been investigated in several studies in relation to the initiation and behaviour of CRC (Ricci-Vitiani 
et al, 2007; Horst et al, 2009a; Choi et al, 2007). The CD133
+
 CRC stem cells are reported to have 
exhibited the ability to transfer cancer to a secondary recipient maintaining the same 
immunophenotype and the global gene expression profile of the primary tumour when compared to 
CD133
- 
cells (Ricci-Vitiani et al, 2007; Horst et al, 2009a). Furthermore, several studies have 
clearly identified the correlation between CD133 expression alone (Horst et al, 2009a; Choi et al, 
2007) or in combination with other protein markers (Horst et al, 2009a) with CRC patient survival 
and have revealed it to be a reliable prognostic marker. In combination with CD44 and CD166 (cell 
surface protein markers), CD133 expression has also been linked to the presentation of low-, 
intermediate-, or high-risk CRC cases with the ability to distinguish between them at an early stage 
of the disease (stage II) (Horst et al, 2009a; Horst et al, 2009b). CD133 is a promising predictive 
and prognostic marker in the diagnosis of CRC and particularly of interest as it is applicable to the 
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early stages of the disease. However, the presence of such cell surface markers on the CRC stem 
cells has not been investigated in relation to the underlying cause of the non-reactive type of CRC.  
 
Table 1.1 Antigens shown to be potential diagnostic, prognostic or immunotherapeutic targets in CRC. 
CTA/ 
panel of 
CTAs 
Chromosome 
location 
Method of 
identification 
First 
identified 
in: 
Potential uses in CRC 
BCP-20 
(FBXO39) 
17p13.1 SEREX 
CRC (Song 
et al, 2011). 
Candidate diagnostic and 
immunotherapeutic target 
(Song et al, 2011). 
PAGE4 
SCP-1 
SPANX 
Xp11.23 
1p13-p12 
Xq27.1 
Database mining 
SEREX 
Differential display 
CRC (Chen 
et al, 2010). 
Predictive panel for liver 
metastasis (Chen et al, 
2010). 
MAGE-A4 Xq28 
T cell epitope 
cloning 
Melanoma 
(De Plaen et 
al, 1999). 
Colon cancer vaccine 
therapy with peptide of 
MAGE-A4 (Takahashi et 
al, 2012). 
STK31 7p15.3 
Three-step 
Microarray 
Analysis 
CRC (Yokoe 
et al, 2008). 
Candidate target for 
immunotherapy (Yokoe et 
al, 2008). 
SSX 
 
MAGE 
Xp11.2 
 
Xq28 
Reverse 
transcription-PCR 
 
CRC (Choi 
et al, 2012). 
Co-expression as 
predictive marker for 
metastasis. 
Candidate targets for 
immunotherapy (Choi et 
al, 2012). 
SSX2 Xp11.22 SEREX 
Melanoma 
(Tureci et al, 
1996). 
Candidate target for 
immune therapy (Ayyoub 
et al, 2004; Smith et al, 
2010). 
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Carcinoembryonic antigen (CEA) is a TAA whose expression levels are often monitored pre- and 
post-treatment in CRC patients as they have been found to be indicative of cancer recurrence (Lin et 
al, 2011) and poor disease prognosis (Yeh et al, 2011; Kira et al, 2012). Patients with elevated post-
treatment CEA expression levels are often monitored more carefully for relapse of CRC and for 
local or distant recurrence (Lin et al, 2011; Kirat et al, 2012). To date, several studies have 
investigated the potential of CEA as an immunotherapeutic target in cases of CRC. Different 
research strategies have incorporated CEA peptides or CEA mRNAs in dendritic cell (DC) vaccines 
(Burgdorf, 2010; Lesterhuis et al, 2010) and in plasmid DNA vaccines (Staff et al, 2011) 
demonstrating that these vaccines are well-tolerated and have immune-stimulatory capacity in 
patients with CRC. However, the overall outcome of these studies indicated that additional vaccine 
modulation is necessary to attain significant clinical impact. More recently, a study to investigate 
whether the vaccination of toll-like receptor activated DCs can induce more potent CTL responses 
and antitumour activity in CEA transgenic mouse tumour models was published (Hong et al, 2012). 
It has demonstrated that the combined activation of TLRs can lead to better maturation status of 
DCs and can also induce more effective antitumour immune responses against CRC. However, 
additional investigation is necessary to evaluate the effectiveness of this approach in human models. 
1.4.3 Clinical significance of CTAs in CRC 
The CTAs that have already been identified within different types of cancer could serve as 
biomarkers for discerning aggressive and non-aggressive cancers and for predicting treatment 
outcome and relapse. Their expression patterns and clinical significance is still under investigation, 
but there are very promising early results. Some of their clinical applications are described in the 
followings sections, and could expand the list of potential CTAs in CRC.  
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1.5  Potential biomarkers for discerning reactive from non-reactive disease 
The expression profile of CTAs in relation to treatment outcome in particular types of solid cancers 
has been previously studied on several occasions (Zou et al, 2012; Modugno et al, 2004; Shan et al, 
2002; Jin et al, 2008; Imai et al, 2011) but further investigation is necessary to compare these 
findings to CRC cases. In this context, a recent study has demonstrated that γ-irradiation de novo 
up-regulates the expression of various CTAs and MHC-I in a randomized fashion. Therefore, 
irradiation could be accounted responsible for the increased immunological response to certain 
tumours, due to the inflammation and cell damage it causes. This would be anticipated to cause the 
immune system to attend the site of damage, mop up cellular debris and present proteins including 
CTAs to the immune system (Sharma et al, 2011). These findings fit with demonstrations in 
leukaemia that elevated tumour antigen expression at disease presentation is associated with 
improved survival (Guinn et al, 2009; Greiner et al, 2008). Identifying and evaluating such TAA 
and CTAs would be beneficial for profiling individual tumours and for combining radiotherapy (or 
other cancer therapy approach) with immunization to maximize the effect of treatment in CRC. 
However, in order to design a combined treatment a thorough understanding about the mechanisms 
of initiating CTAs expression and the likely order of their expression is necessary.  
The exact role of the numerous CTAs in relation to tumour response to various treatments still 
remains poorly defined. Particularly, in cases where adjuvant therapy is in order, it would be 
beneficial to have a panel of biomarkers to predict the likely success of the therapy. Several CTAs 
have been evaluated in gastrointestinal stromal tumour (GIST) – with regards to recurrence, while 
levels of MAGE-A1, MAGE-A3, MAGE-A4, MAGE-C1 and NY-ESO-1 expression were 
investigated in response to imatinib adjuvant therapy (Perez et al, 2011). This study demonstrated 
that CTA
+
 GISTs had a significantly shorter recurrence free survival compared to negative case. 
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Furthermore, the expression of NY-ESO-1 and MAGE-A3 was associated with elevated resistance 
to imatinib and therefore, with continuous tumour progression. Luetkens et al. have also showed 
that PRAME expression remains stable under imatinib treatment and correlates with decreased 
overall survival in patients with CML (Luetkens et al, 2010).  
Similar findings have been reported in several studies of prostate and lung cancer, multiple 
myeloma, AML, liposarcoma and others (Smith et al, 2011; Shiraishi et al, 2011; Boehmer et al, 
2011; Tajima et al, 2003; van Duin et al, 2011; Pollack et al, 2012).  These suggest an important 
role of CTAs in the pathophysiological behaviour of different tumours in response to treatments. 
Further investigation of panel of antigens associated with particular types of cancer and their 
relationship to either reactive or non-reactive disease is yet to be attempted. In this relation, TSP50 
is the only known CTA to have been characterized as a biomarker for disease prognosis in CRC 
(Zheng et al, 2011), but its association with treatment outcome is still to be analyzed. Furthermore, 
investigation of the interrelationships between groups of CTAs in CRC and their expression profiles 
could lead to significant discoveries about the underlying cause of a particular treatment response. 
This could benefit the design of a multivalent cancer vaccine targeting several antigens rather than 
just a single one. 
 
1.6  Potential biomarkers for survival prognosis 
Several studies have investigated the role of the CTAs as biomarkers of prognostic value regarding 
patient survival. Elevated levels of expression of particular CTAs have been shown to correlate with 
poor survival prognosis, particularly in solid tumours. In contrast to expectations some antigens 
have been shown to have above average levels and have better survival rates in patients with 
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haematological malignancies. For example, expression of SSX2IP in the presentation of AML has 
been shown to predict good survival in patients with no detectable cytogenetic rearrangements 
(Guinn et al, 2009). The elevated levels of antigens provide targets for improved immune responses 
in patients post-conventional (chemotherapy, radiotherapy) treatment, when there is cancer cell 
damage and inflammation (danger) signals stimulating an immune response to clear up dead and 
dying cells. Furthermore, the CTAs expressed on non-solid tumours (such as AML) are more 
accessible and “easier to see” by the immune system as they are not hidden within heterogeneous 
layers of cancer cells (as seen in solid tumours). 
The prognostic value of CTAs has also been evaluated in the presentation of osteosarcoma by gene 
microarray where the high expression of MAGE-A could predict distant metastasis and poor 
survival. For patients with and without MAGE-A expressing tumours, the five-year survival rates 
were found to be 39.6% and 80% respectively (Zou et al, 2012). Similarly, increased levels of WT1 
(another CTA) expression have been shown to correlate to poor prognosis and relapse in paediatric 
acute myeloid leukaemia after induction therapy (Lapillone et al, 2006). A number of products of 
translocations have been used in routine labs which detect minimal residual disease and can indicate 
impending relapse with high accuracy (John et al, 2002). The CTA expression in relation to patient 
survival in CRC cases has been the focus of few studies and further investigation is required to 
establish the clinical significance of this relationship (Zheng et al, 2011). 
 
1.7  Potential biomarkers for discerning aggressive from non-aggressive disease 
A recent study on prostate cancer has demonstrated that several CTAs are preferentially expressed 
in either aggressive or non-aggressive disease (Shiraishi et al, 2012). Such biomarkers could be 
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particularly useful in preventing the overdetection and overtreatment of potentially indolent CRC or 
the undertreatment of a more aggressive type of disease. 
 
1.8  Potential immunotherapeutic targets 
In 2005, cancer patients expressing NY-ESO-1 and LAGE-1 antigens entered a Phase I clinical trial 
on a plasmid DNA (pPJV7611) cancer vaccine (Gnjatic et al, 2009), demonstrating the 
effectiveness of CTAs as immunotherapeutic targets. Recently, the first clinical trial of cancer 
vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 
cancer antigen was initiated (Takahashi et al, 2012). A patient with pulmonary metastasis of CRC 
was vaccinated and had shown a significant reduction in the tumour growth.  
 
1.9  Non-reactive disease – overcoming the underlying issues 
CTAs are key molecules in the field of cancer serology. Their progressively expanding family is 
continuously providing potential novel targets for cancer immunotherapy or diagnostic/prognostic 
examinations. However, CTAs have also been evaluated for their role in oncogenesis, particularly 
their contribution to the immortality, invasiveness, immune evasion, hypomethylation and 
metastatic capacity of the neoplasms (Zhang et al, 2010). Investigating the correlation between 
CTAs and the clinical presentation of CRC (reactive or non-reactive type) requires knowledge of 
the molecular mechanisms that govern their expression and physiological functions - mechanisms 
that still remain poorly understood. According to recent studies, genome wide hypomethylation is 
accounted for the aberrant expression of CTAs within CRC cells (Mossman et al, 2010; Robins & 
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Rees, 2001; Glazer et al, 2009). However, the epigenetic factors that dictate which panel of silenced 
genes to be reactivated and the physiological properties of these particular CTAs are still unknown. 
This is an area of actively ongoing research as it is believed that these factors are responsible for the 
heterogenicity in the CTA expression profiles of the individual CRC cases. A better understanding 
of the structural and serological properties of these antigens, their modes of expression and 
functions, should establish whether they are the ones governing the reactive and non-reactive CRC 
phenotypes.  
CTAs in CRC have been associated with low immunogenicity under normal conditions, and only a 
few patients actually recognise the peptide epitopes and exhibit strong CTL or humoral immune 
response to CTAs. This could be partially accounted to the structural stability of the proteins, 
encoded by the CT genes. It has been previously demonstrated that proteins must be cleaved to 
small peptides by intracellular proteinases upon presentation to the immune system (Goldberg & 
Rock, 1992). However, high stability proteins (α-helical secondary protein conformation known to 
provide the most optimal structural stability (Robins & Rees, 2001)) are less likely to undergo 
denaturation and polypeptide chain unfolding. Therefore, CTAs containing large proportions of α-
secondary structure should be more resistant to protein unfolding and subsequent cleavage by the 
proteinases, thus resulting in an unsuccessful presentation to CTLs (low immunogenicity). For 
example, SCP-1 (a CTA of particularly low immunogenicity) has been shown to contain 76.6% α-
helical structure from its total secondary conformation when compared to the highly immunogenic 
NY-ESO-1 CTA, containing only 20.7% (Robins & Rees, 2001). The identification of such 
antigens that are predominantly expressed in non-reactive CRC patients could potentially be 
accounted for the therapy-resistant presentation of the disease. In such cases epigenetic modulation 
to induce expression of other CTAs may highly favour the immunotherapeutic approach to non-
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reactive CRC disease. In this respect, a study has recently reported a successful induction of NY-
ESO-1 expression in CRC cells (but not in normal nontransformed cells) both in vitro and in vivo 
subject to hypomethylating agent 5-aza-2’-deoxycytidine (DAC) treatment (Chou et al, 2012). The 
study reports that DAC-treated CRC cells are susceptible to major histocompatibility complex 
(MHC)-restricted recognition by CD8
+ 
NY-ESO-1-specific T cells. A NY-ESO-1157-165-specific T-
cell receptor was successfully used to generate both CD8
+
 and CD4
+
 NY-ESO-1157-165-specific T 
cells that selectively recognized DAC-treated CRC cells but not non-treated cells. These data reveal 
the great potential of combining epigenetic modulation and adoptive transfer of genetically 
engineered T lymphocytes targeting NY-ESO-1 or other CTAs for the development of a specific 
immunotherapy for CRC.  
Another approach could also include the introduction of sequences capable of disrupting long α-
helical stretches in the regions outside the potential epitopes (Robins & Rees, 2001). Such 
approaches have the potential to improve the treatment response in patients with non-reactive type 
CRC. However, several challenges remain to be overcome, including the insufficient antitumour 
responses due to immunosuppression driven by T lymphocytes known as regulatory T cell (Tregs). 
 
1.10  Infiltrating T lymphocytes  
During the last decade, the search to understand the causes underlying presentation CRC has 
focused on Tregs. They have been shown to play a major role in cancer immunoevasion by directly 
inhibiting or even eradicating both CTLs and T helper lymphocytes (Weinberg, 2007). Tregs 
suppress autoreactive T cells without killing them through incompletely understood, contact-
dependent mechanisms (Curiel, 2007). In healthy individuals they represent 5% to 10% of the 
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population of CD4
+
 lymphocytes. However, in cancer patients, Tregs may increase up to 30% and 
are predominantly found among the tumour infiltrating lymphocytes present (Weinberg, 2007). 
Therefore, the failure of the T and B cells to recognize and eradicate immunogenic cancer cells 
could be accounted to the ability of certain tumours to secrete chemokine CCL22 which recruits 
Tregs and immobilizes the function of the anti-cancer immune response. Indeed patients with 
ulcerative colitis and irritable bowel syndrome have been shown to have higher numbers of 
infiltrating T cells than healthy controls (Holmen et al, 2006) which may play a role in controlling 
cancer-driven inflammation. Tregs in CRC have been shown to exhibit both pro- and anti-tumour 
activities governed by the level of inflammatory stimuli received and dependent of the phase of 
tumourigenesis (early or late) (Mougiakakos, 2011). Following treatment in a phase II clinical trial 
for CRC patients, the level of circulated Tregs was reported to have almost reached normal levels 
accompanied by 70% increase in CTLs responses against CEA epitopes (Correale et al, 2005). 
Therefore, it still remains to be determined whether presence of Tregs in CRC plays a pro- or anti- 
tumour role, how this correlation changes with the stage of the disease and the clinical significance 
of these changes. 
In addition, Tregs appeared to be highly specific for a distinct set of TAAs in CRC patients, 
suggesting that Tregs exert T cell suppression in an antigen-selective manner (Bonertz et al, 2009). 
Several key hallmarks of Tregs in CRC have been identified, highlighting their complex role in the 
progression of the disease, the survival prognosis and their potential as therapeutic targets. Overall, 
it was established that CRC patients develop multivalent and individual T cell responses against a 
broad variety of different CRC-associated TAAs. Therefore, selecting a panel of antigens according 
to pre-existing T cell responses as an intermediary could improve the efficacy of future 
immunotherapies for CRC and should be further investigated. Better understanding of the role and 
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behaviour of Tregs within CRC would improve tumour profiling on an individual basis and could 
aid the choice of the most adequate therapy for each individual case. It could also benefit the 
development of cancer vaccines and other immune-based therapies targeting particular CTAs in 
non-reactive type CRC. 
Tumour-infiltrating CD45RO
+
-cell density is a prognostic biomarker associated with longer 
survival in CRC patients, independent of clinical, pathological, and molecular features (Nosho et al, 
2010). Similar findings have also been reported from another study, linking the density of 
CD45RO
+
 memory T cells in the different regions of CRC with dissemination to lymphovascular 
and perineural structures and to regional lymph nodes in patients – low densities were associated 
with a very poor prognosis (Pages et al, 2005).  However, not only was the type and density of the 
infiltrating immune cells within human CRC  predictive of clinical outcome but also their location 
within the tumour i.e. whether they are located in the centre of the tumour or the invasive margin. A 
strong in situ immune reaction in both regions was shown to correlate with a favourable prognosis 
regardless of the stage (I, II and III CRC) (Galon et al, 2006). Conversely, a weak in situ immune 
reaction predicted a poor clinical outcome even in patients with stage I CRC. This data was further 
supported by Pagès et al 2005 who examined the relationship between the presence of CD8
+
 and 
CD45RO
+
 in two regions of the tumour in patients with early stage CRC with regards to tumour 
recurrence and overall patient survival. High densities of both CD8
+
 and CD45RO
+
 correlated 
significantly with lower rates of CRC recurrence and increased overall survival when compared to 
patients with low densities of both immune cell types within the primary tumours. In contrast, 
extramural vascular invasion and high FOXP3
+
 cell density in lymphoid follicles were independent 
factors for worse survival, whereas a high frequency of lymphoid follicles in histologically normal 
colonic mucosa was associated with better survival (Salama et al, 2012). Therefore, the collective 
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analysis of the type, density and the location of immune cells within the CRC could be used to 
predict patient survival and to identify the high-risk patients who would benefit most from adjuvant 
therapy. 
 
1.11  Intrinsically disordered proteins (IDPs) 
Following a bioinformatics approach implementing the application of two algorithms (FoldIndex 
and RONN) predicting the level of disorder within a sequence, the experimental outcome revealed 
that more than 90% of the examined 228 CTAs were IDPs (Rajagopalan et al, 2011). The latter are 
proteins that lack the typical hydrophobic cores and therefore do not appear as having rigid 3D 
structures (along their entire length or in localized regions) under physiological conditions and 
instead, exist as dynamic ensembles (Rajagopalan et al, 2011; Marsh et al, 2010). However, IDPs 
can evade being detected as “misfolded” and degraded by the cell's surveillance system through 
their ability to undergo “disorder-to-order” transitions upon binding to biological targets – a 
paradox known as the “order/disorder paradox” (Kulkarni et al, 2011). This is achieved as a 
segment of an IDP initially binds with the target, followed then by coalescing of the other protein 
segments facilitating the IDPs’ folding (Zhou et al, 2012). However, recent studies have challenged 
this general view by revealing a phenomenon – uncoupled binding and folding of IDPs (Sigalov et 
al, 2011). The complexity of the binding mechanisms of IDPs has been investigated by others 
(Zhou, 2012; Brown et al, 2011) and a summary of possible pathways have been outlined in Figure 
1.2. 
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Figure 1.2 Diagrammatic representation of the different binding mechanisms and the 
disorder-to-order transition that the IDPs undergo prior to and upon binding to their targets 
(based on Sigalov, 2011). Some IDPs (particularly immune signalling-related IDPs) do not fold 
upon binding to their targets (for example Intermediate 1). Other IDPs undergo partial or complete 
folding upon binding (Intermediate 2 and Intermediate 3) or fold prior to binding to their targets 
(Intermediate 4). The images shown are representative of the disorder-to-order transition that a 
hypothetical IDP would undergo. 
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The properties associated with IDPs give an interesting angle of perception towards the expression, 
behaviour and function of CTAs identified as IDPs. The lack of rigid 3D structures is believed to be 
responsible for the exposure of primary contact sites which enables the faster, more effective and 
promiscuous binding at high concentrations to target molecules (Marsh et al, 2010). Together with 
the fact that intrinsic disorder has been identified as a determinant of genes that are harmful when 
overexpressed (Zhou, 2012), this could be accounted to the correlation between CTAs 
overexpression and disease prognosis. This is further supported by the fact that CTAs appear to 
occupy ‘hub’ positions (highly connected protein nodes) within the complex protein-protein 
interaction (PPI) network (Rajagopalan et al, 2011; Midic et al, 2009). What was interesting in 
these findings was the fact that these networks are dynamic and grow incrementally by establishing 
new nodes. However, a desirable protein for recruitment to a hub position is a protein that is likely 
to participate in a large number of promiscuous interactions when overexpressed such as a CTA that 
is an IDP (Rajagopalan et al, 2011). Eventually, the PPI network becomes dominated by such hubs 
leading to the overexpression of CTAs and to the creation of nodes with novel functions. This is 
accountable for the poorer disease prognosis in later CRC stages and the phenotypic presentation of 
non-reactive CRC disease. This idea is further supported by the fact that high abundance of IDPs is 
believed to result in undesirable interactions and potentially harmful effects of such interactions 
(Zhou, 2012). Perhaps the failure to respond to treatment in non-reactive type CRC could be due to 
targeting common nodes in a protein network rather than CTAs that occupy hub positions. 
Therefore, the search for such antigens could potentially take a turn towards more thorough 
investigation of the structure of the PPI networks established in cases of reactive disease.  
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1.12  Study Aims 
In this study we aimed to identify the differences in the immune response demonstrated by CRC 
patients who respond well to conventional treatment and those who do not. To do this we used 
SEREX to determine which antigens were recognised by patients with reactive disease and to 
compare them with the antigens recognised by patients with non-reactive disease (poor responders. 
We hoped to identify new biomarkers of disease and potential targets for immunotherapy. 
 
Please note: This Introduction was published as part of a review by Boncheva, V., Bonney, S.A., 
Brooks, S.E., Tangney, M., O’Sullivan, G., Mirnezami, A. & Guinn, B.A. (2013) New targets for 
the immunotherapy of colon cancer – does reactive disease hold the answer? Cancer Gene Therapy, 
20, 157-168 (see Appendix I). This Introduction contains work entirely written or images drawn by 
Viktoriya Boncheva, the author of this MPhil thesis, with supervisory guidance from Dr Barbara 
Guinn. 
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CHAPTER 2    Materials and Methods 
 
2.1  First round of primary immunoscreening of a testes cDNA library (SEREX) 
2.1.1 Primary immunoscreening  
A testis cDNA expression library (constructed on 18/07/2011) was prepared by Dr Barbara Guinn 
while working at the Southampton University Hospitals Trust. Primary immunoscreening of that 
library with allogeneic colon cancer serum (Serum ID: CC010/1:10 dilution in 1xTris-buffered 
saline (1xTBS/0.01% NaAzide) diluted down to 1:100 in 1xTBS) was carried out as previously 
described (Sahin et al, 1995). Briefly, on Day 1, a single E. coli XL1-Blue MRF’ colony isolated 
from LB Tetracycline agar plate was grown in 5ml of LB broth (supplemented with 0.2% Maltose 
and 10mM autoclaved MgSO4) for 4 to 5 hours at 37°C and 200rpm until approximately 0.5-0.7 
optical density at 600nm wavelength (OD600) was reached. Subsequently, 600μl of the bacterial 
culture was inoculated with an aliquot of recombinant phages (testis cDNA expression libraries L1 
or L2) and incubated at 37°C in a water bath for 15 minutes to allow infection to occur. Expression 
of recombinant proteins was induced with the addition of 20μl of 1M isopropyl-β-D-galactoside 
(IPTG; Melford Laboratories, UK) and the E. coli XL1-Blue MRF’ cells were mixed with 7ml-8ml 
of NZY top agar (100ml of NZY broth (5g NaCl, 2g, MgSO4, 5g yeast extract, 10g NZ Amine A in 
1L dH2O (Sigma-Aldrich U.K.) at pH 7.5, autoclaved) boiled with 0.7g bacteriological agar (to 
produce 0.7% agar) (Sigma-Aldrich) with 2ml of filtered 10% Maltose and 5ml of filtered dH2O) 
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and plated at a density of 2000-4500 pfu onto 140mm NZY agar plates (5g NaCl, 2.5g, MgSO4, 5g 
yeast extract, 10g NZ Amine A in 1L dH2O at pH 7.5, autoclaved) (Figure 2.1). 
 
Figure 2.1     Dagrammatic representation of how NZY top agar was prepared and phage supernatant 
added to it as described in section 2.1.1.  
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Plates were incubated at 37°C overnight. On the following day, BioTraceTM NT nitrocellulose 
transfer membranes (0.2μm pore size; PALL Life Sciences, UK) were placed on the agar for 3 
hours at 37°C to blot the recombinant proteins.  
Following the incubation period (Day 2), membranes were pricked with a sterile needle (Figure 
2.2) to allow plaque localization at later stages, removed and washed in a tray, containing TBS-
Tween 20 (TBS-T) (10x TBS pH 7.4 purchased from VWR and 0.05%/0.5ml Tween-20 purchased 
form Sigma-Aldrich – per 1L). Any residual bacterial cell lysate or unbound phage were removed 
by gently sweeping across the membrane. The membranes were replaced in 150mm petridishes, 
containing TBS-T and placed on a rotating platform for 10-15 minutes. The TBS-T was then 
replaced with TBS (same as TBS-T without Tween-20) and plates were placed back on the rotating 
platform for another five minutes.  
 
Figure 2.2 Location of needle pricks on a membrane. To enable the accurate location of the 
membranes with regards to positive plaques pin pricks were placed through the membrane into the NZY agar 
below to allow orientation. A compass was then used to locate positive plaques on the immunoscreened 
membrane on the NZY plate later.  
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Membranes were then blocked in 5% (w/v) low fat milk in TBS for 1 hour followed by four times 
TBS-T and one time TBS washings (each wash carried out for five minutes on a rotating platform at 
room temperature (RT)). The membranes were incubated overnight in 20ml of the cleaned CC010 
serum (1:100 dilution).  
On the following day (Day 3), the membranes were washed (as described above) and incubated 
with alkaline phosphatase conjugated rabbit antihuman IgG, Fcγ, fragment specific antibody 
(Pierce, UK; Prod. No. 31318) diluted 1:5000 in 0.5% (w/v) low fat milk in TBS (10ml to each 
plate) for three hours, RT. Membranes were then washed (as before) and reactive plaques were 
visualized in 10ml of alkaline phosphatase (AP) buffer (12.1g Trizma base, 5.844g NaCl, 1.0165g 
MgCl2.6H2O; Sigma-Aldrich) at pH 9.5 containing 33μl of 50mg/ml 5-bromo-4-chloro-3`-
indolylphosphate sodium salt (BCIP: 50mg per 1ml of dH2O) (Sigma-Aldrich) and 330μl of 
10mg/ml nitroblue tetrazolium (NBT: 10mg per 1ml of dH2O) (Sigma-Aldrich). Immunoreactive 
plaques were excised off of the agar with the aid of sterile scalpels alongside several non-reactive 
plaques (used as negative controls in secondary screening) and eluted (in 1.5ml sterile eppendorf 
tubes) in 500μl autoclaved SM buffer (5.8g NaCl, 2g MgSO4.7H2O, 50ml 1M Tris.HCl at pH 7.5, 
5ml of 2% (w/v) gelatin (stored at 4°C) in 1L of dH2O) for one hour at RT, 200rpm. Subsequently, 
10μl of Chloroform (Sigma-Aldrich) were added to each 1.5ml eppendorf tube. Tubes were then 
vortexed, centrifuged at 10,000rpm for one minute and stored at 4°C for secondary 
immunoscreening. Plaques on each plate were counted by dividing the plate into four equivalent 
quadrants, noting the number of plaques present in one of the quadrants and multiplying by four to 
give an average number of plaques for the plate. 
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2.1.2 Secondary immunoscreening 
Positive phages were rescreened by infecting 200μl of E. coli XL1-Blue MRF’ cells at 0.5-0.7 
OD600 with 5μl of phage solution and plating with 2ml to 3ml of top NZY agar and 8μl of 1M IPTG 
onto NZY agar plates. Subsequently, steps were followed as in primary screening. Any positive 
staining plaques were to be isolated to monoclonality with the aid of a glass Pasteur pipette, eluted 
in 500μl autoclaved SM buffer and stored at 4°C for sequencing and tertiary screening.  
2.1.3   Preparation of reagents used for Primary and Secondary immunoscreening 
 LB broth. The LB broth (Lennox L broth) was prepared by adding 1 LB broth tablet (10g/L 
Tryptone, 5g/L Yeast Extract, 5g/L NaCl and 2.2g/L inert binding agents; Sigma-Aldrich) per 50ml 
of deionized water (dH2O) (20 tablets for 1L of dH2O) and autoclaving at 121°C for 20 minutes to 
produce sterile LB broth with pH of 7.5.  
 LB tetracycline plates. The LB tetracycline plates were prepared by autoclaving 100ml of 
LB broth (preparation as described above) with 1.5g Bacteriological agar (70% agarose and 30% 
agaropectin; Sigma-Aldrich) to produce 15% agar. Subsequently, the LB agar was left to cool down 
to around 50°C and following the addition of 125μl of Tetracycline (12.5mg/ml diluted in 70% 
EtOH) approximately 20ml of the agar were poured in a 90mm petridish (avoiding the formation of 
bubbles) and dried for 30 minutes in a laminar flow cabinet. The dried agar plates were wrapped up 
in a plastic bag and stored at 4°C upside down for future use.  
 Inoculation of LB tetracycline plates. Two LB tetracycline plates were inoculated with E. 
coli XL1-Blue MRF’ cells (Figure 2.3) every two weeks to maintain fresh bacterial stock. Older 
colonies would take longer than 5 hours to reach 0.5-0.7 OD600 in 5ml of LB broth. 
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 1M IPTG. A stock of 1M IPTG was prepared by vortexing 238mg of IPTG powder with 
1ml of dH2O until homogenous solution formed. The stock was kept at -20°C for further 
use. It is recommended to keep small aliquots of IPTG (around 200μl) as it cannot be freeze 
thawed too often and also away from direct light (tube could be wrapped up in thin foil) as 
IPTG is light sensitive.  
 10% Maltose. A 50ml stock solution of 10% Maltose was prepared by vortexing 5.1g of 
98% Maltose (powder; Sigma-Aldrich) with 50ml of dH2O until clear homogeneous 
appearance was reached. The stock solution was then filtered through a 0.2μm syringe filter 
(Fisher) in a laminar flow cabinet into a sterile 50ml Falcon tube (Fisher) and were filtered 
again prior each use. 
 
Figure 2.3   Diagrammatic representation of the method employed when spreading a single E. coli XL1-
Blue MRF’ colony onto a LB Tetracycline plate. This technique enabled the isolation of individual colonies 
following an overnight incubation at 37°C. Each of the five steps consisted of four individual streaks (the first 
of each four crosses with the fourth streak of the previous four) with an inoculation loop on the LB agar. 
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 1M MgSO4.7H2O. A 200ml stock solution of 1M MgSO4.7H2O was prepared by mixing 
24.07g of MgSO4.7H2O with 200ml of dH2O and autoclaving at 121°C for twenty minutes. The 
solution was kept at RT and syringe filtered every time prior to its use. 
 
2.2 Determination of serum reactivity and testis cDNA library efficiency 
The results obtained during the first round of primary and secondary immunoscreening with 
SEREX required further investigation to establish the quality of the pooled serum (CC010) and also 
the efficiency of the phage cDNA library used in this investigation. Serum reactivity was 
determined through cross-matching the serum with animal whole blood and cDNA library 
efficiency was tested via blue/white screening for recombinant plaques and via PCR.  
2.2.1 Blood agglutination and serum reactivity test 
Erythrocyte agglutination is a phenomenon observed in cases of cross-matching of erythrocytes and 
serum of incompatible organisms and therefore is a well-established method used predominantly for 
blood typing (Landsteiner, 1900). The basic principle of the technique was applied in this 
investigation – we wanted to demonstrate the reactivity of the patients sera we were using for 
immunoscreening. Animal blood samples and a human blood sample of known type (A+)(stored at 
4°C) were mixed with the cleaned CC010 serum (1:10 dilution)(Figure 2.4). Samples were 
observed for signs of agglutination under a light microscope at 1000x magnification and compared 
to control samples containing only the animal or known blood type sample or the same mixed with 
1xPBS (8g NaCl, 0.2g KCl, 1.44g Na2HPO4 and 0.24g KH2PO4, pH 7.4). Following the addition of 
serum/1xPBS to the corresponding blood samples, the glass slides were kept for 2-3 minutes at RT 
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prior to observation under light microscope (see Figure 3.1 in Results). If blood samples appeared 
dry the agglutination test was repeated with a shortened incubation time at RT.  
 
 
Figure 2.4 Serum reactivity test. Animal blood or human blood of a known group were mixed with 
pre-cleared Dukes’ B serum used for immunoscreening. Agglutination indicated the presence of active 
antibodies in the Dukes’ B sera.  
 
All surfaces and microscope lenses were disinfected with 70% EtOH and slides discarded correctly 
at the end of each agglutination test. Extreme caution was carried out while handling the blood 
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samples and glass slides and personal protective equipment (PPE) – gloves, goggles and laboratory 
coat were worn at all times. Blood samples were discarded in the infectious waste bin alongside 
with disposable PPE and other materials. 
2.2.2 Blue/white screening for recombinant plaques  
Blue/white screening with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (Sigma-
Aldrich) was carried out to establish whether the cDNA phage library used in the first round of 
SEREX primary screening has been packaged efficiently. Following infection of XL1-Blue MRF’ 
bacterial cells with cDNA phages in the presence of X-gal is expected to result in the formation of 
colourless plaques where a recombinant phage was present and in the formation of blue plaques 
where the infectious phage did not contain a cDNA insert. To set up the experiment a single colony 
of XL1-Blue MRF’ was grown in 5ml of LB media as previously described until OD600 of 0.547 
was reached. Four 150mm petridishes were prepared as previously described in Day 1 of SEREX 
primary screening (each plate to screen a different cDNA library so in total four libraries were 
screened), with the addition of X-gal (dissolved in DMSO (dimethylsulfoxide; Sigma-Aldrich)) at 
two different concentrations as detailed in Table 2.1. 
Plates were removed from the incubator on the following day and the plaques were observed 
(Figure 3.2). This experiment was repeated on another occasion and the outcome was affirmative 
of the original findings.  
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Table 2.1 X-gal screen for recombinant phages 
In order of addition: Plate 1 Plate 2 Plate 3 Plate 4 
XL1 - blue at OD600 of 0.547 600µl 600µl 600µl 600µl 
cDNA library (known to give 
around 3500pfu per plate) 
10µl of L1 7µl of L2 1µl of T27 1µl of T28 
Incubation at 37˚C water bath 15 minutes incubation 
1M IPTG 20µl 20µl 20µl 20µl 
50µl of X-gal at concentration 
of: 
50mg/ml 220mg/ml 50mg/ml 220mg/ml 
Plating mixed with 6ml of NZY top agar and plated 
Incubation at 37˚C overnight Around 12 hours 
 
2.2.3 PCR to determine presence of cDNA insert in libraries L1, L2, T27 and T28 
The results from the blue/white selection were further confirmed through PCR by using the four 
cDNA phage libraries as templates and T3/T7 primer pair as described earlier (SEREX). PCR was 
set as follows:  
In each PCR tube - 12.5µl of ReadyMix (without MgCl2) (Sigma-Aldrich), 1.5µl of MgCl2, 0.5µl of 
primer T3, 0.5µl of primer T7, 1µl of template (L1 in tube 1, L2 in tube 2, T27 in tube 3 and T28 in 
tube 4) and 9µl of H2O (provided from Sigma-Aldrich) – final volume 25µl in each PCR tube. A 
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positive control reaction was set with the above solutes and with 0.5µl of GTK-AML-8 plasmid 
(with binding sites for T3 and T7) and 9.5µl of H2O to final volume of 25µl. One negative control 
(containing no template) was used with 10µl of H2O to final volume of 25µl. The so prepared 
samples were placed in a PCR machine at the following program: 94˚C for 2 minutes, followed by 
[94˚C for 30 seconds, 51˚C for 40 seconds, 72˚C for 40 seconds] x 40 cycles and 72˚C for 7 
minutes. Following the completion of the PCR cycles, the samples were analysed on a 1.5% 
agarose gel (1.5g agarose powder (Sigma-Aldrich) in 100ml of 1x TAE buffer (50x TAE purchased 
from Fisher Scientific, Loughborough, England and diluted in distilled water) and boiled until 
homogeneous in a microwave; 5µl of EtBr (Sigma Aldrich, UK) was added per 100ml of 1.5% 
agarose solution after it has been cooled down to around 50°C. The agarose solution was mixed 
thoroughly, avoiding the formation of bubbles and poured gently on a gel tray to allow solidifying). 
Each sample was mixed 1:6 with a 6x loading dye (3ml glycerol (30%), 25mg bromophenol blue 
(0.25%) and dH2O to 10mL) was prepared with reagents from Sigma-Aldrich) and loaded into a 
corresponding well of the gel. The gel tank was switched on and alolowed to run for 45 minutes at 
100V. The gel was observed under UV light (Image 3.3). 
 
2.3 Construction of a new testis cDNA library 
2.3.1 Ligation of cDNA inserts in ZAP Express Vectors and packaging  
Several attempts were made to construct a new cDNA phage library before the reaction was 
successfully optimized to give a positive result. The testes cDNA inserts (already processed 
according to ZAP Express cDNA Synthesis Kit Protocol from Stratagene, UK) were kindly 
provided by Dr Barbara Guinn (University of Bedfordshire, UK). They were prepareded in 
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September 2009 at the University of Southampton and stored at -80°C until required. Following the 
optimisation of the reactions, the first step of the construction of new cDNA expression library were 
the ligation of the cDNA inserts into the ZAP Express Vector according to the protocol provided by 
Stratagene UK usingl reagents from the ZAP Express cDNA Synthesis Kit.  
The reaction was performed as follows: 4µl cDNA (100ng DNA) (from 09/09), 0.5µl ligase buffer, 
0.5µl 10mM rATP, 1µl ZAP Express Vector, 0.5µl T4 DNA ligase (4 U/µl) were added to a sterile 
1.5ml Eppendorf tube. The mixture was incubated at room temperature for two hours.  
Following incubation, 5 µl of ligation were packaged into a Giagapack III Gold Packaging extract 
according to the protocol provided by Stratagene UK. The packaging extract was thawed (by 
holding it between the fingers) from -80°C before the ligated cDNA was added to it. The mixture 
was stirred very carefully with the aid of a sterile pipette tip and centrifuged at 10000rpm for 3-4 
seconds. The mixture was then incubated at room temperature for ninety minutes. Following the 
incubation, 250µl of autoclaved SM buffer and 10µl of Chloroform were added to the ligation 
mixture. The tube was vortexed at low speed, centrifuged at 10000rpm for one minute and then 
stored at 4°C. 
2.3.2 Plating and titering the new library 
Following the instructions on Stratagene protocol, E. coli XL1 Blue were grown to OD600 of 0.5-0.8 
and infected with the newly constructed testes library cDNA containing phagemid. Four 150mm 
NZY agar plates were prepared as described using 1µl, 1.5µl, 2.5µl and 3.5µl of the cDNA library 
respectively per 600µl of E. coli culture. 10µl of 1M IPTG and 40µl of X-gal (250mg/ml in DMF) 
were added along with 7-8ml of NZY top agar to the bacterial culture prior to plating. The four 
plates were then incubated at 37˚C overnight to allow the formation of plaques. Following 
55 
 
incubation, the white and the blue plaques were counted separately and together to give a total 
number of pfu per 1µl (Table 3.1). 
2.3.3 Amplifying the ZAP Express library 
Amplification of the primary library was carried out on the following morning as the primary 
cDNA libraries tend to be unstable and lose efficiently. The manipulations were carried out 
according to the protocol provided by Stratagene. E. coli was grown to OD600 of 0.5-0.8 and four 
600µl aliquots of the bacterial culture were placed in four 15ml sterile Falcon tubes. The first three 
were infected with 35µl of the primary cDNA library and the fourth one – with 45µl. Each mixture 
was supplemented with 20µl of 1M IPTG and 6-7ml of NZY top agar then poured onto 150mm 
NZY plate. The plates were incubated overnight at 37˚C to allow the plaques to form 
(approximately 2mm  in diameter) and the agar was overlayed with 6ml of sterile SM buffer. The 
plates were placed on a rotating platform at 4˚C for 12 hours. The SM buffer was collected from the 
plates in a sterile environment and was pooled together. Chloroform was added to the suspension at 
5% of total volume and the amplified library was left at room temperature for 15 minutes. The 
suspension was centrifuged for 3 minutes at 5000rpm and the clear supernatant was replaced into 
two new, sterile 15ml Falcon tubes. Chloroform at 0.3% of final volume was added, tubes were 
briefly vortexed and centrifuged and then stored at 4˚C.  
This procedure was repeated with the remaining 140µl of primary cDNA library (following ligation 
in ZAP Express vector and packaging). Three plates were prepared as described above with 40µl of 
primary cDNA library used for each one. The plates were overlayed with 8ml of sterile SM buffer 
and incubated. The buffer was collected after overnight incubation on a rotating platform and 
processed as described above. 
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The amplified library was then screened with X-gal (blue/white screening as previously described) 
to check efficiency and recombinancy. Eight NZY plates were prepared, using two random library 
aliquots for the infection of XL1 Blue bacterial cells (1µl of 1:10 dilution, 5µl of 1:10 dilution, 1µl 
of 1:50 dilution and 1µl of 1:100 dilution of each aliquot). Following the incubation time, the total 
number of plaques (sum of white and blue plaques) was determined (Table 3.2).  
The amplified library was pooled together and aliquoted into 1ml sterile tubes - 300µl of cDNA 
library in each. DMSO (12.5% v/v) and Chloroform (7.5% v/v) were added to each aliquot and the 
samples were stored at -80˚C for further use.  
2.3.4 Confirmation of cDNA library efficiency 
A PCR reaction with T3/T7 primer pair was carried out (conditions as described above) to verify 
the recombinancy and efficiency of the newly constructed testis cDNA library. As non-recombinant 
phages are present in the main stock, several aliquots of the cDNA library were used for the 
preparation of four NZY plates (as described in Day 1 of SEREX protocol) in the presence of X-gal 
to differentiate recombinant from non-recombinant plaques. Plates were incubated and on the 
following day twenty two recombinant plaques were selected at random and used as templates in a 
PCR. The aim was to demonstrate that the newly constructed library contains cDNA inserts and that 
they are of various sizes (Figure 3.5). 
 
2.4  Second round of primary immunoscreening with SEREX – optimised protocol 
Primary immunoscreening of testis cDNA phage library with SEREX is a process which takes three 
days for completion. The manipulations carried out at each day were carried out as described in the 
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first round of primary immunoscreening with minor changes accumulated in the process of 
optimising the method.  
Day 1 
A single E. coli XL1-Blue MRF’ colony should be isolated from LB Tetracycline agar plate 
(prepared as described earlier) and grown for 4 to 5 hours in 5ml-7ml of LB broth in 50ml Falcon 
tubes (supplemented with 0.2% Maltose and 10mM autoclaved MgSO4) at 37°C and 200rpm. The 
tubes should be incubated until the culture reaches approximately 0.5-0.7 optical density at 600nm 
wavelength (OD600). This step should be carried out at around 10am in the morning to allow 
sufficient time for the bacterial culture to reach the desired density (the amount of LB broth should 
be considered as larger volumes would require longer incubation times). The cultures should be 
placed at 4°C for at least one hour prior to any further manipulations in relation to the SEREX 
protocol.  
The final step for Day 1 involves the infection of E. coli XL1-Blue (grown to the desired OD – 
preferably 0.6 at 600nm) with the appropriate volume of recombinant cDNA expression library to 
give an efficiency of around 4500 plaque forming units (pfu) per 150mm Petri dish. This process 
should take between thirty to fifty minutes (depending on the number of plates) if preparation and 
planning is carried out beforehand. The following steps were performed. On Day 1we remove an 
appropriate number of NZY plates (up to two weeks old) from the laboratory fridge and placed 
them at 37°C incubator. Plates were placed with their lids uncovering approximately 50% of the 
agar to allow any excess fluid to evaporate. 
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A number of aliquots of bacterial culture were infected with the newly constructed pooled cDNA 
library. 5µl of 1:10 dilution was established to produce around 4000-4500 plaques per 150mm 
plate. The E.coli and phage cultures placed in a water bath set at 37˚C for 15 minutes. 
The appropriate amount of IPTG (20µl of 1M IPTG) was added to each tube of E.coli and phage 
library prior to pouring in the 55
o
C NZY top agar.Tilt the 15ml tube containing bacteria, phage and 
IPTG    had warm  NZY top agar (to final volume of 6ml-7ml) added to it. The lid was closed, the 
tube inverted, to mix the contents evenly. The bacteria, phage and IPTG were poured onto a large 
NZY plate and ensure even spread by rotating and moving back-forth and left-right the plate and 
then left to solidify. We then closed the lids on the petri dishes and place them in an incubator 
(upside-down) at 37˚C overnight. Best results were achieved if incubation was carried out for 12 
hours rather than the 16hrs published previously (Liggins et al, 2005). Plaques were visible the next 
morning around 2mm-3mm in diameter. 
Day 2 and Day 3 
The manipulations carried out on Day 2 and Day 3 of primary immunoscreening with SEREX as 
described in Section 2.1.1. Three allogeneic colon cancer sera were used as follows:  
1. Serum ID: CC014/1:10 dilution in 1xTBS/0.01% NaAzide (pre-cleared  as described in Liggins 
et al, 2005 on 10.06.2010 by Dr Barbara Guinn and stored at -80˚C) was diluted down to 1:200 
in 1xTBS and NaAzide was added to it at concentration of 0.01% of the total volume. The 
serum was diluted on the 6.02.2013 and used for primary and secondary immunoscreening. 
2. Serum ID: CC005/1:10 dilution in 1xTBS/0.01% NaAzide (pre-cleared by Dr Barbara Guinn 
and stored at -80˚C) was diluted down to 1:200 in 1xTBS and NaAzide was added to it at 
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concentration of 0.01% of the total volume. The serum was diluted on the 19.02.2013 and used 
for primary and secondary immunoscreening. 
3. Serum ID: CC010/1:10 dilution in 1xTBS/0.01% NaAzide (pre-cleared by Dr Barbara Guinn 
and stored at -80˚C) was diluted down to 1:200 in 1xTBS and NaAzide was added to it at 
concentration of 0.01% of the total volume. The serum was diluted on the 26.04.2013 and used 
for primary and secondary immunoscreening. 
The overnight incubation with the appropriate serum took place between 5:30pm and 11:30am.  
The results of second round of primary immunoscreening with SEREX as presented in Table 4.1 
(Section 4.1). 
 
2.5  Secondary immunoscreening of testis cDNA library with SEREX 
Plaques, containing immunoreactive cDNA inserts were isolated to monoclonality with the aid of a 
glass Pasteur pipette. The end of the 180mm glass pasteur pipette was allowed to just surround the 
plaque (Figure 2.5) and then pressed firmly down through the NZY agar. The pipette was then 
carefully lifted and the collected plaque was eluted in 250µl of sterile SM buffer (preparation as 
previously described) and stored at 4°C. A new pipette was used for the isolation of each plaque. 
During the first few secondary immunoscreening reactions with SEREX, three positive plaques 
were isolated from each membrane (resembling copies of the original positive plaque isolated 
through primary immunoscreening). However, as this investigation suggested on a later stage, not 
all of them would always be true positives, would be successfully eluted in the SM buffer or even 
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contain a cDNA insert. Therefore, it is advised that as many as possible immunoreactive plaques are 
isolated from each membrane (from secondary immunoscreening) and then run through a PCR 
(T3/T7 primers) to confirm the presence of cDNA inserts. Only the ones that produce a band 
(against positive and negative control PCR reactions) should be kept and processed further 
(sequencing, analysis, etc.). 
 
 
Figure 2.5 Isolation of a single positive colony following secondary screening with SEREX. A 
diagrammatic representation of the process of isolating positive plaques following secondary 
immunoscreening with SEREX. Each positive plaque was picked out from the NZY agar with a sterile glass 
Pasteur pipette which was discarded following its use.  
 
2.6 Isolation of immunoreactive cDNA inserts through PCR and gel extraction 
The size of cDNA inserts was determined through PCR carried out with the aid of T3 and T7 
primer pair as suggested in the Stratagene ZAP Express manual. Individual PCR reactions were 
carried out in an MWG advanced Primus 96 PCR machine under identical conditions:  
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The PCR sample mix was prepared following a strict order in the addition of reagents. PCR tubes 
(StarLabs, U.K.) were lined up on a stand and 12.5µl of ReadyMix (Sigma-Aldrich) was added 
gently to the bottom of each tube avoiding touching the walls of the tube or any other surfaces. The 
next step involved the addition of 1µl of T3 or T7 primer (diluted to 10pMol concentration with the 
addition of sterile H2O). Subsequently, the appropriate volume of H2O was added to complete the 
final volume of the solution to 25µl. Each immunoreactive phage, eluted in SM buffer, served as a 
template for an individual PCR reaction by adding 5µl of the phage solution to the PCR sample 
mix. Finally, the second primer was added to each sample mix. PCR tubes were carefully closed 
and centrifuged for 3-5 seconds to bring the solution to the bottom. Tubes were then placed at the 
PCR thermo-cycler and the following PCR conditions were applied: 94°C for 2 minutes, [94°C for 
30 seconds, 51°C for 40 seconds, 72°C for 40 seconds] x30 cycles, 72°C for 7 minutes and 4°C 
forever. 
Following cDNA amplification, each 25µl product was mixed with a loading buffer (1:6) and 
loaded onto 1% agarose gels (prepared as previously described). Gel electrophoresis, carried out at 
90V for 70 to 90 minutes, was used to determine the approximate size of the products and to 
separate the bands for further processing. After the gels were observed under UV light, each band, 
containing reactive cDNA fragment was excised of the gel with a scalpel and the product was 
extracted from the gel with the aid of a QIAquick Gel Extraction kit (Qiagen, UK). The method for 
extraction was as outlined in the QIAquick Gel Extraction kit protocol for gel cleanup with 
microcentrifuge. The cDNA fragments were eluted in 30µl ddH2O and placed at 4˚C for further use.  
This method was applied each time prior to sending off samples for sequencing.  
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2.7 Tertiary immunoscreening with SEREX 
In tertiary immunoscreening with SEREX, a number of confirmed immunoreactive plaques can be 
immunoscreened simultaneously with the same serum or also with seras of healthy volunteers of 
from patients with non-reactive Duke’s B. The preparation is similar to Day 1 of primary 
immunoscreening. XL-1 Blue E. coli is grown as described earlier to an OD600 of 0.5-0.7. The 
culture is then aliquoted at 600µl in 15ml sterile tubes and mixed with NZY top agar (without 
infecting it with phage cDNA library). The mixture iss then plated on 150mm NZY agar plates and 
left to dry in a laminar flow hood for 15-20 minutes. Following that, the top agar should be 
inoculated with 0.5µl of cDNA phage obtained from secondary immunoscreening with SEREX 
(only the individual reactive plaque) at even distances (Figure 2.6).  
 
Figure 2.6 A diagrammatic representation of tertiary immunoscreening of UOB-COL-1 to UOB-
COL-15 (confirmed antigens). Yellow spots represent actual cDNA samples and red spots – negative 
controls. Placed in a sterile environment on the top of a NZY top agar containing E.coli (no phage cDNA).  
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For each immunoreactive plaque (confirmed antigen UOB-COL-1 to UOB-COL-15) two rows of 
three 0.5µl spots should be placed. In between the two rows, two 0.5µl spots of empty phage were 
placed as negative controls (empty phage isolated via blue/white screening test – eluting a blue, 
non-recombinant plaque in SM buffer). 
 
2.8 Sequencing and sequence analysis of identified antigens 
Sequencing of the isolated PCR fragments was carried out by DNA Sequencing Facility at 
Cambridge University. PCR fragments were isolated as described in section 2.6 and the DNA 
concentration was determined with the aid of NanoDrop 2000. Samples were supplied for 
sequencing at concentration of 20ng per 100 base pair in 10µl of sterile H2O. Primers for the 
sequencing (T3 and T7) were supplied at 10pm/µl H2O (2µl of primer solution per reaction). 
The sequence was read through BioEdit software and then placed in Ensemble Genome database to 
search for genetic match. Sequences were also analysed through NCBI Blast genome database for 
matching genes.  
 
2.9 Cell culture  
The epithelial cell line SW480 was originally derived from a 50 year old male Caucasian with 
Dukes’ type B, colorectal adenocarcinoma (Fogh et al, 1977). This adherent cell line was 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) containing 4.5 g/L 
glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino-acids and 
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supplemented with 10% foetal bovine serum (FBS) and 2.5g/L amphotericin B antifungal antibiotic 
(Sigma-Aldrich). Cells were grown in a humidified atmosphere of 5% CO2 at 37°C. Manipulations 
were carried out in a sterile environment at all times (a laminar flow tissue culture cabinet) and 
were washed in a sterile and RNase-free phosphate-buffered saline (PBS) (137mM NaCl, 2.7mM 
KCl, 10mM Na2HPO4, 1.8mM KH2PO4 dissolved in 1L of deionized water at pH 7.4 - autoclaved 
and stored at 4°C) during procedures and also prior to mRNA extraction.  
 
2.9 mRNA extraction from SW480 cell line and first strand cDNA synthesis 
Total mRNA from SW480 cell line pellets (10
5
 cells per pellet) was extracted using RNeasy Mini 
Kit (Qiagen, UK). The total mRNA isolation was carried out as outlined in the protocol 
accompanying the RNeasy Mini Kit. Briefly, 300µl of buffer RLT was added to a loosened (by 
flicking the tube) SW480 cell pellet and lysis was facilitated by vortexing. The homogenized 
content was briefly centrifuged at 10000rpm to gather down to the bottom of the tube. Then one 
volume of 70% ethanol was added to the homogenized lysate and mixed carefully by pipetting. The 
sample was transferred to a RNeasy spin column placed in a 2ml collection tube and centrifuged for 
fifteen seconds at 10000rpm. The flow-through was discarded. An addition of 700µl of buffer RW1 
to the RNeasy spin column was followed by centrifugation for fifteen seconds at 10000rpm and the 
entire flow-through was discarded. The spin column membrane was washed twice with 500µl at 
10000rpm and then placed in a new 1.5ml eppendorf tube (Fisher Scientific). The total mRNA was 
eluted in 30µl of RNase-free water by centrifugation at 10000rpm. 
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2.10 Designing primers for known antigens 
Firstly, the sequence of the desired gene (known antigen coding gene) was obtained from NCBI Nucleotide 
database [online]. The sequence was then placed in BioEdit software and the length and location of athe 
desired product were determined. This particular sequence was then used in YeastGenome online database 
to construct a pair of primers according to our preferences. The properties of each primer pair were selected 
manually and the database provided a choice of primer pairs. The appropriate primer pairs were selected 
and used for detecting expression of known antigens in SW480 cell line (Table 2.2).           
 
2.11 Identification of antigen expression in SW480 cell line  
In this investigation, SW480 cell line was screened for the expression of eight antigens: TSP50, 
HAGE, BCP-20, WT1, SSX2, SSX2IP, NY-ESO-1 and RAGE via PCR. Total mRNA from SW480 
cell line was isolated and used for the synthesis of cDNA (as described in section 2.9). The cDNA 
from SW480 was used as a template in a PCR reaction (conditions to be determined with 
experimentation). Each primer pair was used on SW480 template (individual reactions) to detect 
expression of that antigen. If the antigen would have been expressed in the cell line it would have 
had an mRNA transcript. Therefore, there would be a presence of cDNA of that antigen in the 
template mixture used for PCR. 
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Table 2.2     PCR primer sequences for antigens investigated for expression in SW480 cell line using 
RT-PCR. 
Antigen Primer sequence 5’-3’ 
 
Temperature 
of Melting 
(Tm) ˚C 
Estimated 
product 
length (bp) 
β-Actin 
F:   GGCATCGTGATGGACTCCG                       
R:   GCTGGAAGGTGGACAGCGA 
69.2 
69.0 
Not known 
GAPDH 
F:   ACCCACTCCTCCACCTTTG                         
R:   CTCTTGTGCTCTTGCTGGG 
64.0 
63.8 
Not known 
TSP50 
F:   TGACGGCATGTGGCCTCAGTT                   
R:   TCAGAGGGCAGCAAGGAGGCT 
72.3 
71.7 
401 
HAGE (near 
3’ end) 
F:   CTGTACTAGTGGGGTAGAGAATTCA         
R:   CACAGAAACGAACATTTATTAACAG 
61.3 
60.4 
351 
HAGE (near 
5’ end) 
F:   TTTGTTGGCGCGGTAATCGGT                 
R:   CATGGCACTTGTGGCAGTGGA 
72.1 
71.8 
351 
HAGE 
F:   CCTTTCAATGTTATCCTGAG                     
R:   TATTCTTCAGATTGACGAAG 
56.2 
54.4 
Not known 
BCP-20 (near 
3’ end) 
F:   ATGAGTCACTCGACGAGGAGC                  
R:   TTTAAAGCCACCTGGAGCCT 
65.9 
64.7 
451 
BCP-20 
(middle) 
F:   TCATTCATCAGCAGCTTGAGC                  
R:   GAACGTGGCATTTGATGTTGA 
65.6 
65.8 
301 
WT1 
F:   GAGAGCGATAACCACACAAC                    
R:  GATGACCAAACTCCAGCTGG 
59.8 
64.7 
Not known 
SSX2 
F:   AAAATCAGAGTCAGACTGCTCCCGGTG           
R:   GTACATGCTGACCAGGAAACAGAGTGA 
73.5 
70.0 
Not known 
SSX2IP 
F:   TGAATGAGCTGCTTGTGCTT                        
R:  GCTGATGCAAATTCCTGTTCT 
63.7 
63.1 
Not known 
NY-ESO-1 
F:   CCCCACCGCTTCCCGTG                              
R:  CTGGCCACTCGTGCTGGGA 
72.6 
72.4 
Not known 
RAGE 
F:   GTGTCTCCTTCGTCTCTACTA                          
R:  GGTGTGCCGATGACATCG 
55.1 
66.7 
Not known 
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CHAPTER 3   Results:  First round of immunoscreening 
with SEREX  
 
3.1 First round immunoscreening with SEREX 
The first round of primary and secondary immunoscreening with SEREX did not yield any 
immunoreactive plaques. Following the SEREX protocol, 259,754 plaques were screened and 73 
potential positives were isolated and further examined. However, none of them was confirmed to be 
immunoreactive following secondary immunoscreening with SEREX. To find out the reason for the 
lack of positive reaction, several tests were carried out. The main concerns being the quality of the 
cDNA library and the reactivity of the patient serum used in these investigations: 
The serum reactivity test revealed that the patient serum triggered an immune reaction that resulted in 
agglutination when added to a sample of sheep whole blood (Figure 3.1). Although, not entirely 
conclusive, the result was indicative that the efficiency of the cDNA library itself should be 
investigated. 
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Figure 3.1     Serum reactivity test. Control sample containing 30µl of sheep blood and 15µl of 
normal PBS saline (A) and test sample containing 30µl of sheep blood and 15µl of CC010 patient 
serum diluted 1:100 (B). Although, the test is improvised, the sheep blood appeared to have reacted 
against the foreign sera. It appears that the serum is reactive and capable of eliciting an immune 
reaction (B) Samples observed at 1000x magnification under light microscope. 
 
Following the serum reactivity test, the efficiency of the cDNA library was investigated. A 
blue/white screening was carried out to determine the presence of cDNA inserts within the phages 
contained in the testis cDNA library. As a result, 100% of the plaques formed within the NZY agar 
appeared blue (Figure 3.2), indicating that the phages within the currently used cDNA library were 
non-recombinant.  
The test was repeated with the same findings.  
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 Figure 3.2      Blue/white screening for recombinant plaques. An aliquot of L2 (upper 
plate) and another of T28 (lower plate) cDNA libraries were used to infect XL-1 blue E. coli as 
in SEREX protocol. The plates were incubated overnight. It can be seen from Image 3.2 that all 
plaques on those two plates appeared blue – containing non-recombinant phage. 
 
 
A PCR was set with samples of four cDNA libraries currently used in SEREX screening. PCR was 
carried as described earlier with T3 and T7 primer pair. As it can be seen from Figure 3.3, the primer 
pair did not amplify a product from none of the four libraries used as templates. The PCR reaction 
was repeated on a separate occasion with the same result. 
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Figure 3.3    PCR for presence of cDNA inserts within L1, L2, T27 and T28 cDNA libraries. The 
products of the PCR were loaded on a 1% agarose gel and gel electrophoresis was carried out for 45 
minutes at 100V. The ladder used was HirepLadder I. No bands seen in lanes for L1, L2, T27 or T28.  
 
  
3.2 cDNA testis library construction and amplification 
Library was constructed and amplified according to the protocol provided by Stratagene. 
Subsequently, four NZY plates were prepared as in SEREX protocol with the addition of X-gal and 
incubated overnight to determine the titer. 
3.2.1  Plating and titering of the primary cDNA library 
The newly constructed library was used in Day 1 of SEREX protocol to confirm the recombinancy 
of the phages and also to determine its titer (plaque forming units per µl). 
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Table 3.1 Plating and titering the primary cDNA library on 150mm NZY plates 
Plate No. 1 2 3 4 
cDNA library added 1µl 1.5µl 2.5µl 3.5µl 
Total number of plaques 33 52 84 109 
Recombinant plaques 27 46 81 101 
Non-recombinant plaques 6 6 3 8 
Plaque forming units 33 per µl 35 per µl 34 per µl 31 per µl 
The number of plaques weredivided by the amount of cDNA library added, to determine the plaque forming 
units (pfu) per µl. The primary library had a very low efficiency and therefore, the entire ligation was used to 
amplify the primary library.  
 
3.2.2 Plating and titering of the amplified cDNA library 
Following amplification (as outlined in Stratagene protocol), the newly amplified cDNA library was 
used in Day 1 of SEREX and eight NZY plates were prepared to determine the pfu per µl. 
Table 3.2 Plating and titering the amplified cDNA library on 150mm NZY plates 
Plate No. 1A 2A 3A 4A 1B 2B 3B 4B 
cDNA library added 
1µl of 
1:10 
5µl of 
1:10 
1µl of 
1:50 
1µl of 
1:100 
1µl of 
1:10 
5µl of 
1:10 
1µl of 
1:50 
1µl of 
1:100 
Total No. plaques 207 1015 42 19 216 1055 47 16 
Recombinant plaques 169 864 39 18 193 924 43 16 
Non-recombinant plaques 38 151 3 1 23 131 4 0 
Plaque forming units (per 
µl) 
2070 2030 2100 1900 2160 2110 2350 1600 
Two sets of four plates were prepared with the use of two random aliquots of the amplified cDNA library – 
aliquot A (plates 1A to 4A) and aliquot B (plates 1B to 4B). Following overnight incubation the plaques 
were counted and the total amount of plaques was used to determine the pfu per µl, taking under account the 
appropriate dilution factor. Dilution of the cDNA library was applied to avoid overgrowth and to allow 
accurate counting of plaques. The average pfu per µl was determined to be 2040 (The sum of all pfu divided 
by eight plates). The titer of the amplified library had been increased in comparison with the titer prior to 
amplification.  
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3.2.3  Confirming the recombinancy of the amplified cDNA library  
Recombinant plaques were selected at random from four NZY plates (Figure 3.4) and used as 
templates for a PCR. The products were analysed on a 1% Agarose gel (each sample mixed with 
loading buffer 1:6). 
 
 
Figure 3.4 Selecting plaques from NZY plate at random for PCR to 
determine the range of cDNA inserts in the library. Each recombinant 
plaque was isolated with the use of a sterile glass Pasteur pipette and placed 
in the PCR mixture to serve as a template. The blue colour represents 
plaques containing non-recombinant phages (reaction of X-gal). 
 
After eighty minutes at 90V, the 1% agarose gels containing the PCR samples were analysed under 
UV light. Images demonstrated that the randomly selected plaques contained cDNA inserts of 
different sizes and the library could now be aliquoted in smaller quantities and used for SEREX. The 
remaining cDNA testis library was processed as described before and stored at -80˚C for future use. 
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A               B 
              
            
Figure 3.5 PCR analysis of the cDNA insert sizes in the testes cDNA library used for 
immunoscreening. Sample lanes 1 to 11 (A) and samples 12 to 22 (B) represent the amplified 
cDNA inserts from twenty two randomly selected plaques as amplified using the T3 and T7 
primer pair. The ladder used was HyperLadder I. The last two lanes on each gel were loaded 
with a positive control – GTK-AML-8 (a cDNA insert described in Guinn et al, 2002 contained 
within the Invitrogen pBK-CMV plasmid) and a PCR reaction containing no template serves as a 
negative control. The bands were bright and clear, however some of the lanes contained 
secondary, faint bands which could be due to contamination which may have taken place during 
the isolation of the individual plaques. It could also be due to the close proximity of the plaques 
within the NZY agar. 
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CHAPTER 4   Results:  Second round of 
immunoscreening following the 
SEREX technique 
 
4.1 Secndary immunoscreening 
Second round of primary immunoscreening was carried out as outlined in section 2.4. A detailed 
table of results can be found in Appendix II.  
Three different patient sera were used throughout the primary immunoscreening of cDNA testis 
library with SEREX (Table 4.1). These were: CC005 (at 1:2000 and 1:200 dilutions), CC010 (at 
1:200 dilution) and CC014 (at 1:200 dilution) and were all obtained from patients diagnosed with 
reactive CRC. 
  
Table 4.1 Primary immunoscreening of testis cDNA library with SEREX.  
Time frame Serum ID: 
No. of plaques 
screened 
No. of potential 
positive plaques 
cored out 
No. of confirmed 
positive plaques 
identified with that 
serum 
29.1.2013 - 
19.7.2013 
CC005 340,044 60 1 
CC010 190,612 10 0 
CC014 290,988 84 14 
Total No. of plaques: 821,644 154 15 
Summary of the results obtained from primary immunoscreening with SEREX. With the aid of three sera 
(CC005, CC010 and CC014), 821 644 plaques were screened in total from a cDNA testis library in the 
course of six months. 
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4.2 Secondary immunoscreening with SEREX 
Second round of secondary immunoscreening was carried out as outlined in section 2.5.  
During primary immunoscreening with SEREX, there were 154 potential positive plaques that were 
cored out and stored for further investigations. Most of them (116 plaques) were used in secondary 
immunoscreening and fifteen of them were confirmed as immunoreactive plaques, containing a 
cDNA fragment that was capable of eliciting immune response (UOB-COL-1 to UOB-COL-15) 
(Table 4.2). Five of these antigens elicited immune response in two of the sera used (CC005 and 
CC014) and their sequence was mapped to four different genes: IGHG3, IGHG2, CYB5R3, 
RPL37A and SLC34A2 (as detailed in Results Section 5). 
Following several uses of the sera and also optimisation of the reaction, the background noise on 
the membranes was significantly reduced. The more the sera were used, the easier it was to 
differentiate the positive from the negative plaques. Some of the immunoreactive plaques, identified 
through primary and secondary immunoscreening had a particularly definitive appearance (Figure 
4.1). 
It should be noted that some of the positive plaques that are recognised through primary or 
secondary immunoscreening do not appear as a clear spot on the membrane but rather as a darker 
ring surrounding a plaque that is negative in appearance. These should not be disregarded and 
should be isolated and confirmed through secondary immunoscreening.  
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Table 4.2 Secondary immunoscreening – confirmed antigens.  
Name Plaque ID 
Serum 
identifi
ed with: 
Confirmed 
with: 
Confirmation 
date 
Copies 
Identified as (see 
section 5.1): 
UOB-COL-1 060213-2-1 CC014 
CC014 19/02/2013 3 IGHG3 gene 
CC005 19/02/2013 3 IGHG3 gene 
UOB-COL-2 190213-5-1 CC014 CC014 28/02/2013 3 IGHG2 gene 
UOB-COL-3 050313-5-5 CC014 
CC005 14/03/2013 3 UNIDENTIFIED 
CC005 27/04/2013 4 UNIDENTIFIED 
UOB-COL-4 050313-6-1 CC014 
CC005 21/03/2013 3 
CYB5R3 gene CC014 07/04/2013 3 
CC005 29/04/2013 4 
UOB-COL-5 050313-6-8 CC014 
CC005 21/03/2013 3 UNIDENTIFIED 
CC014 29/04/2013 3 SLC34A2 gene 
CC005 29/04/2013 5 UNIDENTIFIED 
UOB-COL-6 050313-6-6 CC014 
CC005 21/03/2013 3 
UNIDENTIFIED 
CC014 07/04/2013 3 
UOB-COL-7 050313-7-6 CC014 CC005 21/03/2013 3 UNIDENTIFIED 
UOB-COL-8 190213-3-1 CC005 CC005 07/04/2013 8 UNIDENTIFIED 
UOB-COL-9 050313-7-1 CC014 CC005 11/04/2013 5 UNIDENTIFIED 
UOB-COL-10 050313-6-9 CC014 CC005 11/04/2013 5 UNIDENTIFIED 
UOB-COL-11 050313-5-3 CC014 CC005 11/04/2013 5 RPL37A gene 
UOB-COL-12 050313-6-7 CC014 CC005 11/04/2013 5 UNIDENTIFIED 
UOB-COL-13 050313-7-5 CC014 CC005 11/04/2013 5 UNIDENTIFIED 
UOB-COL-14 050313-4-5 CC014 CC005 14/06/2013 3 UNIDENTIFIED 
UOB-COL-15 050313-5-2 CC014 CC005 14/06/2013 3 UNIDENTIFIED 
Outline of the antigens, confirmed through secondary immunoscreening with SEREX and the outcome of 
their sequencing. UOB-COL-1 and UOB-COL-2 appear to have similar properties and map to the same gene 
IGHG2 (also a copy of UOB-COL-1 confirmed with CC014 is mapped to IGHG3 gene). The sequence 
encoded by the cDNA of UOB-COL-4 appeared to be part of CYB5R3 gene and the one belonging to UOB-
COL-11 – part of RPL37A. Also, the sequence belonging to UOB-COL-5 appeared to be part of the 
SLC34A2 gene. 
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Figure 4.1 UOB-COL-1 and UOB-COL-2 in primary and secondary immunoscreening with 
SEREX. (A) The primary identification of a positive plaque with CC014 (arrow on A), which was isolated 
and labelled as 060213-2-1 (the date – 06.02.13; the membrane number – 2; the plaque number – 1). (B) The 
same plaque was then rescreened via secondary immunoscreening with SEREX and was confirmed to be 
immunoreactive as it was recognised by CC014 (arrows on B.). Three of these positive plaques were isolated 
and labelled as UOB-COL-1-c1 to c3 (UOB-COL-1 – name of the antigen; c1 – plaque number). (C) The 
primary identification of a positive plaque with CC014 (arrow on C.), which was isolated and labelled 
190213-5-1 (date; membrane number; plaque number). (D) The same plaque was them rescreened via 
secondary immunoscreening with SEREX and was confirmed to be immunoreactive as it was recognised by 
CC014 (arrows on D.). Three of these plaques were isolated and labelled as UOB-COL-2-c1 to c3 (name of 
antigen; plaque number). 
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4.3 Tertiary immunoscreening with SEREX 
Tertiary immunoscreening was carried out as outlined in section 2.7.  As the sera obtained from 
patients with immunoreactive CRC (CC005, CC010 and CC014) that were used in SEREX were now 
a few months old, the results obtained from tertiary immunoscreening were inconclusive. Further 
investigations and a repeat of tertiary immunoscreening should be carried out. The results from the 
tertiary immunoscreening of confirmed antigens with CRC sera (CC005, CC010 and CC014) are 
shown in Figure 4.2 and sera from eight healthy volunteers as shown in Figure 4.3 are summarised 
in Table 4.3. 
 
 
Figure 4.2 Tertiary immunoscreening of UOB-COL-1 to UOB-COL-15 with CRC sera. Each 
membrane contains protein products, produced by cDNA phage belonging to antigens UOB-COL-1 to UOB-
COL-15. The two spots in the middle of each section represent negative controls 
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Figure 4.3 Tertiary screening of UOB-COL-1 to UOB-COL-15 with healthy volunteer sera. Each 
membrane contains protein products, produced by cDNA phage belonging to antigens UOB-COL-1 to UOB-
COL-15. The two spots in the middle of each section represent negative controls. Membranes were treated with 
8 different sera obtained from healthy volunteers. 
 
Table 4.3 Summary of results from tertiary immunoscreening of each cDNA with sera from Dukes’ B 
reactive and non-reactive patients and healthy donors. 
 
Antigen id/name 
Dukes B reactive patients Healthy donors (n=8) 
CC005 CC010 CC014  
UOB-COL-1 
IGHG3 √ - √ 
Recognised by HV-2; 3, 
5, 6, 7, 8 
UOB-COL-2 
IGHG2 - - √ Not recognised  
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UOB-COL-3 
Unidentified √ - √ 
Recognised by HV-2, 5, 
6, 7, 8. 
UOB-COL-4 
CYB5R3 gene √ - √ 
Recognised by HV-2, 3, 
4, 5, 6, 7, 8. 
UOB-COL-5 
SLC34A2 √ - √ Recognised by all 
UOB-COL-6 
Unidentified √ - √ 
Recognised by HV-1, 2, 
3, 5, 6, 7, 8 
UOB-COL-7 
Unidentified √ - √ 
Recognised by HV-1, 2, 
3, 5, 6, 7, 8 
UOB-COL-8 
Unidentified √ - - 
Recognised by HV-2, 4, 
5, 6, 7, 8 
UOB-COL-9 
Unidentified √ - √ Not recognised 
UOB-COL-10 
Unidentified √ - √ 
Recognised by HV- 3 
and 4 
UOB-COL-11 
RPL37A √ - √ 
Recognised by HV-2, 3, 
5, 6, 7, 8 
UOB-COL-12 
Unidentified √ - √ Recognised by all. 
UOB-COL-13 
Unidentified √ - √ Recognised by all 
UOB-COL-14 
Unidentified √ - √ Recognised by all 
UOB-COL-15 
Unidentified √ - √ Recognised by all 
Total number of antigens 
recognised 14/15 0/15 14/15  
 
81 
 
 
Figure 4.4 UOB-COL-1 to UOB-COL-7 analysed via PCR. (A) and (B) 1% agarose gels as seen 
under UV light loaded with the products of a PCR reaction. The products are amplified cDNA inserts 
contained within the isolated copies of the seven confirmed immunoreactive plaques to that date. The gel was 
run to confirm the presence of inserts within the positive phage and also the size of the insert itself. Products 
of UOB-COL-1 and UOB-COL-2 seemed to be of a similar size. UC1* - refers to UOB-COL-1 (original stock 
isolated from primary screening. UC1c1* refers to UOB-COL-1, copy (plaque) 1 and so on. 
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CHAPTER 5   Results: Sequencing and antigen 
identification 
 
5.1 PCR of confirmed antigens and preparation for sequencing 
The immunoreactive cDNA inserts were amplified and isolated via PCR. The products were gel 
cleaned and the quality and quantity of the isolated DNA were analysed with Nanodrop 2000. The 
products were then processed as described in section 2.8 (Material and Methods) and sent off for 
sequencing. First lot of antigens (UOB-COL-1 to UOB-COL-5) as seen in Figure 5.1: 
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Figure 5.1 PCR of UOB-COL-1 to UOB-COL-5 in preparation for sequencing. PCR products are 
loaded on a 1% agarose gel. Following observation, the required bands were cut out of the gel and placed in 
1.5ml sterile eppendorf tubes to undergo gel clean up and nanodrop reading prior to being sent for 
sequencing. 
 
After the samples were isolated from the gel and cleaned up, a Nanodrop analisys was carried out to 
confirm the quantity and the quality of the DNA within each sample (Table 5.1). 
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Table 5.1 Nanodrop readings for products of UOB-COL-1 to UOB-COL-5 
Sample ID Date 
Nucleic 
Acid 
Conc. 
Unit A260 A280 
260/ 
280 
260/ 
230 
Sample 
Type 
Factor 
Blank 10/06/13 0.1 ng/µl 0.003 0.012 0.24 0.19 DNA 50 
1 UC1-1 14 10/06/13 3 ng/µl 0.059 0.036 1.64 0.03 DNA 50 
2 UC1-2 14 10/06/13 4 ng/µl 0.079 0.05 1.58 0.02 DNA 50 
3 UC1-3 14 10/06/13 6 ng/µl 0.119 0.079 1.51 0.06 DNA 50 
4 UC1-3 14 10/06/13 2.1 ng/µl 0.042 0.022 1.91 0.02 DNA 50 
6 UC1-3 05 10/06/13 5.1 ng/µl 0.101 0.069 1.48 0.05 DNA 50 
7 UC2-1 14 10/06/13 2.7 ng/µl 0.054 0.019 2.81 0.02 DNA 50 
8 UC2-2 14 10/06/13 5.2 ng/µl 0.104 0.061 1.71 0.02 DNA 50 
9 UC2-3 014 10/06/13 5.2 ng/µl 0.104 0.058 1.79 0.03 DNA 50 
12 UC3-1 05 10/06/13 4 ng/µl 0.079 0.044 1.8 0.02 DNA 50 
13 UC3-1 NEW 05 10/06/13 2 ng/µl 0.039 0.018 2.17 0.01 DNA 50 
15 UC3-3 NEW 05 10/06/13 4 ng/µl 0.081 0.054 1.5 0.02 DNA 50 
17 UC4-1 05 10/06/13 5.6 ng/µl 0.113 0.065 1.74 0.06 DNA 50 
18 UC4-2 05 10/06/13 3.2 ng/µl 0.063 0.04 1.58 0.02 DNA 50 
19UC4-3 05 10/06/13 3 ng/µl 0.06 0.032 1.87 0.01 DNA 50 
21 UC4-2 014 BIG 10/06/13 3.2 ng/µl 0.064 0.035 1.83 0.02 DNA 50 
21 UC4-2 014 SM 10/06/13 3.6 ng/µl 0.072 0.034 2.15 0.03 DNA 50 
22 UC4-3 014 MID 10/06/13 3.8 ng/µl 0.075 0.044 1.71 0.02 DNA 50 
25 UC4-3 05 NEW MID 10/06/13 4.5 ng/µl 0.09 0.054 1.65 0.03 DNA 50 
29 UC5-3 05 BIG 10/06/13 2.5 ng/µl 0.049 0.033 1.51 0.02 DNA 50 
29 UC5-3 05 SM 10/06/13 3.2 ng/µl 0.063 0.043 1.47 0.02 DNA 50 
30 UC5-1 NEW 05 10/06/13 3.3 ng/µl 0.065 0.03 2.17 0.02 DNA 50 
31 UC5-2 NEW BIG 10/06/13 4.4 ng/µl 0.089 0.051 1.73 0.03 DNA 50 
31 UC5-2 NEW SM 10/06/13 3.8 ng/µl 0.076 0.052 1.45 0.04 DNA 50 
32 UC5-3 NEW BIG 10/06/13 3.4 ng/µl 0.067 0.045 1.51 0.03 DNA 50 
 
 
The desired samples were processed as described in section 2.8 and send off for sequencing.  The 
concentration of DNA within the samples was lower than expected and it was difficult to process 
most of the samples for sequencing. The following time, PCR samples are to be used as templates 
for a secondary PCR reaction to attempt to increase the concentration of DNA within each sample.  
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Figure 5.2 PCR of UOB-COL-6 to UOB-COL-9. PCR products are loaded on a 1% agarose gel. 
Following observation, the required bands were cut out of the gel and placed in 1.5ml sterile eppendorf tubes 
to undergo gel clean up and nanodrop reading prior to being sent for sequencing. 
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Table 5.2 Nanodrop readings of UOB-COL-6 to UOB-COL-9.  
Sample ID Date 
Nucleic 
Acid 
Conc. 
Unit A260 A280 
260/ 
280 
260/ 
230 
Sample 
Type 
Factor 
Blank 10/06/13 0.1 ng/µl 0.003 0.016 0.19 0.35 DNA 50 
3 UC6-3 05 10/06/13 6.8 ng/µl 0.136 0.089 1.53 0.06 DNA 50 
4 UC6-1 014 10/06/13 8.5 ng/µl 0.17 0.096 1.77 0.02 DNA 50 
5 UC6-2 014 10/06/13 13.7 ng/µl 0.275 0.149 1.85 0.03 DNA 50 
7 UC7-1 05 10/06/13 6.7 ng/µl 0.133 0.079 1.69 0.03 DNA 50 
8 UC7-2 05 10/06/13 6.8 ng/µl 0.137 0.073 1.87 0.02 DNA 50 
12 UC8-3 05 10/06/13 6.1 ng/µl 0.123 0.062 1.98 0.01 DNA 50 
13 UC8-4 05 10/06/13 7.8 ng/µl 0.155 0.085 1.82 0.02 DNA 50 
16 UC8-7 05 10/06/13 11.8 ng/µl 0.236 0.147 1.6 0.05 DNA 50 
18 UC9-2 05 10/06/13 6.8 ng/µl 0.136 0.083 1.64 0.05 DNA 50 
21 UC9-5 05 10/06/13 9.2 ng/µl 0.184 0.109 1.69 0.03 DNA 50 
Products were analysed on a 1% agarose gel. Selected bands were cut out, gel cleaned and processed further for 
sequencing. 
 
The desired samples were processed and send off for sequencing. The concentration of cDNA qas 
fairly improved in comparison to the data shown in Table 5.1. However, further improvements 
need to take place to increase the product yield following PCR and gel clean up. 
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Figure 5.3 PCR of UOB-COL-9 to UOB-COL-15. Products were analysed on a 1% agarose gel. 
Selected bands were cut out, gel cleaned and processed further for sequencing. Most of the products were 
small (around 100bp) which was inconclusive of whether this is the size of the product or a remaining of 
unused primers. Selected samples were isolated and analysed with a Nanodrop. 
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Table 5.3 Nanodrop readings for products of UOB-COL-9 to UOB-COL-15 
Sample ID Date 
Nucleic 
Acid 
Conc. 
Unit A260 A280 260/280 260/230 
Sample 
Type 
Factor 
blank 05/08/13 0.2 ng/µl 0.004 0.01 0.43 -0.41 DNA 50 
5 UC9c3 005 05/08/13 1.5 ng/µl 0.03 0.015 1.96 0.01 DNA 50 
14 UC11c2 005 05/08/13 5.8 ng/µl 0.117 0.061 1.93 0.03 DNA 50 
16 UC11c4 005 05/08/13 1.5 ng/µl 0.03 0.018 1.65 0.01 DNA 50 
22 UC12c5 005 05/08/13 1.7 ng/µl 0.034 0.029 1.17 0.03 DNA 50 
28 UC14c1 005 05/08/13 2.6 ng/µl 0.052 0.038 1.37 0.03 DNA 50 
30 UC14c3 005 05/08/13 3.9 ng/µl 0.077 0.042 1.86 0.02 DNA 50 
32 UC15c3 005 05/08/13 4.3 ng/µl 0.085 0.052 1.64 0.03 DNA 50 
 
Results of sequencing were analysed and interpretations made appropriately (Section 5.2). 
 
5.2 Sequencing and sequence interpretations 
The sequences of the analysed cDNAs were analysed as described in Section 2.8. This analysis led 
to the following findings: 
 
5.2.1 IGHG3 gene  
 
Gene Description:       IGHG3; Immunoglobulin heavy constant gamma 3 (G3m marker) located 
on chromosome 14 (Image 3.1). 
Location:     Chromosome 14: 106,235,439-106,237,742 reverse strand. 
Transcripts:     This gene has one transcript (splice variant). 
Gene type:     Known IG C gene. 
Prediction method: Immunoglobulin (Ig) and T-cell receptor (TcR) annotation imported from 
the manually curated IG gene set from the Havana project. (It corresponds 
to Havana gene OTTHUMG00000152539 (version 1)). 
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5.2.1.1     UOB-COL-1 clone 1 (serum CC014) identified as a transcript of IGHG3 gene  
Sequence fragment used for identification (T3 primer reading): 
CTNCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGGCTGCAGGAATTCGGCACGAGGGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCT
ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGACCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC
AAGACAGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCG
GACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCATGGAGGTGCATAATGCCAAGACAAAGCCACGGGA
GGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACGGNAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCNCC
ATCGAGAAAACCATCTCCAAAANCAAAGGGCAGCCCCGAGAACCACAGGTGTACANCCTGCCCCCATTCCGGGAGGAGATGACNAATAACCATNTCAGCCTGANTTTACCTGGT
NAAAGGNTTTNTACNCNNANCAACATTATTNTTGTANTNGGAGAGTAATTTGGCAATTNNTTAAATAATTATANATNANTACAANCTCTAA 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome: 14:106235693:106236607-1 
CTCCAGCTCAAGGCGGGACAAGAGCCCTAGAGTGGCCTGAGTCCAGGGACAGGCCCCAGCAGGGTGCTGACGCATCCACCTCCATCCC
AGATCCCCGTAACTCCCAATCTTCTCTCTGCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCAAGGTGCCCAGGTAAGCCAGCCC
AGGCCTCGCCCTCCAGCTCAAGGCAGGACAGGTGCCCTAGAGTGGCCTGCATCCAGGGACAGGTCCCAGTCGGGTGCTGACACATCTGC
CTCCATCTCTTCCTCAGCACCTGAACTCCTGGGAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGATACCCTTATGATTTC
CCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAAGTGGTACGTGGACGGCG
TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCCTG
CACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC
CAAAACCAAAGGTGGGACCCGCGGGGTATGAGGGCCACATGGACAGAGGCCAGCTTGACCCACCCTCTGCCCTGGGAGTGACCGCTGT
GCCAACCTCTGTCCCTACAGGACAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAGCGGGCAGCCGGAGAACAACTA
CAACACCACGCCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       290 to 604 (-) 
Database location:  14      106235993 to 106236307 (+) 
Genomic location:  14      106235993 to 106236307 (+) 
Alignment score:  1499 
E-value:   1.1e-257 
Alignment length:  315 
Percentage identity:  96.19% 
 
5.2.1.2     UOB-COL-1 clone 3 (serum CC014) identified as a transcript of IGHG3 gene 
 
Sequence fragment used for identification (T3 primer reading): 
TAACTCCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGAATTCGGCACGAGGGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTAC
AGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGACCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAC
AGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCATGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCA
ACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCAT
CTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAANAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGNTTC 
 
90 
 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 14:106235693:106236607-1 
CTCCAGCTCAAGGCGGGACAAGAGCCCTAGAGTGGCCTGAGTCCAGGGACAGGCCCCAGCAGGGTGCTGACGCATCCACCTCCATCCC
AGATCCCCGTAACTCCCAATCTTCTCTCTGCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCAAGGTGCCCAGGTAAGCCAGCCC
AGGCCTCGCCCTCCAGCTCAAGGCAGGACAGGTGCCCTAGAGTGGCCTGCATCCAGGGACAGGTCCCAGTCGGGTGCTGACACATCTGC
CTCCATCTCTTCCTCAGCACCTGAACTCCTGGGAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGATACCCTTATGATTTC
CCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAAGTGGTACGTGGACGGCG
TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCCTG
CACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC
CAAAACCAAAGGTGGGACCCGCGGGGTATGAGGGCCACATGGACAGAGGCCAGCTTGACCCACCCTCTGCCCTGGGAGTGACCGCTGT
GCCAACCTCTGTCCCTACAGGACAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAGCGGGCAGCCGGAGAACAACTA
CAACACCACGCCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       292 to 606 (-) 
Database location:  14      106235993 to 106236307 (+) 
Genomic location:  14      106235993 to 106236307 (+) 
Alignment score:  1515 
E-value:   1.7e-260 
Alignment length:  315 
Percentage identity:  97.14% 
 
 
5.2.1.3     UOB-COL-1 clone 3 (serum CC005) identified as transcript of IGHG3 gene  
 
Sequence fragment used for identification (T3 primer reading): 
GGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGAATTCGGCACGAGGGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGG
ACTCTACTCCCTCAGCAGCGTGGTGACCGTGACCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGC
GCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCAC
GTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCATGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGC
ACGTTCCGTGTGGTCAGCGTCCTCACCGTCNTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCATCTCN
AAAACCAAAGGGNAGCCCCTANAACCACA 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 14:106235693:106236607:-1 
CTCCAGCTCAAGGCGGGACAAGAGCCCTAGAGTGGCCTGAGTCCAGGGACAGGCCCCAGCAGGGTGCTGACGCATCCACCTCCATCCC
AGATCCCCGTAACTCCCAATCTTCTCTCTGCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCAAGGTGCCCAGGTAAGCCAGCCC
AGGCCTCGCCCTCCAGCTCAAGGCAGGACAGGTGCCCTAGAGTGGCCTGCATCCAGGGACAGGTCCCAGTCGGGTGCTGACACATCTGC
CTCCATCTCTTCCTCAGCACCTGAACTCCTGGGAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGATACCCTTATGATTTC
CCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAAGTGGTACGTGGACGGCG
TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCCTG
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CACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC
CAAAACCAAAGGTGGGACCCGCGGGGTATGAGGGCCACATGGACAGAGGCCAGCTTGACCCACCCTCTGCCCTGGGAGTGACCGCTGT
GCCAACCTCTGTCCCTACAGGACAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAGCGGGCAGCCGGAGAACAACTACAACA
CCACGCCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA 
 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       280 to 594 (-) 
Database location:  14      106235993 to 106236307 (+) 
Genomic location:  14      106235993 to 106236307 (+) 
Alignment score:  1516 
E-value:   1.0e-260 
Alignment length:  315 
Percentage identity:  96.83% 
 
 
 
5.2.2 IGHG2 gene  
 
Gene Description:       IGHG2; Immunoglobulin heavy constant gamma 2 (G2m marker) located on 
chromosome 14. 
Location:     Chromosome 14: 106,109,389-106,111,127 reverse strand. 
Transcripts:     This gene has one transcript (splice variant)  
Gene type:     Known IG C gene. 
Prediction method:     Immunoglobulin (Ig) and T-cell receptor (TcR) annotation imported from the 
manually curated IG gene set from the Havana project. (It corresponds to 
Havana gene OTTHUMG00000152482). 
 
5.2.2.1   UOB-COL-2 clone 1 (serum CC014) identified as a transcript of IGHG2 gene  
 
Sequence fragment used for identification (T3 primer reading): 
AAGTCCGCGGNGGCGGCCGCTCTAGACTGTGGATCCCCCGGGCTGCAGGAATTCGGCACGAGGGTGGNANTTAGGNGCTCTGACCAGCGGCGTGCACACCATTCCCGGCTGTCNTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGACCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAG
ACAGTTGAGCGCAAATGTTGTGTCAAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGNCAGTCTTCCTCTTCCCCTCAAAACCCAAGGACACCCTCATGATCTCCCNGACC
CCNGAGGTCNCGTGCNTGNTGGTGAANAGNGAGANNACAAA 
 
Fragment matched on Ensemble Genome Browser: 
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>chromosome 14:106110533:106111299:-1 
GGAGGGGGCTAAGGTGACGCAGGTGGCGCCAGCCAGGTGCACACCCAATGCCCGTGAGCCCAGACACTGGACCCTGCCTGGACCCTC
GCAGATAGACAAGAACCGAGGGGCCTCTGCGCCCTGGGCCCAGCTCTGTCCCACACCGCGGTCACATGGCACCACCTCTCTTGCAGCC
TCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGGGCCCTGGGCTGCCTGGTCAAGGA
CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCA
CAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGGTGAGAGGCCAGCTCAGGGAGGGAGGGTGTCTGCTGGAAGCCAGGCTCA
GCCCTCCTGCCTGGACGCACCCCGGCTGTGCAGCCCCAGCCCAGGGCAGCAAGGCAGGCCCCATCTGTCTCCTCACCCGGAGGCCTCT
GCCCGCCCCACTCATGCTCAGGGAGAGGGTCTTCTGGCTTTTTCCACCAGGCTCCAGGCAGGCACAGGCTGGGTGCCCCTACCCCAGG
CCCTTCACACACAGGGGCAGGTGCTTGGCTCAGACCTGCCAAAAGCCATATCCGGGAGGACCCTGCCCCTGACCT 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       73 to 240 (-) 
Database location:  14      106110833 to 106110999 (+) 
Genomic location:  14      106110833 to 106110999 (+) 
Alignment score:  803 
E-value:   5.9e-134 
Alignment length:  168 
Percentage identity:  97.62% 
 
5.2.2.2   UOB-COL-2 clone 2 (serum CC014) identified as transcript of IGHG2 gene  
Sequence fragment used for identification (T3 primer reading): 
GCAGGAATTCGGCACGAGGGTGGANCTCATGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGACCT
CCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCA
CCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACNAAGACCCC
GAGGTCCAGTTCAACTGGTACGTGGACGGCATGGAGGTGCATAATGNCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCA
CCATGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAANNATCTCCAAAACCAAAGGGCNNNCCCGAGAANCACAGGTG
TACACCCTGNCCCNATCCCGGGAGGANATNACNAGGAACCATGTCANNNTGANNTGCNTGGTCNANGGCNTCTACCCCAGTNGACNTCCTCNTGGANNGNTACAGCAATGGGAAGT
TTGG 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 14: 106109660:106110586:-1 
TGCTTGGCTCAGACCTGCCAAAAGCCATATCCGGGAGGACCCTGCCCCTGACCTAAGCCGACCCCAAAGGCCAAACTGTCCACTCCCT
CAGCTCGGACACCTTCTCTCCTCCCAGATCCGAGTAACTCCCAATCTTCTCTCTGCAGAGCGCAAATGTTGTGTCGAGTGCCCACCG
TGCCCAGGTAAGCCAGCCCAGGCCTCGCCCTCCAGCTCAAGGCGGGACAGGTGCCCTAGAGTAGCCTGCATCCAGGGACAGACCCCA
GCTGGGTGCTGACACGTCCACCTCCATCTCTTCCTCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCA
AGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTT
CAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTG
GTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAG
CCCCCATCGAGAAAACCATCTCCAAAACCAAAGGTGGGACCCGCGGGGTATGAGGGCCACATGGACAGAGGCCGGCTCGGCCCACC
CTCTGCCCTGGGAGTGACCGCTGTGCCAACCTCTGTCCCTACAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCC
GGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCTCCGTGGAGTGGGAGA
GCAATGGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGC 
 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
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Alignment information: 
Query location:  unnamed       232 to 558 (-) 
Database location:  14      106109960 to 106110286 (+) 
Genomic location:  14      106109960 to 106110286 (+) 
Alignment score:  1618 
E-value:   9.2e-279 
Alignment length:  327 
Percentage identity:  98.17% 
 
 
 
 
5.2.3 CYB5R3 gene  
Gene Description:       CYB5R3; Cytochrome b5 reductase 3 located on Chromosome 22 
Location:     Chromosome 22: 43,013,846-43,045,574 reverse strand. 
Transcripts:     This gene has nine transcripts (splice variants) 
Gene type:     Known protein coding. 
Prediction method:  Annotation for this gene includes both automatic one from Ensembl and a 
Havana manual curation. It corresponds to Havana gene 
OTTHUMG00000150745 (version 5). 
 
5.2.3.1   UOB-COL-4 clone 1 (serum CC005) identified as transcript of CYB5R3 gene  
Sequence fragment used for identification (T3 primer reading): 
CGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGAATTCGGCACGAGGCATCCCTGATGGCAGAACTCCCACAACCACATGTATTTATTCCTCTGCTCCTAAACC
GTCCCCTCCTTCCCTCACCCCCAGCACAGGGGGATTCTGAGCAGTGCCTCTTGTCTGAGGGACATATCAGTGACCTCGACGTTGCCTTTAGACTACAGTTGTGTTAGCCTCTTGCGTAT
TGGCTTTTTCAGAGTCATTTATGAGCAAAAAAAAAAAAAAAAA 
 
 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 22:43014540:43015353:-1 
GTCACCCCCACTCCCGCCTCAGGGCCAGGCCCAGGCCTCACCACCTGACGCTGCATGAGACATTGACACCAGAAAGCCCTCTTGGGG
GCACTGCTCCCTACCCCAGGGCCCTGGCCAGCCGGGAGCTTGGCTCTCCTCTGGCTAGAGTGGGAAGAGGGGGCTGGCCATGGGGCC
CTCCCAGAACCTCAGCATTTCCTTCCAGCCCATCCAAACACTGAGGCAGCCTTGGGGAACCCCGAGCTGGGGGGTTGGCAGCCCACTG
CACCGCCTCAGGGTTTTGGGGTCCTGGGCTGGGGCCACCATCCCTGATGGCAGAACTCCCACAACCACATGTATTTATTCCTCTGT
CCTAAACCGTCCCCTCCTTCCCTCACCCCCAGCACAGGGGGATTCTGAGCAGTGCCTCTTGTCTGAGGGACATATCAGTGACC
TCGACGTTGCCTTTAGACTACAGTTGTGTTAGCCTCTTGCGTATTGGCTTTTTCAGAGTCATTTATGAGCAGAAAAAAAAAAAG
TAAAACTTTGCTAATATTAACCCTTCTCTAGCTCCTCGAGGGTCTGTGACCTGCAACACAAGGGGTGGGGTCAGGAAAGGGCTGGGGA
AGACCTAGCATTTTTTTTTTCTTTTTTTTTTTTTTTTGAGACGGAGTCTCCCTTTGTCACCCAGGCTGGAGTGGCATGATCTCAGCTCACT
ACAACCTCCACCTCTCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTAAAAGTGCCCACCACCACACCCAGCT
AGTTTTTGTATTTTTTTTTTTTTTTTTTTGAG 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
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*THIS STYLE: Location of Exons 
 
 
Alignment information: 
Query location:  unnamed       61 to 275 (-) 
Database location:  22      43014840 to 43015053 (+) 
Genomic location:  22      43014840 to 43015053 (+) 
Alignment score:  1043 
E-value:   1.1e-176 
Alignment length:  215 
Percentage identity:  99.07% 
 
5.2.3.2   UOB-COL-4 clone 3 new (serum CC005) identified as transcript of CYB5R3 gene  
Sequence fragment used for identification (T3 primer reading): 
GGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGNCTGCAGGAATTCGGCACGAGGCATCCCTGATGGCANAACTCCCACAACCACATGTATTTATTCCTCTGCTCCTAAACCGTCCC
CTCCTNCCCTCACCCCCAGCACAGGGGGATTCTGAGCAGTGCCTCTTGTCTGAGGGACATATCAGTGACCTCGACGTTGCCTTTAGACTACAGTTGTGTTAGCCTCTTGCGTATTGGCT
TTTTCAGAGTCATTTATGAGCAAAAAAAAAAAAAAAA 
 
 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 22:43014540:43015353:-1 
GTCACCCCCACTCCCGCCTCAGGGCCAGGCCCAGGCCTCACCACCTGACGCTGCATGAGACATTGACACCAGAAAGCCCTCTTGGGG
GCACTGCTCCCTACCCCAGGGCCCTGGCCAGCCGGGAGCTTGGCTCTCCTCTGGCTAGAGTGGGAAGAGGGGGCTGGCCATGGGGCC
CTCCCAGAACCTCAGCATTTCCTTCCAGCCCATCCAAACACTGAGGCAGCCTTGGGGAACCCCGAGCTGGGGGGTTGGCAGCCCACTG
CACCGCCTCAGGGTTTTGGGGTCCTGGGCTGGGGCCACCATCCCTGATGGCAGAACTCCCACAACCACATGTATTTATTCCTCTGT
CCTAAACCGTCCCCTCCTTCCCTCACCCCCAGCACAGGGGGATTCTGAGCAGTGCCTCTTGTCTGAGGGACATATCAGTGACC
TCGACGTTGCCTTTAGACTACAGTTGTGTTAGCCTCTTGCGTATTGGCTTTTTCAGAGTCATTTATGAGCAGAAAAAAAAAAAG
TAAAACTTTGCTAATATTAACCCTTCTCTAGCTCCTCGAGGGTCTGTGACCTGCAACACAAGGGGTGGGGTCAGGAAAGGGCTGGGGA
AGACCTAGCATTTTTTTTTTCTTTTTTTTTTTTTTTTGAGACGGAGTCTCCCTTTGTCACCCAGGCTGGAGTGGCATGATCTCAGCTCACT
ACAACCTCCACCTCTCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTAAAAGTGCCCACCACCACACCCAGCT
AGTTTTTGTATTTTTTTTTTTTTTTTTTTGAG 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       56 to 270 (-) 
Database location:  22      43014840 to 43015053 (+) 
Genomic location:  22      43014840 to 43015053 (+) 
Alignment score:  1033 
E-value:   16.9e-175 
Alignment length:  215 
Percentage identity:  98.14% 
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5.2.4 RPL37A gene  
Gene Description:     Ribosomal protein L37a located on Chromosome 2. 
Location:     Chromosome 2: 217,362,912-217,443,903 forward strand. 
Transcripts:  This gene has twelve transcripts (splice variants). 
Gene type:     Known protein coding. 
Prediction method:     Annotation for this gene includes both automatic one from Ensembl and a 
Havana manual curation. It corresponds to Havana gene 
OTTHUMG00000133052 (version 4). 
 
5.2.4.1   UOB-COL-11 clone 2 (serum CC005) identified as transcript of RPL37A gene  
Sequence fragment used for identification (T3 primer reading): 
CGCGGTGGCGGCCGCTCTAGAAACTAGTTGGATCCCCCGGGGCTGCAGGAATTCGGCACGAGGCTAGGTCGCGGCGACATGGCCAAACGTACCAAGAAAGTCGGGATCGTCGGTAA
ATACGGGACCCGCTATGGGGCCTCCCTCCGGAAAATGGTGAAGAAAATTGAAATCAGCCAGCACGCCAAGTACACTTGCTCTTTCTGTGGCAAAACCAAGATGAAGAGACGAGCTG
TGGGGATCTGGCACTGTGGTTCCTGCATGAAGACAGTGGCTGGCGGTGCCTGGACGTACAATACCACTTCCGCTGTCACGGTAAAGTCCGCCATCAGAAGACTGAAGGAGTTGAAAG
ACCAGTAGACGCTCCTCTACTCTTTGAGACATCACTGGCCTATAATAAATGGGTTAATTTATGTAAAAAAAAAAAAAAAA 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 2:217363693:217364421:1 
CCGTGTTCTCTCCTGTCTCCATGCCTTTGCAGGAGACACCATTGTCGGAAGCTCCCCAAGGCGGAGGGGCGGGGGCGCCTTGGCTGGG
CCTGGCGCGCTCCAGCCGGGTTAACGCCGGGCCTTCGGAGCGCGCGGCCAGCCCTGGGCACTGGTTTCGTTGGGTTGAATTTAGGGAA
AACTAGGTCATATGTAATTCACATGTCGGTCACACGTCAGTGAGGTGGAGGAACGGTGTGTGGAGGCTCCAGGGCCTGCCTGGGTTCC
AGGTCTATCACTGGTTTCTCCCTTCACTCTAAACAGGCCAAACGTACCAAGAAAGTCGGGATCGTCGGTAAATACGGGACCCGCT
ATGGGGCCTCCCTCCGGAAAATGGTGAAGAAAATTGAAATCAGCCAGCACGCCAAGTACACTTGCTCTTTCTGTGGCAAAGTA
AGTAAGGCAAAGTCTCTGGTGAGAGGAGAGGGAGGGCAGGTTTCTTACCCAAGTGAGGCCTGACTTCAAGGTATTTTATAAGCCGTG
TGCTGGTGGGCAGTTGGAATTACTCATACCGTTGATTATGAGTTTTAAGATAAAAGTGTTGATGGTAACTTCAGATTTTGTGAGACGTT
TTTCATTTAAAGAAAACCGCTTAAACGTTAATGGGTAAAATAATCATTTGACAGAGTGCCCCCAGCCTAAGCCAAACCTGCTTTGTGG
GAAATGATTCCATCAGTTTTGTCTACTGATGTT 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       82 to 210 (+) 
Database location:  2      217363993 to 217364121 (+) 
Genomic location:  2      217363993 to 217364121 (+) 
Alignment score:  649 
E-value:   1.4e-106 
Alignment length:  129 
Percentage identity:  100.00% 
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5.2.4.2   UOB-COL-11 clone 4 (serum CC005) identified as transcript of RPL37A gene 
Sequence fragment used for identification (T3 primer reading): 
CGGNGGGCGGCCGCTCTAGAACTAGTTGGNATCCCCCGGGNCTGCAGGTAATTCGGCACGAGGCTACNGTTTNCGGCGNACATGGCCAAACGTACCAAGAAAGTCGGGATCNTNTT
GTAAATACGGGACCCGCTATGGGGCCTCCCATCCG 
 
Fragment matched on Ensemble Genome Browser: 
>chromosome 2:217363724:217364357:1 
GGAGACACCATTGTCGGAAGCTCCCCAAGGCGGAGGGGCGGGGGCGCCTTGGCTGGGCCTGGCGCGCTCCAGCCGGGTTAACGCCGG
GCCTTCGGAGCGCGCGGCCAGCCCTGGGCACTGGTTTCGTTGGGTTGAATTTAGGGAAAACTAGGTCATATGTAATTCACATGTCGGT
CACACGTCAGTGAGGTGGAGGAACGGTGTGTGGAGGCTCCAGGGCCTGCCTGGGTTCCAGGTCTATCACTGGTTTCTCCCTTCACTCT
AAACAGGCCAAACGTACCAAGAAAGTCGGGATCGTCGGTAAATACGGGACCCGCTATGGGGCCTCCCTCCGGAAAATGGTGAA
GAAAATTGAAATCAGCCAGCACGCCAAGTACACTTGCTCTTTCTGTGGCAAAGTAAGTAAGGCAAAGTCTCTGGTGAGAGGAGAGGG
AGGGCAGGTTTCTTACCCAAGTGAGGCCTGACTTCAAGGTATTTTATAAGCCGTGTGCTGGTGGGCAGTTGGAATTACTCATACCGTT
GATTATGAGTTTTAAGATAAAAGTGTTGATGGTAACTTCAGATTTTGTGAGACGTTTTTCATTTAAAGAAAACCGCTTAAACGTTAATG
GGTAAAATAATCATTTGACAGAGT 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       117 to 151 (+) 
Database location:  2      217364024 to 217364057 (+) 
Genomic location:  2      217364024 to 217364057 (+) 
Alignment score:  150 
E-value:   5.2e-18 
Alignment length:  35 
Percentage identity:  97.14% 
 
 
5.2.5 SLC34A2 gene  
Gene Description:     SLC34A2; Solute carrier family 34 (type II sodium/phosphate contrasporter), 
member 2. 
Location:     Chromosome 4: 25,656,923-25,680,370 forward strand. 
Transcripts:  This gene has six transcripts (splice variants). 
Gene type:     Known protein coding. 
Prediction method:     Annotation for this gene includes both automatic one from Ensembl and a 
Havana manual curation. It corresponds to Havana gene 
OTTHUMG00000097757 (version 3). 
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5.2.5.1   UOB-COL-5 clone 1 (serum CC014) identified as transcript of SLC34A2 gene 
Sequence fragment used for identification (T3 primer reading): 
CTCNCGCGGTGGCGGCCGCCTCTAGAACTAGTGGATCCCCCGGGGCTGCAGGAATTCGGCACGAGGGCAAGATGGGTCACCAGCAGCTGTACTGGAGCCACCCGCNAAAATTCGGC
CAGGGTTCTCGCTCTTGTCGTGTCTGTTCAAACCGGCACGGTCTGATCCGGAAATATGGCCTCAATATGTGCCGCCAGTGTTTCCGTCAGTACGCNAAGGATATCGGTTTCATTAAGT
TGGACTAAATGCTCTTCCTTCAGAGGATTATCCGGGGCATCTACTCAATGAAAAACCATGATAATTCTTTGTATATAAAATAAACATTTGAAAAAAAAAANAAAAA 
Fragment matched on Ensemble Genome Browser: 
>chromosome 3:196263098:196263974 
GTTTCATAAACATAAACAAGGATGCCATGACCCTGGGAAATAACATTTTTTGGAAAATAATTTTTAAACTTTTGAAATTATTTTTTTCT
TTTTTTGAGACAGAGTCTCGCTTTGTAGCCTAGGCTGGTGTGCAGTGGCGCGATCTTGGCTCGCTGCAACCTCTGCCTCCTGGATTCAA
GCGATTGTCCTGCCTCAGCCGCCTGAGTAGCTGGGATTACAGGCGTGAGCCACCACGCCCGGGGAATTTTTGTATGTTTAGAAGAGAC
GGGGTTCCCCTTTTACCTCGTTGCACTCCTGAGAGCAAGATGGGTCACCAGCAGCTGTACTGGAGCCACGCGCGAAAATTCGGCC
AGGGTTCTCGCTCTTGTCGCGTCTGCTCAAACCGGCACGGTCTGATCCGGAAATATGGCCTCAATATGCGCCGCCAGTGTTTC
CGTCAGTACGCGAAGGATGTCGGTTTCATTAAGTTGGACTAAATGATCTTCCTTCAAAGGGTTATCCAAGGCATCTACTCAAT
GAAAAACCATGATCATTCTTTGTACATAAAATAAACATTTGAAAAACCCAAAAAAAAAAAAAAAAAAAAGAGATGGGGTTTCAC
CATGTTGGCCAGGCTGGTTTTGAACTCCTGGTCTCAAGTTATCTGCCCGCCTCGTCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA
ATGTGCTCAGCCCTGGAAATTTAAAATAGATTGATTGTAAAGAAATCTACTTGGGCAAAAAAATTTTAAATTTGAATACTGAAATAAT
AATGGTTCCTTAGAGCCATAAAGTGTTTATTAACAAGAAATACAGTTGATAAAAGATATGTATGATTGCCCAACTTACATAGAAAAGA
AAAAAATGGAA 
*THIS STYLE: Location of selected alignment 
*THIS STYLE: Location of other alignments 
*THIS STYLE: Location of Exons 
 
Alignment information: 
Query location:  unnamed       67 to 340 (-) 
Database location:  3      196263398 to 196263676 (+) 
Genomic location:  3      196263398 to 196263676 (+) 
Alignment score:  1234 
E-value:   1.2e-210 
Alignment length:  277 
Percentage identity:  93.50% 
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CHAPTER 6    Results:  Identification of known antigens 
expressed in SW480 cell line 
 
 
6.1. mRNA extraction from SW480 cell line and cDNA synthesis 
Total mRNA was extracted from the SW480 cell line and used to synthesize cDNA fragments that 
are suitable for a PCR. The samples were stored at small aliquoted in the -20 lab freezer. 
 
6.2 PCR optimization and antigen identification 
The newly synthesized cDNA from the mRNAs isolated from SW480 cell line was used to set a 
PCR reaction in the search for the expression of known antigens. Two individual cDNA samples 
were used as templates for the PCR reactions (cDNA 1 and cDNA 2) (Section 6.1).  
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Figure 6.1 Expression of known antigens in SW480 cell line. (A) cDNA 1 used as a template and (B) 
cDNA 2 used as a template; β-Acting and GAPDH were the housekeeping genes chosen to serve as positive 
controls in both occasions. Lane 9 on (A) and (B) is a negative control, containing only the template and no 
primers. 
 
It appeared that the PCR conditions used for this reaction were suitable to amplify β-Acting and 
GAPDH in both occasions. Also NY-ESO-1 expression was detected in both cDNA samples from SW480. 
However, HAGE and WT1 primer pairs did not amplify a product in these reactions. Interestingly, cDNA 1 
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had produced a double band for HAGE near 3’ end (Figure 6.1 A) in comparisosn to a single band for the 
same target sequence in cDNA 2 (Figure 6.1 B). 
  
Figure 6.2 Expression of known antigens in SW480 cell line. PCR conditions appeared favourable 
for the detection of WT1 expression, although the amount of the PCR product appeared low. Further 
optimisation should increase the concentration of DNA produced, knowing that WT1 is expressed in SW480 
cell line. No product amplified by the NY-ESO-1 primer pair (conditions unfavourable). Also, TSP50 had a 
smear on the gel and will need further optimisation of the conditions. 
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For the following PCR reaction (Figure 6.3), the conditions were altered to resemble the ones used 
in Figure 6.1 as the bands produced there appeared well-defined. 
  
Figure 6.3 Expression of known antigens in SW480 cell line. Some of the bands observed in Figure 
6.3 were very clear (BCP-20 mid, BCP-20 N5’ end, RAGE and SSX2). However, HAGE N5’ end primer 
pair did not produce a band regardless of the PCR conditions being similar to the ones in Figure. 6.1. WT1 
primer pair did not produce a band as the annealing t˚ was reduced by 2˚C in comparison to Figure 6.2. 
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Table 6.1 Expression of known antigens in SW480 cell line as identified by PCR. 
Antigen Primer sequence 5’-3’ 
 
Temperature 
of Melting 
(Tm) ˚C 
Best 
annealing 
temperature 
for product  
(Ta) 
Estimated 
product 
length (bp) 
Product 
length as 
seen 
(average 
bp) 
β-Actin 
F:   GGCATCGTGATGGACTCCG                       
R:   GCTGGAAGGTGGACAGCGA 
69.2 
69.0 
50˚C - 60˚C Not known 620 
GAPDH 
F:   ACCCACTCCTCCACCTTTG                         
R:   CTCTTGTGCTCTTGCTGGG 
64.0 
63.8 
50˚C - 60˚C Not known 220 
TSP50 
F:   TGACGGCATGTGGCCTCAGTT                   
R:   TCAGAGGGCAGCAAGGAGGCT 
72.3 
71.7 
50˚C and 
52˚C 
401 300 
HAGE (near 
3’ end) 
F:   CTGTACTAGTGGGGTAGAGAATTCA         
R:   CACAGAAACGAACATTTATTAACAG 
61.3 
60.4 
50˚C 351 450 
HAGE (near 
5’ end) 
F:   TTTGTTGGCGCGGTAATCGGT                 
R:   CATGGCACTTGTGGCAGTGGA 
72.1 
71.8 
50˚C and 
52˚C no 
product 
351 Not seen 
HAGE 
F:   CCTTTCAATGTTATCCTGAG                     
R:   TATTCTTCAGATTGACGAAG 
56.2 
54.4 
50˚C and 
52˚C no 
product 
Not known Not seen 
BCP-20 (near 
3’ end) 
F:   ATGAGTCACTCGACGAGGAGC                  
R:   TTTAAAGCCACCTGGAGCCT 
65.9 
64.7 
52˚C 451 600-800 
BCP-20 
(middle) 
F:   TCATTCATCAGCAGCTTGAGC                  
R:   GAACGTGGCATTTGATGTTGA 
65.6 
65.8 
50˚C 301 360 
WT1 
F:   GAGAGCGATAACCACACAAC                    
R:  GATGACCAAACTCCAGCTGG 
59.8 
64.7 
52˚C Not known 420 
SSX2 
F:   AAAATCAGAGTCAGACTGCTCCCGGTG           
R:   GTACATGCTGACCAGGAAACAGAGTGA 
73.5 
70.0 
50˚C Not known 1100 
SSX2IP 
F:   TGAATGAGCTGCTTGTGCTT                        
R:  GCTGATGCAAATTCCTGTTCT 
63.7 
63.1 
50˚C no 
product 
Not known Not seen 
NY-ESO-1 
F:   CCCCACCGCTTCCCGTG                              
R:  CTGGCCACTCGTGCTGGGA 
72.6 
72.4 
50˚C Not known 450 
RAGE 
F:   GTGTCTCCTTCGTCTCTACTA                          
R:  GGTGTGCCGATGACATCG 
55.1 
66.7 
50˚C Not known 1000 
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CHAPTER 7 General Discussion  
 
SEREX has been used to identify novel antigens such as NY-ESO-1 (Chen et al, 1997), CT antigens 
such as PASD1 (Guinn et al, 2005) and known tumour antigens such as SSX2IP (Guinn et al, 2005). 
We used the SEREX technique to identify which antigens are being recognised by Duke’s B colon 
cancer sera. We focussed on patients who had reactive disease to see what they react to and how that 
differs to patients with non-reactive Duke’s B colon cancer. We choose to use SEREX as it can 
identify IgG responses and has already been shown to identify antigens also recognised by CD8
+
 T 
cells. It is these cells which are capable of specifically killing tumour cells based on the MHC class I 
presentation of tumour specific antigens. 
Most SEREX antigens which have been identified have been transcription factors. Nuclear antigens 
with poor immunogenicity. Those antigens which naturally engage B cell – antibody mediated 
responses as the tumour cell are likely to have already caused the lysis of their host cell. Imunogenic 
antigens which are presented on MHC class I, antigens created by mutation or overexpression will 
have led to the elimination of tumour cells during the early stages of tumour development.  
However it is thought that the antigens identified by SEREX are poorly immunogenic and played no 
part in the early elimination of the tumour cell (and hence still exist). In 2004, Robert Schreiber 
(Schreiber, 2004) described the three phases of immune surveillance and evasion (Figure 7.1). In. the 
early stages of tumour development the immune system recognizes and eliminates tumour cells very 
efficiently and prevents solid tumor from forming. This is proven to occur as patients who are 
immune compromised (those with AIDS, SCID or post-transplant) as these patients have enhanced 
rates of tumour development, suggesting that in healthy individuals when the immune system is 
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intact it can destroy tumours before they are detectable. Eventually, a process of selection gives rise 
to a cancer cell that can evade immune survelliance by virtue of down regulated tumour antigen, 
MHC, the absence of co-stimulatory molecules  which can induce anergy. At this mid-stage the 
tumour may exist as a heterogeneous ball of cells, some of which have more acquired more or 
different mutations. Genetic instability is one of the hallmarks of cancer (Figure 7.2) and as the 
tumour evolves it acquires mutations that lead to grow and develop while avoiding immune 
destruction. In this phase, there is no net growth of tumor. Cells are still being eliminated and 
replaced in the tumor. This can continue for years. Then, some tumor cells escape, micrometasis in 
the case of colon cancer and invade the deeper layer of tissues in the bowel, leading to a detectable 
cancer. 
 
Figure 7.1 The three Es hypothesis. Figure based on Schreiber, 2004 theory, image taken from Zitvogel et 
al, 2006. The three phases of tumour development – (1) elimination where the tumour is detected and 
destroyed by the immune system (2) equilibrium – where as many tumour cells are killed by the immune 
system as are being born as daughter cells (3) escape where the tumour cells exceed the ability of the immune 
system to kill them and the tumour becomes detectable. 
(1) 
(2) 
(3) 
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Figure 7.2 The seventh hallmark of cancer. Following the six hallmarks of cancer self-sufficiency in growth 
signals, insensitivity to growth signals, tissue invasion and metastasis, limitless replicative potential, sustained 
angiogenesis and evading apoptosis described by Hannahan and Weinberg in 2000, a number of authors have 
noted the seventh hallmark of cancer appears to be lack of immune rejection (Dunn et al, 2004; Zitvogel et al, 
2006; Curiel, 2007). Based on the three E’s theory of Schreiber, 2004 this would change the tumour from one 
in equilibrium to one that has escaped immune surveillance and can grow unchecked. Usually, the point at 
which tumours are clinically detectable and impacting on human health. 
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By the time patients have been diagnosed it is often late in the cancer development then it has 
impacted on health and wellbeing. Cancer tends to kill due to metastases when the cancer cells fill up 
spaces required for normal healthy functions. Many treatments work well at first and then tumours 
become resistant to the treatment. Colon cancer is often treated by surgery and chemotherapy. 
However micrometastases can lead to subsequent relapse and death. It has been hoped that 
immunotherapy can help remove these micrometastases and delay or prevent relapse. However in 
2004 Rosenberg et al described the very poor results of immunotherapy trials at their centre which 
they felt reflected the general state-of-the-art in other Institutions.  The paper described the 2.6% 
success of all immunotherapy clinical trials when assessing outcomes for patients undergoing 
immunotherapy clinical trials (n=440) in the Surgery Branch of the National Cancer Institute from 
1995-2004. Objective responses were determined based on the Response Evaluation Criteria in Solid 
Tumors (RECIST) whereby an objective remission was scored as at least a 50% decrease in the sum 
of the products of the perpendicular lesions without a 35% growth of any lesions and no appearance 
of new lesions.    
The big problems that immunotherapy faces are:- 
• Anti-tumour immunity is autoimmunity. 
• The generation of significant anti-tumour immunity requires breaking self tolerance. 
Rosenberg’s publication led to the need for a rethink of how we develop immunotherapy and a 
decision was made to focus efforts on specific antigen targets to focus funding and effort. To this end 
in 2010 a list of top 20 antigens which should be targeted by immunotherapy and required/deserved 
further investigation was published. 
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To prioritize the myriad of identified antigens, Cheever et al. (2009) devised a list of criteria to 
define the “ideal” target antigen with the order representing the weight of each characteristics. These 
include inducing clinical effects, being immunogenic, playing a critical role in cell differentiation and 
proliferation of the malignant cells or proteins which characterize the malignant cell, expression 
restricted to malignant cells, expression in malignant stem cells, high number of patients bearing 
antigen-positive cells, includes multiple antigenic epitopes and expressed on the cell surface. 
However there is no antigen that fulfills all of the criteria some antigens seem to be more suited for 
use in clinical vaccination than others.  
In our study, based on an idea by Professor Gerald O’ Sullivan, Cork Cancer Research Centre, 
University College Cork, we wished to determine what antigens were recognised by the immune 
cells in Duke’s B reactive disease. This small cohort of patients has relatively early colon cancer, at 
the stage at which it is most often diagnosed. On conventional treatment these patients respond 
significantly better as detailed by Murphy et al, 2000. The group noticed that a proportion of patients 
(7/12) with Duke’s B reactive disease had clearance of their micrometastases after surgery. In 
contrast 9/24 patients without detectable micrometastases before surgery had micrometastases after 
surgery, suggesting in the former group a role of the immune system in tumour clearance after 
surgery. The presence of micrometasases after surgery has been shown to be an indicator of residual 
disease and poor prognosis (O’Sullivan et al, 1997) and indeed the clearance of micrometastases 
post-surgery has been suggested to be a good prognostic indicator (Murphy et al, 2000). The 
importance of an immune response and primary colon cancer with regards to patient survival has 
already been established particularly through the detection of tumour infiltrating lymphocytes (Jass, 
1986; Graham & Appelman, 1990; Ropponen et al, 1997), a Crohn’s-like lymphoid reaction and 
extramural vein invasion (Harrison et al, 1994) played key roles in the refinement of Jass 
108 
 
classification system (Jass et al, 1987). Murphy et al, 2000 showed that histopathological 
identification of the inflammatory reaction in the primary tumour can provide a reproducible 
prognostic indicator of a 10-year survival advantage to these patients. 
Antibody responses from B cells, require CD4 help, and therefore should also stimulate CD8 
responses. CD8 responses are believed to be essential for effective anti-tumour responses. If we can 
stimulate these and break tolerance then we can cause tumour lysis. These T cells have the potential 
to remove micrometastases which are a major issue in colon cancer patients with non-reactive Duke’s 
B colon cancer and are believed to be one of the most important indicators of their survival prospects. 
In our study we identified two antigens involved in inflammatory responses. UOB-COL-1-c1 was 
found to encode the immunoglobulin heavy constant gamma 3 (G3m marker), IGHG3 gene (Figure 
7.3), located on chromosome 14 at 14q32.33, which encodes IgG3, and was recognised by sera from 
patients CC005 and CC014.  
The IGHG3 gene is protein coding and has been shown to be associated with disease including heavy 
chain disease (HCD) and gamma heavy chain disease. Heavy chain disease is a lymphoproliferative 
disease whereby the variant monoclonal Ig heavy (H) chain fragments are found in serum or urine. It 
has been shown that the gene for the gamma-3 chain had undergone extensive NH2-terminal deletion 
(Alexander et al, 1982). Gamma Heavy chain disease occurs due to an overproduction of the heavy 
chain of antibodies leading to their abnormal production. This disease mostly affects older adults and 
shows similarity to malignant lymphoma in symptoms where they are apparent.  
Five super pathways were identified as having IGHG3 involved in them, these are the classical 
antibody-mediated complement activation, Fc gamma receptor (FCGR) dependent phagocytosis, 
109 
 
immune system, immune response, Fc epsilon RI pathway and IL4-mediated signaling events 
(Figure 7.4). 
 
 
Figure 7.3 Human immunoglobulin constant genes IGHC represented on a single line. Image taken 
http://www.imgt.org/IMGTrepertoire/LocusGenes/exon-
intron/Human/IGH/IGHC/Hu_IGHCorg.html (Lefranc & Lefranc, 2001). The line drawings depict the 
human immunoglobulin constant genes IGHG2 and IGHG3, cDNAs within which were identified by our 
SEREX studies. Large exons are not to scale. Upper line indicated the length of the exons, lower line the 
length of introns, are in base pairs. Numbers in parenthesis are the IMGT/LIGM-DB accession numbers. 
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Figure 7.4. Immune response shown in terms of CD16 signaling in NK cells. Taken from 
http://pathwaymaps.com/maps/2249_map.png. Signalling via IgG3 in indicated by a pink arrow with a blue 
outline at the top of the image.  
 
 
111 
 
IGHG3 has three functional partners as identified by The Human Gene Compendium developed by 
the Weismann Institute (http://www.genecards.org/). The three most likely partners are (A) 
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1). Phosphoinositide 3-kinases are a 
family of lipid kinases capable of phosphorylating the 3'OH of the inositol ring of phosphoinositides. 
They are responsible for coordinating a diverse range of cell functions including proliferation, cell 
survival, degranulation, vesicular trafficking and cell migration. To date IGHG3 has been found most 
frequently to play a role in the regulation of insulin; (B) Phosphatidylinositol-4,5-Bisphosphate 3-
Kinase, Catalytic Subunit Alpha (PIK3CA) is the catalytic subunit, which uses ATP to phosphorylate 
Phosphatidylinositol, Phosphatidylinositol 4-phosphate and Phosphatidylinositol 4,5-bisphosphate to 
generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role in recruiting PH 
domain-containing proteins to the membrane and activating signal cascades involved in cell growth, 
survival, proliferation, motility and morphology as well as cell signalling in response to a range of 
growth factors (Bunney & Katan, 2010). PIK3CA has been found to be oncogenic and has been 
implicated in cervical cancers (Ma et al, 2000); and the final most likely partner for IGHG3 is (C) 
IGHG1 Immunoglobulin Heavy Constant Gamma 1 (G1m Marker). 
In 2001 Lawrence et al described the increase in IGHG3, a novel immune function gene, in inflamed 
colonic tissue (both ulcerative colitis and Crohn’s disease) as one of several genes whose expression 
had not previously been linked to inflammatory bowel disease. To do this they had examined global 
gene expression profiles using DNA microarrays.  In total about 20% of the 170 differentially 
regulated genes were common to both forms of irritable bowel disease, probably reflecting common 
events secondary to inflammation. This would fit with the idea that immune reactive colon cancer has 
an inflammatory element. Indeed Murphy et al, 2000 paper had demonstrated an association between 
the occurrence of an inﬂammatory reaction, clearance of micrometastases and prognosis in patients 
112 
 
with immune reactive Dukes B colon cancer. IGHG3 has subsequently been shown to be 
overexpressed in non-squamous non-small cell lung cancer (Remmelink et al, 2005) breast cancer 
(Bin Amer et al, 2008), prostate cancer (Ledet et al, 2012) and malignant mesothelioma, the latter as 
part of a panel of nine autoantigens which may aid disease detection when using protein microarrays. 
The role of IGHG3 expression in cancer cells remains unclear although there have been some reports 
that IgG secreted by cancer cells can directly promote the growth and survival of cancer cells (Wang 
et al, 2013) including colon cancer cells (Barbera-Guillem et al, 2002; Qiu et al, 2003). 
UOB-COL-2-cl and UOB-COL-2-c2, both recognised by CC014 sera, respectively, encoded part of 
the immunoglobulin heavy constant gamma 2 (IGHG2) gene located on chromosome 14 at 14q32.33. 
This is an important paralogue of IGHG3 although not, until now, implicated directly as having a role 
in any cancer and with little to add about its function except that it is a component of the IgG2 
immunoglobulin providing the heavy chain.  
The three other interesting and previously identified genes which we found through the 
immunoscreening of the testes cDNA library with immune reactive Duke’s B colon cancer were 
CYB5R3, RPL37A and SLC34A2. CYB5R3 gene encodes the NADH-cytochrome b5 reductase 3 
protein. This protein is membrane bound (i.e. ER and mitochhondria) in somatic cells and functions 
by desaturating and elongating fatty acids, in drug metabolism and in cholesterol biosynthesis. With 
regards to a possible role in cancer, CYB5R3 has been shown to be a putative biomarker of cancer 
migration in mice with a mutated K-ras in whom lung tissues were analysed (Lee et al, 2009). In 
breast cancer CYB5R3 has been shown to be downregulated, negating its’ ability to detoxify reactive 
hydroxylamine metabolites of known mammary carcinogens (Rhoads et al, 2011) 
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Ribosomal protein L37a (RPL37A) is a ribosomal protein, and ribosomes are the organelles which 
catalyse protein synthesis. RPL37A belongs to the L37AE family of ribosomal proteins, it has a C4-
type zinc finger-like domain and resides in the cytoplasm. RPL37A that has been found to be 
upregulated in high grade astrocytomas (MacDonald et al, 2007) and to have a general association 
with lifetime glioblastoma survival and overall glioblastoma survival (P-value < 0.05 in both cases)( 
Serão et al, 2011). In breast cancer RPL37A expression can be used in conjunction with MTSS1 and 
SMYD2 was shown to be able to predict the response of breast cancer patients to neoadjuvant 
doxorubicin and cyclophosphamide (Baros Filho et al, 2010).  
Solute carrier family 34 member 2, the protein encoded by SLC34A2 gene is a membrane bound pH-
sensitive sodium-dependent phosphate transporter (NaPi-2b) which belongs to the SLC34A 
transporter family. As a member of the sodium-dependent phosphate transporter family, NaPi2b is 
primarily involved in the maintenance of phosphate homeostasis in the human body. The role of 
NaPi2b in oncogenic transformation and malignant growth is not well understood. However, it has 
been reported to be overexpressed in 70-90% of epithelial ovarian cancers (Gryshkova et al, 2011). 
SLC34A2 has been found to be upregulated in a number of different well-differentiated tumours in 
comparison to poorly differentiated ones (Shyian et al, 2011), suggesting that it may play a role in 
cell differentiation processes during carcinogenesis. SLC34A2 is also shown to be involved in the 
development of breast cancer in an independent study (Chen et al, 2010). These suggest that the 
SLC34A2 gene could be an efficient diagnostic and therapeutic marker in cancer. In our study, 
SLC34A2 was recognised by both CC014 and CC005 patient sera which makes it an gene of interest 
for further investigation in relation to Duke’s B (Chapter 8 future directions). 
We immunoscreened a testes cDNA library to enhance our chances of finding a cancer-testes (CT) 
antigen. CT antigens are particularly desirable for immunotherapy because they are expressed in 
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cancer tissues and only in immune protected sites which lack MHC class I. The lack of MHC class I 
means they cannot present self-antigens to the immune system. Immunologically protected sites 
include mostly important reproductive tissue such as the placenta and testes and exposed but essential 
tissues such as the eyes. It’s important that when a fleck of dust goes in the eye you don’t have an 
immune response that renders you blind. Some antigens have expression limited to non-essential 
healthy tissue such as the breast. For women with cancer, if the option is life-saving cancer treatment 
and the risk of auto-immune response to the breast tissue then this may be considered a worthy 
option. Of course all patients would need to provide informed consent prior to treatment, especially 
in clinical trials and in all clinical situations patients have the right to refuse treatment except if they 
are children or vulnerable adults.    
Most antigens identified by SEREX are overexpressed and not mutated. A growing interest in 
identifying mutated proteins in cancer as these would act as cancer unique targets. However there are 
a vast number of different mutations and so focus would remain on the most commonly mutated 
antigens such as p53 nucleotide 273 for example.  
We also immunscreened our testes cDNA library with sera from three different Duke’s B reactive 
patients to maximise not only the discovery of new antigens specific to Duke’s B reactive disease but 
also to show very quickly whether any of these antigens were recognised by two or more patients. 
We found a number of antigens which were recognised by more than one patient serum and we 
subsequently screened the same antigens with sera from healthy donors. Most of the antigens were 
recognised by at least some of the eight healthy volunteer sera with few exceptions (Table 4.3). 
However, the sera was used on two occasions only and meant that there was a significant background 
noise and therefore, the high chance of false positives. Further use of the sera should clear out the 
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background staining and lead to more conclusive results. Within our time-frame we were unable to 
screen the fifteen antigens with sera from patients with non-rective Duke’s B. This should remain a 
future direction and would complete our investigations. 
The testes cDNA used to make the library was commercially purchased however the frequency of 
phage which lacked an insert was quite high (around 30%). To determine whether the heavy chain 
IgG antigens identified through the immunoscreening of the library were due to B cell comtamination 
within the library Ms. Payalben Savaliyva, a fellow PhD student in Dr Guinn’s group, 
immunoscreened the testes cDNA library with anti-IgG/secondary antibody. However no positives 
were found following the immunoscreening of 300+ pfus. This suggests that the heavy chain 
fragments (IGHG3 and IGHG2) were not contamination but reacted with by patient sera reflecting 
the immune/inflammatory component of Duke’s B reactive disease, although this requires further 
investigation to validate it (discussed in Chapter 8 Future directions). We also checked the size of the 
cDNA inserts in the library we prepared and found a range of insert sizes indicating the library 
represented the breadth of testes cDNAs and was not limited in some way during its amplification. 
RT-PCR analysis was used to see whether any known antigens were overexpressed by colon cancer 
samples and to optimise this study we initially analysed SW480, K562 and HL60. Only data from 
SW480 are shown in results chapter 6. 
 
116 
 
CHAPTER 8   Future directions  
 
To complete this study, the most important next steps would be to complete tertiary 
immunoscreening with healthy donor and non-reative Dukes’ B colon cancer sera and determine 
which of the antigens identified are solely recognised by sera from patients with Dukes’ B reactive 
disease.  
Despite our immunscreening of a testes cDNA library with sera from patients with Duke’s B reactive 
disease we did not find any CT antigens, as far as we are aware. Further immunoscreening of the 
library to reach the agreed standard of immunoscreening 10
6 
pfus may have helped us identify some 
CT antigens (Sahin et al, 1995).  With the antigens we have identified we would want to investigate 
whether they are expressed by colon cancer tumour cells from patients with reactive and non-reactive 
disease. We would expect tumour antigens to have expression that is either restricted to tumour tissue 
or elevated in tumour tissue compared to healthy tissue. Most CT antigens are expressed at very low 
levels in healthy tissues if at all, so 1/100
th
 of the levels in cancer tissues. Some people believe any 
expression in healthy tissues, even at much lower levels, negates their title as CT antigens. However 
some of the most tissue restricted CT antigens show very small amounts of expression in healthy 
tissue, which is not immune protected such as PASD1 in pancreatic tissue (Guinn et al, 2005) and 
SSX2 in thyroid tissue (Tureci et al, 1996). 
We would also have liked to analyse the expression of known tumour and CT antigens in patients 
with Duke’s B colon cancer (reactive vs. non-reactive disease) compared with healthy colon tissue. 
We had started to optomise RT-PCR for a number of known CT antigens but many still needed 
further work to ensure we could reproduce results consistently with nice clean PCR products. WE 
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had performed our tests on SW480, K562 and HL60 but realised for some of the PCR reactions, new 
primers and slightly different PCR conditions were required. Once RT-PCR was optimised we had 
hoped to perform quantitative RT-PCR with the help of collegeaues at the Genomics Centre, King’s 
College London. We would also suggest that progress in this project includes the 
immunocytochemistry confirmation of the antigens identified in patient tissue (FFPE sections). This 
wuld have followed tertiary screening when a short-list of Dukes’ B reactive disease antgens were 
available. In addition enzyme linked immunosorbance assay (ELISA) could be used to detect the 
antigens or the antibodies to the antigens in patient sera. In light of the identification of IGHG3 and 
IGHG2 we could have analysed patient sera for the presence of cytokines to help us understand the 
cytokines playing a role in Dukes’ B reactive disease.  Mostly simply this could be done by ELISA. 
We would be keen to determine whether RPL37A is a biomarker for survival in Dukes’ B colon 
cancer and indeed all colon cancer patients. This could be investigated using cDNA microarrays 
which have been used to analyse Dukes’ B tissue to determine whether RPL37A and survival in 
patients show an association. 
Further analysis of the as yet unidentified sequences identified by secondary immunoscreening has 
recently led to the realisation that UOB-COL-5 encoded SLC34A2. Further analysis of the 
remaining, and as yet unidentified sequences, is likely to lead to the identification of these remaining 
sequences as our understanding of the human genome and it’s availability for in silico analysis 
continues to expand. 
There are a number of different options for immunotherapy. These range from the modification of 
tumour cells to enhance MHC expression, tumour antigen expression or more typically cytokine 
expression for adoptive transfer of whole cell vaccines. Adoptive therapy of immune system cells 
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such as T cells or NK cells where these cells are isolated, purified and expanded ex vivo to has been 
shown to be effective where numbers of tumour specific adoptively transferred cells are high enough 
(reviewed in Hinrichs and Rosenberg, 2014). Modification of TCR receptors to recognise specific 
epitopes presented in the context of MHC on cancer cells have been used by a number of groups to 
enhance the effectiveness of adoptively transferred T cells (Stauss et al, 2008). Any of the antigens 
we have identified could be used as targets for immunotherapy, hopefully stimulating immune 
responses in patients with Duke’s B non-reactive disease or enhancing responses in patients with 
reactive disease who may be part of the small percentage that do not clear their micrometastses after 
surgery. Antigens identified by SEREX would need to be validated. This would require the 
demonstration of whether they were expressed in healthy tissues which would impact cancer specific 
targeting. We would also need to determine the frequency of expression in patients to determine 
whether targeting this antigen would be valid and at what stage of malignancy expression is found. 
As two of the antigens were IgG heavy chains it would be interesting to determine whether these 
proteins are being secreted into the serum or blood of patients and could allow early detection or act 
as biomarkers for disease – differentiating patients with reactive disease from those with non-reactive 
disease without the need to take bone marrow aspirates for micromestastases. 
The depletion of regulatory T cells (CD4
+
 CD25
+
) using anti-CD25
+
 antibodies has been shown to 
enhance anti-tumour responses (Whelan et al, submitted) and it is likely immunotherapy will not 
only need to be used in conjunction with conventional therapies but also in synergy with other 
immunotherapy protocols to achieve full tumour clearance. 
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REVIEW  
New targets for the immunotherapy of colon cancer—does 
reactive disease hold the answer? 
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Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, posing a serious demographic 
and economic burden worldwide. In the United Kingdom, CRC affects 1 in every 20 people and it is often detected once well 
established and after it has spread beyond the bowel (Stage IIA–C and Stage IIIA–C). A diagnosis at such advanced stages is 
associated with poor treatment response and survival. However, studies have identified two sub-groups of post-treatment CRC 
patients - those with good outcome (reactive disease) and those with poor outcome (non-reactive disease). We aim to review the 
state-of-the-art for CRC with respect to the expression of cancer-testis antigens (CTAs) and their identification, evaluation and 
correlation with disease progression, treatment response and survival. We will also discuss the relationship between CTA expression 
and regulatory T-cell (Treg) activity to tumorigenesis and tumor immune evasion in CRC and how this could account for the clinical 
presentation of CRC. Understanding the molecular basis of reactive CRC may help us identify more potent novel immunotherapeutic 
targets to aid the effective treatment of this disease. In this review, based on our presentation at the 2012 International Society for the 
Cell and Gene Therapy of Cancer annual meeting, we will summarize some of the most current advances in CTA and CRC research 
and their influence on the development of novel immunotherapeutic approaches for this common and at times difficult to treat disease. 
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THE GLOBAL CHALLENGE  
‘You have cancer’—the diagnosis that millions of people around 
the world hear every year and also the second leading cause of 
death worldwide. The number of new cancer cases each year is 
gradually increasing and the mortality rate is expected to rise from 
7.6 million in 2008 to over 17 million in 2030.
1,2
 On average, one 
of every three people is expected to experience some type of 
cancer in the course of their lifetime and this frequency is 
expected to increase
3
 as the population ages. The World Health 
Organization reports that an increasing percentage of all newly 
diagnosed cancer cases annually occurs in low- and middle-
income countries and this is attributed to a wide range of 
behavioral, genetic and environmental risk factors.
4
 Nevertheless, 
the increase in the average life expectancy and the adoption of an 
unhealthy lifestyle (such as smoking, physical inactivity and poor 
diet) worldwide have also contributed to the rise of a new trend in 
the cancer demography. Newly diagnosed cancers from the low- 
and middle-income countries today account for 451% of the total 
number and their share in the global burden is expected to 
continue to increase with the growth and aging of the population.
4
 
In addition, the lack of resources for early cancer detection and 
effective treatments in the developing world contributes to an 
increase in cancer-related deaths.  
Today, some of the most commonly diagnosed cancers both in 
economically developing and developed countries include 
prostate, breast, lung and colorectal cancer (CRC)—‘the big 
four’—accounting for nearly 50% of the total cases diagnosed.
5
 
 
 
 
Cancer is a global challenge, opposing a serious demographic and 
economic burden with worldwide economic costs estimated to be as 
high as £572 billion per year. These alarming statistics resulted in 
the development of national strategies and action plans for cancer 
control including prevention, early detection and effective 
treatment.
6
 However, the demand for the development of new 
approaches to cancer screening and therapy is recognized globally 
and brings the research attention on these aims sharply into focus. 
 
 
COLORECTAL CANCER  
CRC is one of the most commonly diagnosed cancers worldwide. It 
affects the bowel and the rectum and is rare in people under 40, 
with almost 85% of cases being diagnosed in persons over 65 years 
of age.
6
 Statistics show that men and women are affected equally, 
while it is the third most common type of cancer in men (after 
prostate and lung cancer) and the second most common cancer in 
women (after breast cancer).
6
 One in every 20 people in the UK 
develops CRC with only half of them surviving beyond 5 years, 
mainly because it is often detected once well established and after it 
has spread beyond the bowel. The disease stage at the time of 
diagnosis governs both the choice of treatment and the prognosis. 
CRC is staged to reflect how far the cancer has spread and whether 
or not it has reached nearby structures such as lymph nodes or 
distant organs. The most commonly used staging system for CRC is 
that of the American Joint Committee on Cancer, 
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also known as tumor nodes metastases system.
7
 It describes three 
key pieces of information: ‘T’—how far has the primary tumor 
grown; ‘N’—the extent of spread to nearby lymph nodes; and ‘M’— 
describes whether the cancer has metastasized. The information 
from the T, N and M is combined to determine the cancer stage 
grouping from Stage I (the least advanced) to Stage IV (the most 
advanced). Two of the older staging systems include Duke’s
8
 and 
Astler–Coller
9
 but these are very rarely used today. 
Stage I (A–C) (Duke’s A–C) CRC is reported to be an 
asymptomatic malignancy, developing slowly by the progressive 
accumulation of genetic mutations within precancerous bowel 
lesions and polyps. Diagnosis at this stage reduces the risk of 
death from CRC, giving 90% chance of survival beyond 5 years
10,11
 
and significantly low levels of disease recurrence. However, most 
cases of CRC are detected once the cancerous cells have moved 
beyond the middle layers of the colon (Figure 1). This is classified 
as Stage IIB (Duke’s B) and is one of the most commonly 
diagnosed forms of CRC. Currently, the course of treatment for 
CRC patients is fairly similar regardless of the significant 
differences in the biological features of each CRC case. Usually, 
the most effective approach is tumor resection, followed by chemo- 
or radiotherapy for Stage III and sometimes for Stage II CRC 
patients. However, recent studies suggest that not all Stage III 
patients benefit from these therapies and that 25% of Stage II 
cases are under treated.
12,13
 Furthermore, a number of non-
aggressive tumors are frequently overtreated, leading to the patient 
experience of unnecessary and severe side effects. Methods such 
as, fecal occult blood test, sigmoidoscopy, colonoscopy, virtual 
colonoscopy and double contrast barium enema offer 
improvements in the detection rates of CRCs.
14
 However, their 
diagnostic value is limited with regards to costs, risks, lack of 
sensitivity especially in early stages and inconvenience to the 
patient.
15
 Therefore, the focus remains on developing efficient 
methods for the early detection of CRC such as the identification of 
early disease biomarkers which could be used in non-invasive 
(urine and blood serum) tests. Such molecular biosensors for CRC 
would enable widespread screening alongside general health 
examinations and may further reduce the mortality rate associated 
with late stage detection of CRC.
16
 
 
 
 
 
Murphy et al
17
 suggested that there are two sub-groups of 
patients with Stage IIB CRC—those with good treatment outcome 
(reactive disease) and those with poor treatment outcomes (non-
reactive disease). Whether the difference between these two 
groups of patients can be determined by differences in humoral 
responses warrants further investigation and provides the basis of 
our own current studies. Tumor biomarkers offer an opportunity to 
translate unique CRC biological features into diagnostically 
pertinent information and would enable persona-lized treatments, 
which could inform conventional and immu-notherapeutic 
interventions. This would enable discerning treatment strategies for 
aggressive and non-aggressive cancers and the clear ‘up front’ 
distinction of reactive from non-reactive disease. 
In part, to address this need, researchers are investigating 
immune responses in cancer patients to identify new immu-
notherapy targets and biomarkers. They are hoping to identify and 
evaluate tumor-associated antigens (TAAs) and cancer-testis 
antigen (CTAs) that could prove to be efficient diagnostic, 
prognostic or immunotherapeutic targets in CRC.
18
 Recent 
developments in the fields of genomics and proteomics have 
greatly contributed to these studies, enabling the identification of 
multiple potential antigens within a single experiment.
19
 
Techniques, such as DNA microarray analysis, protein microarrays, 
peptide-major histocompatibility complex (pMHC) tetramers, 
serological identification of antigens by recombinant expression 
cloning (SEREX), serological proteome analysis (SERPA) and 
peptide elution from MHC for mass spectrometry analysis are now 
commonly used to evaluate the expression profiles of genes and 
proteins as well as antigen recognition within different types, sub-
types and stages of cancer. Their application in a number of 
studies conducted on acute myeloid leukemia (AML),
20,21
 diffuse 
large B-cell lymphoma,
22
 lung cancer
23
 and osteosarcoma
24
 have 
already proven successful and have led to the discovery of a large 
panel of antigens with prognostic and immunotherapeutic 
relevance. It has also provided an insight into the biological 
complexity and individuality of each cancer case, demonstrating 
considerable heterogenicity among patients and within tumor types. 
Therefore, genomics, proteomics or a combination of multiple 
methods could aid the discovery of novel biomarkers specific for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Shows a malignant primary tumor that has moved beyond the middle layers of the colon and has also metastasized to a 
nearby lymph node. These are stages IIB (Duke’s B) onwards. 
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CRC and contribute to the development of personalized 
therapies, which would maximize efficiency and minimize side 
effects for the patient. 
 
 
THE SEARCH FOR TUMOR ANTIGENS SPECIFIC FOR CRC  
The desire to identify TAAs has inspired and attracted 
researchers for more than four decades. Most efforts were driven 
by the aim to uncover specific epitopes on cancer cells, which 
could elicit immune responses in the autologous host.
25,26
 In the 
1970s, a method known as ‘autologous typing’ was used 
successfully to identify a number of antigens including alpha 
fetoprotein (in hepatoma and germ cell tumors), carcinoembryonic 
antigen (CEA)  
(in gastrointestinal cancers), prostate-specific antigen (in prostate 
cancer), CA125 (in ovarian cancer) and AU (in melanomas).
27,28
 
This novel serological technique offered a substantial improve-
ment over existing methods as it enabled the analysis of the 
cellular (T-cell defined) anti-tumor human immune responses in 
an autologous manner where only tumor-specific antigens could 
be recognized.
27
 However, autologous typing did not completely 
fulfill the original hopes for its success because of several 
limitations. The major disadvantage arose from its reliance on 
cultured tumor cell lines and not all tumor types could be 
propagated ex vivo to allow autologous typing to be performed. 
Furthermore, only a small fraction of the total number of patients  
was found to have demonstrable levels of autologous antibody 
with specificity for cell surface antigens on their tumor.
25,26
 In the  
cases when the technique was successful and a tumor antigen 
was identified, the low titer of antibodies that were often detected 
made any further biochemical or molecular characterization of the 
antigens almost impossible. However, the method of autologous 
typing contributed to the identification of a number of human 
tumor antigens, which were categorized into four classes: 
differentiation antigens—for example, gp-100; mutational 
antigens—for example, abnormal forms of p53; retroviral 
antigens—Epstein–Barr virus and human papilloma virus; and CT 
antigens.
26
 
 
CT antigens  
CTAs were classified as TAAs with restricted expression in testis, 
placenta and various types of cancer.
26
 In the field of cancer 
serology they were quickly identified as the ideal targets for 
tumor-specific immunotherapeutic approaches.
29–33
  
The selective expression pattern of CTAs is considered to be a 
consequence of gene activation by DNA demethylation
34,35
 and 
histone post-translational modifications
36
 both occurring 
constitutively in the testis, but also in tumor cells.
35
 Some CTAs 
have been found to be expressed in healthy tissues such as liver, 
pancreas and spleen but at a significantly lower level (o1%) when 
compared with their expression in testis.
31
 Around 70 families of 
CTAs have been identified to date and further classified as X-
CTAs and non-X-CTAs depending on the chromosomal location 
to which the genes are mapped.
37
 The genes for distinct X-CTAs 
have been previously reported to encode for different antigenic 
peptides that are presented with HLA class I or HLA class II allo-
specificities, eliciting both cell-mediated and humoral immune 
responses.
38
 The blood–testis barrier and the lack of HLA class I 
expression on the surface of germ cells prevents the cells of the 
immune system from interacting with the CTAs expressed there.
39
 
It has been suggested that as the B and T cells have not been 
previously challenged by CTAs the immune response should be 
able to recognize CTAs as non-self structures when expressed on 
cancer cells
39
 circumventing the need to break tolerance. These 
findings suggest that CTAs can be viewed as promising molecular 
targets for the development of immunotherapeutic interventions 
for specific cancer types without the possibility of triggering  
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autoimmune responses. The identification of CTAs specific for a 
particular type of cancer is a promising approach for the 
development of peptide or recombinant full-length protein anti-
cancer vaccines and for antigen-specific adoptive T-cell transfer as 
part of cancer therapy.
40
 In that respect, NY-ESO-1 (a CTA with 
strong immunogenicity still detectable at sera dilutions of 1 in 40 
000
41
) has been of interest in relation to the development of cancer 
vaccine trials. Several ongoing trials have been based on this 
antigen alone or its use in combination with an immune enhancer 
are currently ongoing.
42,43
 However, the expression of other CTAs 
within various types of cancer and at different disease stages 
appears to be heterogeneous and further investigation is required 
for the identification of effective immunotherapeutic targets.  
Although, CTA expression is generally correlated with tumor 
progression and immunogenicity in various types of cancer, little is 
known about this in relation to CRC. In addition, CTAs were often 
found to be poorly expressed (low level, heterogeneous 
expression) in CRC
44
 highlighting the need for the identification of 
further immunogenic CTAs involved in CRC development. Such 
proteins would be candidates for cancer-specific therapy trials and 
may provide effective biomarkers for diagnosis, prognosis and 
monitoring of CRC disease progression. 
 
Serological identification of antigens by recombinant expression 
cloning  
The limited success of autologous typing demonstrated the need 
for a more comprehensive experimental approach for the 
identification of TAAs. It was not until the mid-1990s when a new 
autologous immunoscreening technique was shown to circumvent 
some of the limitations of autologous typing. This method was 
called SEREX.
45
 It allowed the identification of numerous TAAs 
based on their recognition by antibodies in diluted pre-cleared 
autologous patient sera and in a small number of experiments. The 
advantages of SEREX were quickly recognized and a substantial 
pool of data encompassing serologically relevant antigens within 
cancer began to collect. SEREX was capable of identifying 
immunoglobulin G antibody responses to both highly (NY-ESO-1) 
and weakly immunogenic TAAs.
46,47
 Approximately one-third of 
these antigens were novel and referred to as SEREX-defined 
antigens. In addition, sera was shown to be able to detect CD8 
þ
 T-
cell recognized TAAs, including NY-ESO-1,
41
 MAGE-1 and 
tyrosinase
41,45,48
 as well as TAAs recognized by immunoglobulin G 
antibodies, which are also known to require CD4 
þ
 T-cell help (NY-
ESO-1).
45,46,48–51
 These findings demonstrate that the cellular and 
humoral immune system work in concert and are both stimulated 
by TAAs in the case of cancer. Furthermore, several antigens (NY-
ESO-1, MAGE-1 and hMena)
52
 that elicit humoral as well as cell-
mediated immune responses have also been successfully identified 
through SEREX. Studies have investigated CD8 þ and CD4 þ T-cell 
recognition of SEREX-defined antigens and the data showed that 
co-immunization with such proteins in combination with a cytotoxic 
T lymphocyte (CTL) epitope enhanced CD8 
þ
 induction in a CD4 
þ
 
T-cell-dependent manner.
53,54
 
The continuously increasing number of SEREX antigens led to 
the creation of a Cancer Immunome Database, a free repository for 
the antigens identified by this serological approach.
55
 The success 
of SEREX lies in its reliance on the construction of a cDNA library 
from human tissues (cell lines, primary tumor or normal donor 
testes) and their expression in a prokaryotic system.
45
 
Immunoscreening with SEREX permits quick and effective 
extraction, processing, sequencing and subsequent molecular 
analysis of the protein of interest as both the TAA and its coding 
cDNA are present in the same plaque. However, the use of SEREX 
has several limitations. It has been previously reported that 
SEREX-defined antigens are predominantly nuclear proteins which 
are often transcription factors
41
 and/or ubiquitously expressed.
55,56
 
As such, they rarely show evidence of mutations or other structural 
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abnormalities and are often weakly immunogenic, incapable of 
eliciting and sustaining strong humoral immune responses.
25
 In 
addition, phage can only express proteins in their primary structure, 
which may cause the failure to detect antigenic sequences 
consequent to eukaryotic post-translational modifications.
57
 
Regardless of the limitations, SEREX-defined antigens are already 
being investigated as diagnostic markers (testis-specific protease 
(TSP50) in ovarian and CRCs)
58
 and as immunotherapeutic targets 
(OVA66 in ovarian cancer,
59
 KIF20A in pancreatic cancer
60
). 
 
Serological proteome analysis  
SERPA is a powerful tool used for the identification and validation 
of immunogenic TAAs. Similar to SEREX, it uses the antibody 
repertoire contained within the sera of a cancer patient to 
successfully identify TAAs.
61
 In comparison to SEREX, SERPA 
does not require the use of a cDNA library, making this method less 
time consuming and less labor intensive. Furthermore, SERPA is 
better suited for the detection of possible post-translational 
modification and protein isoforms as it relies on the separation of 
complex mixtures of proteins extracted from cell cultures or tumors. 
The separation is performed via the use of a two dimensional gel 
electrophoresis (2-DE).
62
 A number of TAAs have been identified to 
date using SERPA in various types of cancer including 
lymphoma,
63
 renal cell carcinoma,
64
 ovarian cancer,
65
 and CRC.
66
 
These studies have established the specificity of SERPA and its 
great potential in uncovering immunogenic TAAs and identifying 
tumor markers. However, similar to SEREX, most of the antigens 
identified by SERPA are predominantly weakly immunogenic 
intracellular proteins and very rarely membrane-associated 
ones.
67,68
 This and the finding that a number of antigens found by 
T-cell cloning have also been found by SEREX suggests that most 
antigens induce B and T-cell responses,
69
 although not necessarily 
to the same epitope(s). In addition, SERPA has demonstrated a 
drawback associated with the use of 2-DE: low abundance (such as 
regulatory and signal transduction proteins and receptors
70
), 
hydrophobic or insoluble proteins (such as membrane proteins
70
) 
are inherently difficult to detect.
67
  
      SEREX and SERPA are two methodologies that seem comple-
mentary to each other as they identify two different sets of antigens 
(SEREX for the identification of antigens with altered expression; 
SERPA for the identification of antigenic proteins resulting from 
post-translational modifications). Therefore, the identification and 
validation of CRC-related CTAs using SERPA and SEREX 
independently or as a combined approach is worthy of further 
consideration. 
 
Recombinant antigen expression on yeast surface (RAYS)  
RAYS is another serological strategy applied to the process of 
discovering immunogenic CTAs. RAYS permits the expression of 
immunogenic proteins on the surface of yeast allowing for a more 
natural folding of the protein and partial glycosylation (by virtue of it 
being a eukaryotic system).
57
 This permits the analysis of proteins 
in their natural conformation when compared to the prokaryotic 
expression utilized by SEREX. This method has demonstrated 
specificity and sensitivity for the detection of an antibody response 
to a conformation-dependent epitope— the CRC antigen A33. 
Therefore, the CTAs that have escaped detection because of the 
fact that they elicit immune responses only after undergoing the 
appropriate post-translational modifica-tions could potentially be 
identified via RAYS. To date, RAYS has allowed the confirmation of 
antigen immunogenicity through screening of eukaryotic cDNA 
expression libraries derived from pancreatic cancer
71
 and prostate 
cancer. 
72
 RAYS offers a less time-consuming analysis of the 
serological autoreactivity in cancer patients and it has provided an 
effective anti-cancer vaccine platform (recognizing NY-ESO-1) in 
prostate cancer patients.
72 
 
 
 
 
However, its further development is required to allow the 
detection of novel target antigens (such as is achieved with 
SEREX or SERPA) and its application in CRC requires further 
analysis. 
 
Serum antibody detection array  
To evaluate the seroreactivity of a number (or a panel) of SEREX-
defined antigens in a particular type of cancer, a spot 
immunoassay, known as serum antibody detection array, has 
been successfully developed and utilized.
73
 Although, several 
antigens have been evaluated in cases of colon cancer (MAGE-
A3, SSX2 and NY-ESO-1
73
), additional improvements in the 
sensitivity of serum antibody detection array are still required. 
 
Protein microarrays  
Protein microarrays allow the rapid and easy detection of tumor 
antigens using patient sera.
74,75
 Recent studies have 
demonstrated the efficiency of the technique in the rapid 
identification of immunogenic membrane-based TAAs with high 
reproducibility of the experimental analyses of lung and brain
74
 
and ovarian
76
 cancers. In this context, protein microarrays has a 
great advantage as this methodology allows the construction and 
simultaneous analysis of a large panel of candidate tumor 
biomarkers (~9,000). However, it should be noted that although 
protein microarrays have vast screening potential they are limited 
to defined proteins from an albeit not insubstantive pool.  
Understanding the molecular interactions between T-cell 
receptors on CTL and peptide/MHC class I complexes on tumor 
cells is an essential tool for the development of immunogenic 
vaccines.
77
 Several such vaccines have already been designed 
based on TAA epitopes and have been implemented in Phase I 
and II clinical trials for different types of cancer (human papilloma 
virus,
78
 WT1,
79
 human telomerase reverse transcriptase
80
 and 
HLA-A24 
þ
 HRPC
81
 peptide vaccinations). The strength of 
vaccine-mediated immunological responses generally need to be 
enhanced and this will be much more feasible in patients in 
subsequent (Phase III) clinical trials who are likely to have less 
advanced disease. However, the results obtained from clinical 
trials to date warrants further investigation. 
 
pMHC (tetramer) microarrays  
The development of pMHC microarrays has allowed the rapid 
identification of antigen-specific populations of T cells in the 
peripheral blood of patients.
82
 This approach has proven useful 
for epitope prioritization, and for the detection of multiple T-cell 
populations in cancer patients undergoing conventional 
treatments or tumor-associated peptide vaccine trials.
82,83
 We are 
using the pMHC array to identify which epitopes are recognized 
by peripheral T cells from colon cancer patients during 
conventional treatment (Bonney et al., in preparation). 
 
TUMOR PROFILING IN PATIENTS WITH CRC  
A number of studies have been conducted over the last decade 
aiming to identify novel biomarkers that would prove to be 
efficient in CRC profiling as prognostic, predictive or therapeutic 
biomarkers. The recent improvements in proteomics and geno-
mics methods has greatly aided this aim and has led to the 
identification of a number of CTAs and TAAs relevant to CRC. 
However, the clinical significance of only a small fraction of these 
potential markers in CRC has been evaluated to date. 
 
CTAs in CRC  
NY-ESO-1 has been recently studied in relation to CRC. It was 
demonstrated that some CTAs are capable of eliciting strong 
humoral and cell-mediated immune responses in some patients 
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with CRC.
84
 However, its expression in CRC is often highly 
heterogeneous, when present, which poses an obstacle in the 
development of a generalized immunotherapy. As discussed earlier 
in this review, NY-ESO-1 has also been targeted in several vaccine 
clinical trials worldwide involving CRC patients. Recently, a new 
Phase I trial of a fusion protein vaccine is being organized targeting 
solid tumors expressing NY-ESO-1 and this investigation includes 
Stage I–IV CRC.
85
 In addition, NY-ESO-1 expression was shown to 
correlate with CRC stages and local lymph node metastasis
86
 
making it a potential prognostic biomarker for CRC.  
   TSP50 was originally identified as abnormally expressed in 
breast cancer cells
87
 and has recently been studied for the first time 
in CRC patient samples. The expression of TSP50 was found to 
correlate with the clinicopathological characteristics and disease-
specific survival for CRC patients.
88
 Furthermore, the study 
demonstrated that TSP50 expression is highly specific for CRC as 
compared with colorectal adenomas and normal tissues, allowing 
the easy differentiation between them. TSP50 is an attractive 
predictive biomarker for poor survival in patients with early stages 
CRC (Stage I and II), but not in patients with advanced stage 
disease. As such, it is the only effective predictive biomarker 
reported to date for patients with early stage CRCs.
88
  
    CABYR is a calcium-binding tyrosine phosphorylation-regulated 
fibrous sheath protein and its expression was first identified in 
human spermatozoa (
89
; reviewed in Chiriva-Internati et al.).
90
 
Subsequent detection of CABYR in lung carcinoma and its absence 
in healthy tissues, led it to be considered as a novel CTA, which 
has been shown to have some immunogenic properties that could 
serve as a basis for the development of immunotherapy for cancer 
patients.
91
 Additional studies on CABYR expression in brain,
92
 
hepatocellular
93
 and other carcinomas
94
 have shown that there are 
at least five different isoforms of this protein, which could have 
unique roles in the process of carcinogenesis. Following these 
discoveries a recent study has reported a frequent overexpression 
of CABYR a/b and c isoforms in CRC tumors when compared with 
adjacent normal tissues.
95
 However, a more comprehensive 
investigation is required to determine whether CABYR expression 
correlates with tumor stages and is a suitable therapeutic vaccine 
candidate in CRC. 
 
SPAG9 is another antigen found to be exclusively expressed in 
testis
96
 that is a particularly attractive target for immunotherapy in 
epithelial ovarian cancer,
97
 thyroid cancer
98
 and in CML. 
99
 A recent 
study has investigated the expression of SPAG9 in CRC patients 
aiming to explore its possible role in colon cancer tumorigenesis 
and its effectiveness in eliciting a humoral immune response.
100
 
Interestingly, the study has reported a close relationship between 
SPAG9 expression and early stages of CRC development 
Immunotherapy of colon cancer  
V Boncheva et al  
161  
suggesting that it could serve as an early  diagnostic biomarker for 
CRC patients. The investigation had also demonstrated that 
SPAG9 could have a key role in the tumor development and could 
also serve as a target for the development of immunotherapeutic 
methods.  
Other CTAs, found to exhibit a strong correlation with CRC 
presentation are listed in Table 1. 
 
TAAs in CRC  
CD133 is a cell surface protein marker found on undifferentiated 
cancer cells that exhibit stem-like properties. These cells account 
for the propagation, growth and recurrence of AML
110,111
 and 
CRC
112,113
 and for the resistance of these cancers to current 
therapies. The functional importance of CD133 expression has 
been investigated in several studies in relation to the initiation and 
behavior of CRC.
113–115
 The CD133 
þ
 CRC stem cells are reported 
to have exhibited the ability to transfer cancer to a secondary 
recipient maintaining the same immunophenotype and the global 
gene expression profile of the primary tumor when compared with 
CD133 
_
 cells.
113,114
 Furthermore, several studies have clearly 
identified the correlation between CD133 expression alone
114,115
 or 
in combination with other protein markers
116
 with CRC patient 
survival and have revealed it to be a reliable prognostic marker. In 
combination with CD44 and CD166 (cell surface protein markers), 
CD133 expression has also been linked to the presentation of low-
, intermediate- or high-risk CRC cases with the ability to 
distinguish between them at an early stage of the disease (stage 
II).
114,116
 CD133 is a promising predictive and prognostic marker in 
the diagnosis of CRC and particularly of interest as it is applicable 
to the early stages of the disease. However, the presence of such 
cell surface markers on the CRC stem cells has not been 
investigated in relation to the underlying cause of the non-reactive 
type of CRC.  
CEA is a TAA whose expression levels are often monitored pre- 
and post-treatment in CRC patients as they have been found to be 
indicative of cancer recurrence
117
 and poor disease 
prognosis.
118,119
 Patients with elevated post-treatment CEA 
expression levels are often monitored more carefully for relapse of 
CRC and for local or distant recurrence.
117,119
 To date, several 
studies have investigated the potential of CEA as an 
immunotherapeutic target in cases of CRC. Different research 
strategies have incorporated CEA peptides or CEA mRNAs in 
dendritic cell vaccines
120,121
 and in plasmid DNA vaccines
122
 
demonstrating that these vaccines are well-tolerated and have 
immune-stimulatory capacity in patients with CRC. However, the 
overall outcome of these studies indicated that additional vaccine 
modulation is necessary to attain significant clinical impact. More 
recently, a study to investigate whether the vaccination of toll-like
 
Table 1.   Antigens determined to have potential as diagnostic, prognostic or immunotherapeutic targets in CRC 
 
CTA/panel of Chromosome Method of identification First identified Potential uses in CRC 
 
CTAs location  in  
 
     
 
BCP-20 17p13.1 SEREX CRC101 Candidate diagnostic and immunotherapeutic  
(FBXO39)    target101 
 
 
PAGE4 Xp11.23 Database mining CRC102 Predictive panel for liver metastasis102 
 
SCP-1 1p13-p12 SEREX   
 
SPANX Xq27.1 Differential display 
Melanoma
103 
 
 
MAGE-A4 Xq28 T-cell epitope cloning Colon cancer vaccine therapy with peptide of 
 
    MAGE-A4
104 
 
STK31 7p15.3 Three-step microarray CRC105 Candidate target for immunotherapy
105 
 
  analysis 
CRC
106 
 
 
SSX Xp11.2 Reverse transcription-PCR 
Co-expression as predictive marker for 
metastasis 
 
MAGE Xq28   Candidate targets for immunotherapy106 
 
SSX2 Xp11.22 SEREX Melanoma107 Candidate target for immune therapy108,109 
  
Abbreviations: CRC, colorectal cancer; CTA, cancer-testis antigen; SEREX, serological identification of antigens by recombinant expression cloning;  
SSX, synovial sarcoma X antigen. 
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receptor activated dendritic cells can induce more potent CTL 
responses and antitumour activity in CEA transgenic mouse tumor 
models was published.
123
 It has demonstrated that the combined 
activation of TLRs can lead to better maturation status of dendritic 
cells and can also induce more effective antitumour immune 
responses against CRC. However, additional investigation is 
necessary to evaluate the effectiveness of this approach in human 
models. 
 
CLINICAL SIGNIFICANCE OF CTAS IN CRC  
The CTAs that have already been identified within different types of 
cancer could serve as biomarkers for discerning aggressive and 
non-aggressive cancers and for predicting treatment outcome and 
relapse. Their expression patterns and clinical significance is still 
under investigation, but there are very promising early results. Some 
of their clinical applications are described in the followings sections, 
and could expand the list of potential CTAs in CRC. 
 
Potential biomarkers for discerning reactive from non-reactive 
disease  
The expression profile of CTAs in relation to treatment outcome in 
particular types of solid cancers has been previously studied on 
several occasions
24,52,58–60
 but further investigation is necessary to 
compare these findings with CRC cases. In this context, a recent 
study has demonstrated that g-irradiation de novo upregulates the 
expression of various CTAs and MHC-I in a randomized fashion. 
Therefore, irradiation could be accounted responsible for the 
increased immunological response to certain tumors owing to the 
inflammation and cell damage it causes. This would be anticipated to 
cause the immune system to attend the site of damage, mop up 
cellular debris and present proteins including CTAs to the immune 
system.
124
 These findings fit with demonstrations in leukemia that 
elevated tumor antigen expression at disease presentation is 
associated with improved survival.
125,126
 Identifying and evaluating 
such TAA and CTAs would be beneficial for profiling individual 
tumors and for combining radiotherapy (or other cancer therapy 
approach) with immunization to maximize the effect of treatment in 
CRC. However, in order to design a combined treatment a thorough 
understanding about the mechanisms of initiating CTAs expression 
and the likely order of their expression is necessary.  
    The exact role of the numerous CTAs in relation to tumor 
response to various treatments still remains poorly defined. 
Particularly, in cases where adjuvant therapy is in order, it would be 
beneficial to have a panel of biomarkers to predict the likely success 
of the therapy. Several CTAs have been evaluated in gastrointestinal 
stromal tumor—with regards to recurrence, while levels of MAGE-
A1, MAGE-A3, MAGE-A4, MAGE-C1 and NY-ESO-1 expression 
were investigated in response to imatinib adjuvant therapy.
127
 This 
study demonstrated that CTA 
þ
 gastrointestinal stromal tumors had a 
significantly shorter recurrence free survival compared with negative 
cases. Furthermore, the expression of NY-ESO-1 and MAGE-A3 
was associated with elevated resistance to imatinib and therefore, 
with continuous tumor progression. Luetkens et al.
128
 have also 
showed that PRAME expression remains stable under imatinib 
treatment and correlates with decreased overall survival in patients 
with CML. 
     Similar  findings  have  been  reported  in  several  studies  of 
prostate and lung cancer, multiple myeloma, AML, liposarcoma and 
others.
129–134
 These suggest an important role of CTAs in the 
pathophysiological behavior of different tumors in response to 
treatments. Further investigation of a panel of antigens associated 
with particular types of cancer and their relationship to either reactive 
or non-reactive disease is yet to be attempted. In this relation, 
TSP50 is the only known CTA to have been characterized as a 
biomarker for disease prognosis in CRC,
88
 but its association with 
treatment outcome is still to be analyzed. Furthermore, investigation  
 
 
 
of the interrelationships between groups of CTAs in CRC and 
their expression profiles could lead to significant discoveries 
about the underlying cause of a particular treatment response. 
This could benefit the design of a multivalent cancer vaccine 
targeting several antigens rather than just a single one. 
 
Potential biomarkers for survival prognosis  
Several studies have investigated the role of the CTAs as 
biomarkers of prognostic value regarding patient survival. 
Elevated levels of expression of particular CTAs have been 
shown to correlate with poor survival prognosis, particularly in 
solid tumors. In contrast to expectations some antigens have 
been shown to have above average levels and have better 
survival rates in patients with hematological malignancies. For 
example, expression of SSX2IP in the presentation of AML has 
been shown to predict good survival in patients with no 
detectable cytogenetic rearrangements.
125
 The elevated levels of 
antigens provide targets for improved immune responses in 
patients post-conventional (chemotherapy, radiotherapy) 
treatment, when there is cancer cell damage and inflammation 
(danger) signals stimulating an immune response to clear up 
dead and dying cells. Furthermore, the CTAs expressed on non-
solid tumors (such as AML) are more accessible and ‘easier to 
see’ by the immune system as they are not hidden within 
heterogeneous layers of cancer cells (as seen in solid tumors).  
The prognostic value of CTAs has also been evaluated in the 
presentation of osteosarcoma by gene microarray where the high 
expression of MAGE-A could predict distant metastasis and poor 
survival. For patients with and without MAGE-A expressing 
tumors, the 5-year survival rates were found to be 39.6% and 
80% respectively.
24
 Similarly, increased levels of WT1 (another 
CTA) expression have been shown to correlate to poor prognosis 
and relapse in pediatric AML after induction therapy.
135
 A number 
of products of translocations have been used in routine labs, 
which detect minimal residual disease and can indicate 
impending relapse with high accuracy.
136
 The CTA expression in 
relation to patient survival in CRC cases has been the focus of 
few studies and further investigation is required to establish the 
clinical significance of this relationship.
88
 
 
Potential biomarkers for discerning aggressive from non-
aggressive disease  
A recent study on prostate cancer has demonstrated that several 
CTAs are preferentially expressed in either aggressive or non-
aggressive disease.
137
 Such biomarkers could be particularly 
useful in preventing the overdetection and overtreatment of 
potentially indolent CRC or the undertreatment of a more 
aggressive type of disease. 
 
Potential immunotherapeutic targets  
In 2005, cancer patients expressing NY-ESO-1 and LAGE-1 
antigens entered a Phase I clinical trial on a plasmid DNA 
(pPJV7611) cancer vaccine,
138
 demonstrating the effectiveness of 
CTAs as immunotherapeutic targets. Recently, the first clinical 
trial of cancer vaccine therapy with artificially synthesized 
helper/killer-hybrid epitope long peptide of MAGE-A4 cancer 
antigen was initiated.
104
 A patient with pulmonary metastasis of 
CRC was vaccinated and had shown a significant reduction in the 
tumor growth. 
 
NON-REACTIVE DISEASE—OVERCOMING THE 
UNDERLYING ISSUES  
CTAs are key molecules in the field of cancer serology. Their 
progressively expanding family is continuously providing potential 
novel targets for cancer immunotherapy or diagnostic/prognostic 
examinations. However, CTAs have also been evaluated for their 
role in oncogenesis, particularly their contribution to the
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immortality, invasiveness, immune evasion, hypomethylation and 
metastatic capacity of the neoplasms.
139
 Investigating the 
correlation between CTAs and the clinical presentation of CRC 
(reactive or non-reactive type) requires knowledge of the molecular 
mechanisms that govern their expression and physiological 
functions—mechanisms that still remain poorly understood. 
According to recent studies, genome wide hypo-methylation has 
accounted for the aberrant expression of CTAs within CRC 
cells.
140–142
 However, the epigenetic factors that dictate which panel 
of silenced genes to be reactivated and the physiological properties 
of these particular CTAs are still unknown. This is an area of 
actively ongoing research as it is believed that these factors are 
responsible for the heterogenicity in the CTA expression profiles of 
the individual CRC cases. A better understanding of the structural 
and serological properties of these antigens, their modes of 
expression and functions, should establish whether they are the 
ones governing the reactive and non-reactive CRC phenotypes.  
     CTAs in CRC have been associated with low immunogenicity 
under normal conditions, and only a few patients actually recognize 
the peptide epitopes and exhibit strong CTL or humoral immune 
responses to CTAs. This could be partially accounted to the 
structural stability of the proteins, encoded by the CT genes. It has 
been previously demonstrated that proteins must be cleaved to 
small peptides by intracellular proteinases prior to presentation to 
the immune system.
143
 However, high stability proteins (a-helical 
secondary protein conformation known to provide the most optimal 
structural stability
141
) are less likely to undergo denaturation and 
polypeptide chain unfolding. Therefore, CTAs containing large 
proportions of a-secondary structure should be more resistant to 
protein unfolding and subsequent cleavage by the proteinases, 
thus resulting in an unsuccessful presentation to CTLs (low 
immunogenicity). For example, SCP-1 (a CTA of particularly low 
immunogenicity) has been shown to contain 76.6% a-helical 
structure from its total secondary conformation when compared 
with the highly immunogenic NY-ESO-1 CTA, containing only 
20.7%.
141
 The identification of such antigens that are predominantly 
expressed in non-reactive CRC patients could potentially be 
accounted for the therapy-resistant presentation of the disease. In 
such cases epigenetic modulation to induce expression of other 
CTAs may highly favor the immunotherapeutic approach to non-
reactive CRC disease. In this respect, a study has recently reported 
a successful induction of NY-ESO-1 expression in CRC cells (but 
not in normal nontransformed cells) both in vitro and in vivo subject 
to hypomethylating agent 5-aza-2
’
-deoxycytidine (DAC) 
treatment.
144
 The study reports that DAC-treated CRC cells are 
susceptible to MHC-restricted recognition by CD8
+
 NY-ESO-1-
specific T cells. A NY-ESO-1157–165-specific T-cell receptor was 
successfully used to generate both CD8
+
 and CD4
+
 NY-ESO-1157–
165-specific T cells that selectively recognized DAC-treated CRC 
cells but not non-treated cells. These data reveal the great potential 
of combining epigenetic modulation and adoptive transfer of 
genetically engineered T lymphocytes targeting NY-ESO-1 or other 
CTAs for the development of a specific immunotherapy for CRC.  
     Another approach could also include the introduction of 
sequences capable of disrupting long a-helical stretches in the 
regions outside the potential epitopes.
141
 Such approaches have 
the potential to improve the treatment response in patients with 
non-reactive type CRC. However, several challenges remain to be 
overcome, including the insufficient antitumour responses due to 
immunosuppression driven by T lymphocytes known as regulatory 
T cell (Tregs). 
 
Infiltrating T lymphocytes  
During the last decade, the search to understand the causes 
underlying presentation CRC has focused on Tregs. They have 
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been shown to have a major role in cancer immunoevasion by 
directly inhibiting or even eradicating both CTLs and T-helper 
lymphocytes.
145
 Tregs suppress autoreactive T cells without killing 
them through incompletely understood, contact-dependent 
mechanisms.
140
 In healthy individuals, they represent 5-10% of the 
population of CD4
+
 lymphocytes. However in cancer patients, 
Tregs may increase up to 30% and are predominantly found among 
the tumor-infiltrating lymphocytes present.
145
 Therefore, the failure 
of the T and B cells to recognize and eradicate immunogenic 
cancer cells could be accounted for by the ability of certain tumors 
to secrete chemokine CCL22, which recruits Tregs and immobilizes 
the function of the anti-cancer immune response. Indeed patients 
with ulcerative colitis and irritable bowel syndrome have been 
shown to have higher numbers of infiltrating T cells than healthy 
controls
147
 which may have a role in controlling cancer-driven 
inflammation. Tregs in CRC have been shown to exhibit both pro- 
and anti-tumor activities governed by the level of inflammatory 
stimuli received and dependent of the phase of tumourigenesis 
(early or late).
148
 Following treatment in a Phase II clinical trial for 
CRC patients, the level of circulating Tregs was reported to have 
almost reached normal levels accompanied by 70% increase in 
CTLs responses against CEA epitopes.
149
 Therefore, it still remains 
to be determined whether presence of Tregs in CRC has a pro- or 
anti- tumor role, how this correlation changes with the stage of the 
disease and the clinical significance of these changes.  
In addition, Tregs appeared to be highly specific for a distinct set 
of TAAs in CRC patients, suggesting that Tregs exert T-cell 
suppression in an antigen-selective manner.
150
 Several key 
hallmarks of Tregs in CRC have been identified, highlighting their 
complex role in the progression of the disease, the survival 
prognosis and their potential as therapeutic targets. Overall, it was 
established that CRC patients develop multivalent and individual T-
cell responses against a broad variety of different CRC-associated 
TAAs. Therefore, selecting a panel of antigens according to pre-
existing T-cell responses as an intermediary could improve the 
efficacy of future immunotherapies for CRC and should be further 
investigated. Better understanding of the role and behavior of Tregs 
within CRC would improve tumor profiling on an individual basis 
and could aid the choice of the most adequate therapy for each 
individual case. It could also benefit the development of cancer 
vaccines and other immune-based therapies targeting particular 
CTAs in non-reactive type CRC.  
Tumor-infiltrating CD45RO(+)-cell density is a prognostic 
biomarker associated with longer survival in CRC patients, 
independent of clinical, pathological and molecular features.
151
 
Similar findings have also been reported from another study, linking 
the density of CD45RO(+) memory T cells in the different regions of 
CRC with dissemination to lymphovascular and perineural 
structures and to regional lymph nodes in patients— low densities 
were associated with a very poor prognosis.
152
 However, not only 
was the type and density of the infiltrating immune cells within 
human CRC predictive of clinical outcome but also their location 
within the tumor, that is, whether they are located in the center of 
the tumor or the invasive margin. A strong in situ immune reaction 
in both regions was shown to correlate with a favorable prognosis 
regardless of the stage (I, II and III CRC).
153
 Conversely, a weak in 
situ immune reaction predicted a poor clinical outcome even in 
patients with stage I CRC. These data were further supported by 
Page`s et al.
154
 who examined the relationship between the 
presence of CD8(+) and CD45RO(+) in two regions of the tumor in 
patients with early stage CRC with regards to tumor recurrence and 
overall patient survival. High densities of both CD8(+) and 
CD45RO(+) correlated significantly with lower rates of CRC 
recurrence and increased overall survival when compared with 
patients with low densities of both immune cell types within the 
primary tumors. In contrast, extramural 
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vascular invasion and high FOXP3 
þ
 cell density in lymphoid 
follicles were independent factors for worse survival, whereas a 
high frequency of lymphoid follicles in histologically normal colonic 
mucosa was associated with better survival.
155
 Therefore, the 
collective analysis of the type, density and the location of immune 
cells within the CRC could be used to predict patient survival and 
to identify the high-risk patients who would benefit most from 
adjuvant therapy. 
 
Intrinsically disordered proteins (IDPs)  
Following a bioinformatics approach that implements the 
application of two algorithms (FoldIndex and RONN) predicting the 
level of disorder within a sequence, the experimental outcome 
revealed that 490% of the examined 228 CTAs were IDPs.
156
 The 
latter are proteins that lack the typical hydrophobic cores and 
therefore do not appear as having rigid 3D structures (along their 
entire length or in localized regions) under physiological conditions 
and instead, exist as dynamic ensembles.
156,157
 However, IDPs 
can evade being detected as ‘misfolded’ and degraded by the 
cell’s surveillance system through their ability to undergo ‘disorder-
to-order’ transitions upon binding to biological targets—a paradox 
known as the ‘order/ disorder paradox’.
158
 This is achieved as a 
segment of an IDP initially binds with the target, followed then by 
coalescing of the other protein segments facilitating the IDPs’ 
folding.
159
 However, recent studies have challenged this general 
view by revealing a phenomenon—uncoupled binding and folding 
of IDPs.
160
 The complexity of the binding mechanisms of IDPs has 
been investigated by others
161,162
 and a summary of possible 
pathways have been outlined in Figure 2. 
The above mentioned properties associated with IDPs give an 
interesting angle of perception towards the expression, behavior 
and function of CTAs identified as IDPs. The lack of rigid 3D 
structures is believed to be responsible for the exposure of 
 
 
 
 
primary contact sites, which enables the faster, more effective and 
promiscuous binding at high concentrations to target mole-cules.
157
 
Together with the fact that intrinsic disorder has been identified as 
a determinant of genes that are harmful when overexpressed,
161
 
this could account for the correlation between CTA overexpression 
and disease prognosis. This is further supported by the fact that 
CTAs appear to occupy ‘hub’ positions (highly connected protein 
nodes) within the complex protein–protein interaction (PPI) 
network.
156,163
 What was interesting in these findings was the fact 
that these networks are dynamic and grow incrementally by 
establishing new nodes. However, a desirable protein for 
recruitment to a hub position is a protein that is likely to participate 
in a large number of promiscuous interactions when overexpressed 
such as a CTA that is an IDP.
156
 Eventually, the PPI network 
becomes dominated by such hubs leading to the overexpression of 
CTAs and to the creation of nodes with novel functions. This 
accounts for the poorer disease prognosis in later CRC stages and 
the phenotypic presentation of non-reactive CRC disease. This 
idea is further supported by the fact that a high abundance of IDPs 
is believed to result in undesirable interactions and potentially 
harmful effects of such interactions.
161
 Perhaps the failure to 
respond to treatment in non-reactive type CRC could be due to 
targeting common nodes in a protein network rather than CTAs that 
occupy hub positions. Therefore, the search for such antigens 
could potentially take a turn towards more thorough investigation of 
the structure of the PPI networks established in cases of reactive 
disease. 
 
CONCLUSIONS  
Research over the last four decades has proven that CTAs hold a 
prominent role within the field of cancer serology and could be 
excellent diagnostic, prognostic and immunotherapeutic biomarkers 
in CRC. Furthermore, examination of their structural 
 
 
 
 
 
 
 
Intermediate1. IDP does not fold upon binding 
to its target. 
 
 
TARGET 
 
Intermediate 2. IDP binds to target and 
undergoes disorder-to-order transition to fold into 
its native structure. 
 
 
 
 
 
 
 
 
Unfolded IDP bound to its 
target. Active complex. 
 
 
 
Intermediate3. A segment of IDP undergoes disorder-
to-order transition upon binding to the target. 
Subsequently, it folds into its native structure. 
 
 
IDP 
 
Intermediate4. IDP undergoes disorder-to-
order transition and folds to its natural structure 
prior to binding to the target. 
 
 
 
Folded IDP bound to its 
target. Active complex. 
 
 
Figure 2. Diagrammatic representation of the different binding mechanisms and the disorder-to-order transition that the IDPs undergo before and 
upon binding to their targets (based on reference
160
). Some IDPs (particularly immune signalling-related IDPs) do not fold upon binding to their 
targets (for example, Intermediate 1). Other IDPs undergo partial or complete folding upon binding (Intermediate 2 and Intermediate 3) or fold 
before binding to their targets (Intermediate 4). The images shown are representative of the disorder-to-order transition that a hypothetical IDP 
would undergo. 
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properties and selective expression patterns may enable the 
understanding of the underlying molecular mechanisms that 
govern the reactive and non-reactive presentation of CRC. 
Nevertheless, the panel of CTAs with potential clinicopathological 
significance in relation to CRC still remains to be conclusively 
clarified. As this review pointed out, a large number of CTAs to 
date have been proven to be excellent prognostic biomarkers or 
targets for the development of peptide or protein vaccines in 
different solid tumors. However, the attempts to characterize such 
potent targets and to evaluate their significance in relation to CRC 
are still at their starting point. Up to date, the comprehensive 
analysis of the CTAs in relation to CRC have demonstrated that 
their secondary structural conformation and the presence of a 
large number of a-helical formations may be accounted for the 
reduced immunogenicity and treatment response of the CTAs 
associated with non-reactive type CRC. A solution to this potential 
problem has also been recently identified and evaluated— 
epigenetic modulation, which could induce the expression of 
highly immunogenic CTAs, that could subsequently be targeted 
by chemo- or immunotherapy. Particular attention should also be 
paid to the infiltration of Tregs within the tumor mass at different 
stages of the disease. Tregs have been associated with a rather 
complex and ambiguous role in the process of tumourigenesis in 
CRC patients as they have been demonstrated to exhibit both 
pro- and anti-tumor activities. Further study would be require to 
gain a better understanding on whether they play different roles in 
the presentation of reactive versus non-reactive CRC. Never-
theless, research on CTAs expression in CRC should follow the 
findings that these proteins are also exhibiting particular proper-
ties characteristic for IDPs.  
    In summary, the numerous studies and the significant data 
gathered regarding the expression pattern of CTAs and their role 
in carcinogenesis have not yet provided an explanation for the 
differences in the clinical presentation of CRC. However, they 
have demonstrated the complex variety of CTA expression 
mechanisms and their implications in hematological and solid 
cancers. The fact that certain CTA expressions could be 
indicative of poor prognosis in solid cancers but suggest good 
overall outcome in hematological malignancies brings to the fore 
a number of new challenges on the journey towards advancing 
clinical tumor immunotherapy. Still the main question remains 
unanswered: Can we transfer what triggers a good response in 
reactive disease to a patient with a poor anti-tumor response and 
improve the overall outcome? Identifying highly immunogenic 
peptides is a basic requirement for the development of 
immunotherapy vaccines. However, solid tumors, such as CRC 
pose additional obstacles on the road to mounting an immune 
response due to the fact that the antigens expressed within CRC 
cells are not readily accessible/easily recognized by the immune 
system. The heterogenicity in the nature of the tumor cells 
comprising CRCs and their multi-layered structure are the main 
reasons for evading immune recognition. However, understanding 
the underlying molecular basis of reactive disease could lead 
researchers to overcome these issues. Despite the amount of 
data gathered to date, the search for tumor-specific 
immunotherapy targets has remained elusive but as our 
understanding of how to induce effective immune responses 
grows so does our likelihood of improving patient outcomes. 
 
FUTURE PERSPECTIVES  
The identification of novel CTAs for CRC and evaluating the 
clinical significance of existing ones should be one of the main 
priorities in this field. As previous research has indicated, a 
number of CTAs could be effective prognostic biomarkers in CRC 
when evaluated as a panel of antigens rather than individually.  
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The same approach could also be promising for the development of 
multivalent cancer vaccines that will target a panel of antigens in a 
particular tumor type. 
It would also be beneficial to investigate the implications of high 
expression of novel CTAs on patient survival and treatment 
outcome. Furthermore, understanding the mechanisms of CTAs 
expression and epitope presentation to CTLs might provide new 
targets for epigenetic modulation or adjuvant therapies. 
Nevertheless, investigating the role of the known CRC-associated 
CTAs in relation to particular drug treatments or therapies should 
not be overlooked. As discussed earlier, a combined approach for 
the treatment of CRC might hold the key to the development of 
more successful therapies for CRC patients. Treatment with 
hypomethylating drugs on cancers with low CTA expression 
followed by immunotherapy has already shown promising results in 
both in vitro and in vivo studies. These findings should be further 
investigated in cases with CRC to provide a more conclusive idea 
of their effectiveness.  
As suggested already, a more thorough investigation should 
enable the discovery of CTAs, which are also IDPs. Understanding 
the properties and the function of IDPs could assist a more 
comprehensive understanding of the physical and serological 
properties of CTAs and how they relate to CRC reactivity. 
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activity is known, lenalidomide has moderate CNS penetra-bility 
(Table I). In keeping with this, the patient had a com-plete 
neurological remission; pre-treatment neurological signs and 
symptoms resolved entirely and no plasma cells were detected either 
morphologically or by flow cytometry in the CSF. Despite the exquisite 
responsiveness in the CNS, the patient died with systemic disease 40 
d later. Whilst it is not possible to determine the relative efficacy of 
dexamethasone or lenalidomide in this patient, we believe that the 
degree of CSF penetrability lends rationale to including lenalidomide 
as part of CNS-directed therapy for future patients. 
 
In patients with relapsed or refractory myeloma, lenalido-mide can 
overcome resistance to conventional chemotherapy and has been 
shown to be effective in improving treatment outcomes both in terms 
of progression-free and overall sur-vival (Dimopoulos et al, 2007; 
Weber et al, 2007). No guide-lines for therapy or prevention of 
meningeal myelomatosis are available, which has resulted in large 
variation in treat-ment schedules. The therapeutic options include 
craniospinal irradiation, intrathecal chemotherapy, and systemic 
chemo-therapy, alone or in combination with each other. In this 
 
 
patient, progression occurred quickly after single agent bortezo-
mib with dexamethasone. Increasingly, three- and four-drug 
combinations have been shown to be superior to conventional 
therapy in improving progression-free survival (Palumbo & 
Cavallo, 2012). It is to be hoped that these regimens would 
further reduce the risk of CNS disease. 
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High and low, but not intermediate, PRAME expression levels are 
poor prognostic markers in myelodysplastic syndrome at disease 
presentation 
 
 
 
 
 
The PReferentially expressed Antigen of the Melanoma Gene 
(PRAME) has been shown to be overexpressed in multiple 
solid cancers and in human germ-line tissues but only weakly 
expressed, if at all, in other healthy tissues leading to its clas-
sification as a cancer-testis (CT) antigen. High expression of 
PRAME has been associated with poor survival and short-
ened disease-free survival in a number of solid cancers. How-
ever, evidence of an association between PRAME expression 
and survival in haematological malignancies has not been so 
 
 
 
 
 
clear. In acute promyelocytic leukaemia, typified by the 
t(15;17) translocation, low PRAME expression has 
indicated shortened overall survival (OS) (Santamaria et 
al, 2008), while high PRAME expression has also been 
associated with t(8;21), a favourable cytogenetic 
aberration, in acute myeloid leukaemia (AML) patients 
(van Baren et al, 1998). In addi-tion, PRAME expression 
was found to be associated with progression-free 
survival or OS in acute leukaemia by some groups 
(Greiner et al, 2006; Tajeddine et al, 2008) but not 
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Fig 1. Normalized signal intensity of PRAME-targeted probe sets representing PRAME expression levels in (A) the mononuclear fraction of 
cells from 73 MDS patients. ANOVA analysis showed no difference in the relative PRAME expression across WHO groups. Bars represent 
the group median and data points were coloured based on IPSS category; (B) the CD34
+
 fraction of cells from 183 MDS patients [and 17 
healthy donors (NBM)] revealed that PRAME expression was statistically different across WHO sub-groups (P = 0 0152). Elevated PRAME 
levels were also found in CD34
+
 cells from MDS patients with atypical cytogenetic aberrations when compared to those isolated from the 
NBM of healthy donors (P = 0 0489) (Figure 1B). Bars represent the group median and data points were coloured based on detected 
cytogenetic aberrations. ANOVA, analysis of variance; IPSS, International Prognostic Scoring System; WHO, World Health Organization; 
NBM, normal bone marrow; MDS, myelodys-plastic syndrome; RA, refractory anaemia; RA, refractory anaemia with ringed sideroblasts; 
RCMD, refractory cytopenia with multilineage dysplasia; RAEB1/2, refractory anaemia with excess blasts, type 1/2. 
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Fig 2. Kaplan–Meier survival curves based on relative PRAME expression in (A) the total mononuclear fraction (MNC, Data set A; n = 92 patients) and 
(B) the CD34
+
 only fraction (Data set B; n = 166 patients for which follow-up data were available). Both cohorts of patients were stratified into two 
groups; those with a level of PRAME expression that lay within the interquartile range (n = 49 for MNC and n = 83 for CD34
+
) and those with an 
expression level outside of this range (n = 43 for MNC and n = 83 for CD34
+
); i.e. those with expression in the upper or lower quartiles. Each line 
represents patient survival according to these criteria. Patients with an intermediary expression of PRAME in their mononuclear cells or CD34
+
 cells have 
the longest survival, whereas those with much higher or lower expression of PRAME have the shortest survival. 
 
others (Paydas et al, 2005; Guinn et al, 2009). Evidence for the 
direct involvement of PRAME in carcinogenesis and disease 
progression was demonstrated in acute leukaemia cells when 
PRAME inhibition was shown to lead to apoptosis (Tanaka et al, 
2011). However, other groups have reported that high expression of 
PRAME is a marker of a favourable outcome and good OS may be 
partly due to its association with a decreased expression of several 
other genes (HSPB1,  
S100A4, CDKN1A, IL8 and IGFBP2) in childhood AML patients 
(Tajeddine et al, 2008). 
 
Little evidence exists for the role of PRAME as a prognos-tic 
marker in myelodysplastic syndrome (MDS), the excep-tion 
being a recent report (Qian et al, 2011) showing that 11/56; 19 
6% of MDS patients had PRAME gene promoter 
hypomethylation, a frequency that was higher in patients who 
were cytogenetically abnormal (5/21, 24%) compared with those 
who were cytogenetically normal (5/33, 15%). Qian et al (2011) 
also found that PRAME promoter hypome-thylation was 
elevated in MDS patients with subtypes associ-ated with more 
blasts [refractory anaemia with excess blasts 
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(RAEB) and RAEB in transformation] than those associated 
with less blasts [refractory anaemia (RA) and RA with ringed 
sideroblasts](37% versus 3%, P = 0 002). PRAME methyla-
tion status was identified as an indicator of OS (P = 0 026) 
with the 50% survival time for patients with hypomethylated 
PRAME being 11 months compared to 26 months for those 
with PRAME methylation. Qian et al (2011) performed 
multivariate analysis and showed that International Prognos-
tic Scoring System (IPSS) classification (Low/Intermediate-1 
versus Intermediate-2/High) and PRAME methylation status 
were independent prognostic factors (P = 0 009 and 0 005, 
respectively). 
 
To further investigate whether PRAME levels at disease 
presentation could be used to indicate MDS patient survival 
we examined the mononuclear gene expression profiles 
(GEPs) of 92 presentation MDS patients (Data set A) (Mills et 
al, 2009) as well as a set of CD34
+
 GEPs from 183 MDS 
patients and 17 healthy donors (Gene Expression Omnibus 
Accession number GSE19429) (Data set B) (Pellagatti et al, 
2010). All samples were run on Affymetrix U133 Plus 2 
microarrays and normalized using Robust Multiarray Averag-
ing (RMA). Analysis of variance (ANOVA) of Data set A found 
no difference in the relative mononuclear levels of PRAME 
expression in MDS patients across the World Health Organi-
zation (WHO) groups (Fig 1A). However, analysis of expres-
sion profiles from the CD34
+
 cells of Data set B revealed that 
PRAME expression was statistically different across WHO 
sub-groups (P = 0 0152). In addition, there were sig-nificantly 
higher levels of PRAME expression in MDS patients with at 
least three cytogenetic aberrations [including both 5q deletion 
(del(5q)) and chromosome 7 deletion (del (7)) or a deletion on 
7q (del(7q))] when compared to CD34
+
 cells from the normal 
bone marrow (NBM) of healthy donors (P = 0 0183). Elevated 
PRAME levels were also found in CD34
+
 cells from MDS 
patients with atypical cytogenetic aberrations when compared 
to those from the NBM of healthy donors (P = 0 0489) (Fig 
1B).  
Kaplan–Meier analysis of MDS patients with PRAME 
expression above and below median levels showed there 
was no statistical difference between PRAME expression 
levels and OS (mononuclear cells P = 0 9744; CD34
+
 P = 0 
7781). However, when we used PRAME expression levels to 
divide the patients in Data set A into quartiles, we found that 
those with a PRAME expression level in the upper (Q1) or 
lower (Q4) quartiles showed poorer survival than those with 
an intermediate (Q2 and Q3) expression level. By combining 
patients into two groups, a significant reduction in OS was 
observed in patients with extreme PRAME expression levels 
(Q1 and 4) compared to those with PRAME expression within 
the interquartile range (Q2 and 3) (P-value of 0 0166 by Log-
rank test) (Fig 2A). When patients in Data set B were similarly 
divided into two groups (Q1 and Q4 versus Q2 and Q3), in 
this case based on PRAME expression levels mea-sured in 
the CD34
+
 compartment, a comparable reduction in OS was 
revealed (P-value of 0 0207 by Log-rank test) 
 
 
(Fig 2B). We performed a Fisher’s exact test for indepen-
dence, based on PRAME expression in the upper (Q1), 
inter-mediate (Q2 and Q3) and lower (Q4) quartiles versus 
the four IPSS groups on samples from Data set A. 
Although numbers were small, a P-value of 0 4944 
indicated that PRAME is unlikely to be a surrogate for 
IPSS score, at least in this cohort. 
 
Our data suggests a Goldilocks effect of the level of 
PRAME expression as a biomarker for survival. In this 
regard, either very high or very low levels of PRAME 
expression correlate with poor survival (Fig 2A,B). This 
apparent paradox may be explained by low levels of 
PRAME expression allowing leukaemia cells to evade the 
immune system, whilst higher levels of PRAME may 
reflect a higher tumour load and/or more aggressive 
leukaemia cells present at disease presentation. We 
believe that this is the first demonstration of a correlation 
between high and low PRAME expression levels in MDS 
and survival. The demon-stration of a Goldilocks effect, 
with regards to the level of PRAME expression and 
survival, may explain the variable interpretations of the 
impacts of PRAME levels on patient survival and should 
be considered when investigating other tumour-
associated/CT antigens as potential biomarkers in the 
future. 
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SEREX: serological identification of antigens by recombinant expression cloning; SSX2IP: Synovial 
Sarcoma X breakpoint 2 interacting protein; WT1: Wilms’ tumour antigen 1.  
ABSTRACT 
First complete remission rates are high in patients with acute myeloid leukaemia (AML) with 
some variation depending on the presence of specific cytogenetic and molecular aberrations. 
However the remission is often not long lasting and relapse occurs after standard chemotherapy 
within 2 years. Therefore besides chemotherapy, non-specific immunotherapy in the form of 
allogeneic haematopoietic stem cell transplantation is an integral part of consolidation and 
salvage therapy in the treatment of AML. A large number of leukaemia-associated antigens 
(LAAs) which can act as potential targets for specific immunotherapy have been identified and 
the number is still increasing. To date, several of these antigens are being utilised in clinical 
vaccination trials, either as active specific immunotherapy in form of peptide vaccination or as 
passive specific immunotherapy as adoptive cell therapies. In this review we will illustrate the 
role of newly defined LAAs as well as the results of already performed clinical vaccination trials 
with known LAAs to give an overview and evaluation of the state-of-the-art. 
 
 
INTRODUCTION 
Allogeneic haematopoietic stem cell transplantation (HSCT) and donor leukocyte infusion (DLI) 
with its crucial graft-versus-leukaemia (GvL)-effect demonstrate the important role of 
immunotherapy in the treatment of leukaemia and other malignant haematologic diseases (Figure 
1). The GvL-effect is based on a predominantly cytotoxic T lympphocyte (CTL) mediated 
immune response which targets minor histocompatibility antigens (mHAgs) (Kloosterboer et al., 
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2004) and leukaemia-associated antigens (LAAs). The use of unselected immunotherapy in the 
form of HSCT and DLI can initiate graft-versus-host disease (GvHD) with devastating 
consequences indicating the need to develop more leukaemia-specific immunotherapies. At this 
point, LAAs which show an expression that is almost specific to leukaemia cells and more 
importantly to leukaemic stem cells (LSC), come into play. These act as gate keepers to CTLs 
which are able to be exquisitely specific in their elimination of malignant cells. However due to 
the low frequency of LAA-specific CTLs, studies have been inaugurated to expand LAA-specific 
T-cells in vitro for passive immunotherapy as a form of adoptive T-cell transfer or in vivo for 
active immunotherapy with the help of peptide vaccination to induce or potentiate LAA-specific 
T-cell responses.  
 
 
LAAs 
The first tumour-associated antigen, called melanoma associated antigen (MAGE), was identified 
in the early 1990s by T-cell expression cloning. The subsequent development of the serological 
identification of antigens by recombinant expression cloning (SEREX) technique has allowed the 
rapid identification of antigens from a range of tumour types. A repository detailing more than 
2,000 antigens found by this technique has been developed and called the cancer immunome 
database (http://ludwig-sun5.unil.ch/CancerImmunomeDB/).  
 
To prioritize the myriad of identified antigens, Cheever et al. (2009) devised a list of criteria to 
define the “ideal” target antigen with the order representing the weight of each characteristics 
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(Table 1). Although there is no antigen that fulfills all of the criteria some LAAs seem to be more 
suited for use in clinical vaccination than others.  
 
We focus our review on a short list of LAAs which best fit the criteria. All of these antigens bear 
epitopes that are recognized by CD8+ T cells (CTLs) and for some of them humoral immune 
responses have been described as well (Greiner et al., 2006). The importance of immune 
mechanisms in the success of leukaemia immunotherapy is strengthened by a study using 
microarray analysis in which an association between elevated LAA expression and survival in 
AML patients was found. Expression of at least one of three LAAs - receptor for hyaluronic-acid 
mediated motility (RHAMM), preferentially expressed antigen of melanoma (PRAME), or G250 – 
had a favourable prognostic score (p = 0.005)(Greiner et al., 2006). Similar results were also 
found for the coexpression of three LAAs Synovial Sarcoma X breakpoint 2 interacting protein 
(SSX2IP), Survivin or RHAMM in AML (p = 0.0071)(Guinn et al., 2009). Together with the 
knowledge that several LAA-specific CTLs are skilled to lyse autologous leukaemic blasts 
(Molldrem et al., 1996, Gao et al., 2000), these data led to the hypothesis that the coexpression 
of distinct LAAs on leukaemic blasts facilitates their eradication by eliciting T-cell responses 
following conventional therapy, in a subgroup of patients who respond well to treatment. We 
hypothesised that cell lysis and inflammation around the site of the tumour in these patients 
causes the appropriate “danger” signals to elicit a longer lasting remission due to the effective 
induction of the immune response to kill surviving tumour cells.  
 
LAA EXPRESSION IN LSC  
One reason for the limited and often short-term success of conventional chemotherapy in the 
treatment of AML is that the agents used are not able to eliminate chemoresistent or quiescent 
LSC. Efforts have been made to uncover this subpopulation through their markers to allow 
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minimal residual disease (MRD) monitoring by real-time PCR. For AML patients with a 
nucleophosmin-1 (NPM1)-mutation in their blasts it is the NPM1-mutation load which is a 
prognostic marker for relapse of the disease. Wilms’ tumour antigen 1 (WT1) represents another 
molecular marker for early assessment of MRD as the expression levels in normal 
haematopoietic progenitor cells are at least ten times less than those in leukaemic cells (Inoue et 
al., 1997). Therefore, it is of particular interest to develop therapies to eradicate MRD and 
several working groups have performed gene expression profiling on LSCs to characterize the 
differences between leukaemic and normal HSCs.  LAAs that are expressed by LSCs are of 
special interest as they form the contact point for LSC killing by CTLs and therefore for LSC-
specific immunotherapy. 
 
PROMISING RESULTS FOR VACCINATION TRIALS WITH KNOWN LAAS  
 
PRAME 
 
PRAME was identified as a human melanoma associated antigen recognized by autologous CTL 
although its function still remains unclear. PRAME has been shown to be overexpressed in 
multiple solid cancers and in human germ-line tissues but not or only weakly expressed in other 
healthy tissues. Therefore, PRAME is classified as a cancer-testis antigen (CTA). However, 
unlike most of the other CTAs, PRAME expression has been demonstrated in several 
haematological malignancies including AML and chronic myeloid leukaemia (CML). 
 
A growing body of evidence now indicates that PRAME antigen is an effective MRD marker for 
leukaemia. This could permit prognostic evaluation of each patient shortly after treatment. 
Interestingly, independent studies on adult AML (Zhou et al., 2007, Greiner et al., 2006) have 
163 
 
reported that high expression of PRAME is a marker of a favourable outcome and good overall 
survival. This has been accounted for, at least in part, by the finding that PRAME alters the 
expression of several genes (Hsp27, S100A4, p21, IL-8 and IGFBP-2) involved in 
carcinogenesis, and cancer progression in the case of childhood AML (Tajeddine et al., 2008). 
Similar findings have been reported in cases of acute promyelocytic leukaemia where low 
PRAME expression has indicated shortened relapse-free and overall survival when compared to 
patients with high PRAME expression (Santamaria et al., 2008). However, another study 
suggested that PRAME was directly involved in carcinogenesis and disease progression and its 
inhibition led to the apoptosis of leukaemic cells (Tanaka et al., 2011).  
 
Although PRAME has been targeted in a number of clinical trials for solid tumours in published 
and ongoing clinical trials, in myeloid leukaemia the main focus has been the demonstration of 
PRAME responses post-treatment. This indicates the tumour-specific targetting of CTLs (Li et 
al., 2006) reflecting the immunogenicity of PRAME in the appropriate context. 
 
RHAMM 
RHAMM is an extracellular matrix protein involved in cell differentiation, proliferation and motility. It 
was shown to be immunogenic and to induce humoral and cellular immune responses (Greiner et al., 
2005). mRNA of RHAMM was found to be expressed in AML patients in contrast to normal tissues 
and strong expression of RHAMM mRNA was only found in the testis, placenta and thymus.  
 
A clinical phase I/II peptide vaccination trial with RHAMM-R3 involving two cohorts of patients 
overexpressing RHAMM has been performed. The HLA-A2- restricted RHAMM-R3 peptide was 
emulsified in incomplete Freund’s adjuvant and as a second adjuvant, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) was administered on day 0 until day +2. The patients were 
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vaccinated four times subcutaneously and in a biweekly interval. Altogether, the trial showed no 
drug-induced adverse events higher than the common toxicity criteria (CTC) grade 1 skin 
category. The first 10 patients were vaccinated with 300µg of the peptide and the following 9 
patients with 1000 µg of the peptide (Greiner et al., 2010). The first cohort showed specific 
immune responses in 70% of the patients and positive clinical effects in 50% of the patients with 
a reduction of blasts in the bone marrow in patients with myeloid disorders or a decrease in free 
light chain serum levels in patients with multiple myeloma (MM). In one patient with 
myelodysplastic syndrome (MDS), erythrocyte transfusions were no longer necessary.  
 
In the second cohort with the higher RHAMM-R3-peptide dose, 44% of vaccinated patients 
showed an increase in RHAMM-R3-specific T cells in tetramer and ELISpot assays as surrogate 
parameters for the immunogenic effects of the vaccine. A decrease in specific T-cell responses 
could be observed in some patients after vaccination was stopped, maybe indicating a failure to 
induce high-avidity T–cell activity, or memory responses, against the LAA.   
 
WT1 
WT1 has emerged as one of the most promising targets for AML immunotherapy while also 
being applicable to the treatment of other haematological and solid tumours. Despite its 
ubiquitous expression during embryogenesis, WT1 expression in normal individuals is limited to 
renal podocytes, gonadal cells and a small proportion of normal CD34+ cells where expression is 
significantly lower (10-100 fold). The WT1 gene was originally defined as a tumour suppressor 
gene, however, recent studies suggest that in adults with solid and haematopoietic malignancies 
it also exhibits an oncogenic function.  WT1 is often overexpressed and detected in tumour-
bearing patients where it can induce specific CTL and antibody responses (Li et al., 2008). In 
addition blocking of WT1 expression has been shown to significantly slow the growth of 
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leukaemic blast cells (Yamagami et al., 1996). These properties make WT1 an attractive target 
antigen for developing WT1-based adoptive T cell therapy and vaccination strategies against 
various types of cancers. 
 
WT1 peptide vaccines have been studied in vitro and in clinical trials (Rezvani et al., 2008) 
showing some immune responses but poor persistence. Three peptide vaccines, each encoding 
a different previously described WT1-derived, HLA-A2-restricted epitope, were tested in 
“humanised“ mice expressing a chimeric HLA-A2 molecule (Chaise et al., 2008) and induced 
killing of human WT1+HHD+ leukaemic cells ex vivo.  
 
Oka et al., (2004) performed a phase I clinical trial of a WT1-derived vaccine involving patients 
with a variety of solid and haematopoietic malignancies. In 2004 the outcome of the trial had 
demonstrated the safety of the vaccine and their capacity to expand WT1-specific CTLs. The 
first phase II trial for WT1 peptide vaccination was conducted on patients with AML and MDS 
whose blasts expressed WT1 (Keilholz et al., 2009). The aim of the study was to investigate the 
safety and efficacy of a combination of GM-CSF (days 1-4) as an immune-enhancement 
adjuvant along with the WT1.126-134 peptide and keyhole limpethemocyanin vaccine (on day 
3). The vaccination was reported to have been well tolerated and to have led to blast reduction 
and overall increase in WT1-tetramer+ T cells in the blood and bone marrow of AML patients, 
suggesting its clinical efficacy in AML patients. Further details of recruiting or ongoing phase I 
and II clinical trials targeting WT1 can be found in Table 2. 
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NEW TARGETS FOR IMMUNOTHERAPY 
Aurora kinase A and B 
Aurora kinases are a family of serine/threonine protein kinases (Auroras A, B and C) which play 
an important role in chromosomal seggregation and cell division (Meraldi et al., 2004). Aurora 
kinase A and B have both been shown to be elevated in AML patient samples. Aurora kinase 
inhibitors, in the form of small molecule therapies, have entered Phase I clinical trials for solid 
tumours (Arkenau et al., 2012) while specific antibodies have been used in Phase I/II clinical 
trials on AML patients (Dennis et al., 2012). Both have been shown to be safe, tolerable and to 
have some preliminary efficacy. In vitro such inhibitors have been shown to be able to induce 
growth arrest in a BCR-ABL independent manner and to circumvent imatinib resistance in BCR-
ABL+ cells (Mancini et al., 2012). Chemotherapy appears to potentiate the effect of aurora kinase 
inhibitors in AML (Yoshida et al., 2011). Recently, epitopes derived from Aurora kinase A and B 
have been shown to elicit CD8+ T cell responses in patients with AML (Schneider et al., 2012) 
which may provide an alternative way of killing leukaemic blast cells with upregulated Aurora 
kinase levels. 
 
G250 
G250/CA IX is a membrane associated protein and part of the carbonic anhydrase family. It is 
described as a marker of hypoxia and is regulated by hypoxia-inducible factor alpha. The LAA 
G250/CA IX is expressed in variant solid malignancies but also AML, whereas no expression 
could be detected in normal cells. No clinical  trials have been initiated targetting G250 in AML 
although there have been for other solid tumours, particularly renal cell carcinoma (reviewed 
most recently in (Santoni et al., 2012)). 
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HAGE 
HAGE is a member of the DEAD-box family of ATP-dependent RNA helicases. Other members 
are involved in tumour cell proliferation suggesting a role for HAGE in the RNA metabolism 
and/or control of cell cycle within tumour cells. Like most CTAs, HAGE expression correlates 
with hypomethylation of the promoter region and increased expression has been associated with 
disease progression (Adams et al, 2002; Chen et al., 2011). HAGE expression has been 
demonstrated in CML patients (Adams et al., 2002, Chen et al., 2011). Recent studies indicated 
that the knockdown of HAGE expression by small interfering RNA (siRNA) led to a significant 
decrease in Neuroblastoma RAS protein expression with a concomitant decrease in activation of 
the AKT and ERK signaling pathways in malignant melanoma-initiating cells which are thought 
to play a central role in melanoma progression (Linley et al., 2012). In addition Linley et al 
showed a significant decrease in the tumour growth of ABCB5
+
 melanoma cells in non-obese 
diabetic/severe combined immunodeficiency mice. This demonstrates that therapies targeting 
HAGE helicase may have direct effects on all cancer cells in which HAGE plays a role. 
   
MUC1 
The highly glycosylated type I transmembrane glycoprotein mucin-1 (MUC1) is overexpressed in 
many human adenocarcinomas and it is expressed in MM and some B-cell lymphomas. Brossart 
et al. found MUC1 expression in 67% of AML blast cells, especially FAB M4 and M5 subtypes 
(Brossart et al., 2001). In addition the group showed that MUC1 specific CTLs could be induced 
by peptide pulsed dendritic cells (DCs) from healthy donors, and that these could lyse HLA-A2 
positive MUC1 positive tumour cell lines and primary AML blasts. MUC1 has been shown to 
stabilize the BCR-ABL oncoprotein typical of CML cells and to play a role in the pathogenesis of 
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the disease by promoting CML blast cell self renewal while inhibiting differentiation and 
apoptosis (Kawano et al., 2007). Silencing MUC1 has also been shown to increase CML cell 
sensitivity to imatinib by the same group. 
 
NPM1 
The mutated NPM1 (NPM1mut) protein plays a special role in AML, as it is a prognostic marker 
and AML with NPM1mut belongs to the favorable group of the ELN classification. Mutations in the 
NPM1 gene are one of the most frequent single gene mutations in AML (25%-30%) and they 
predominantly occur in AML with normal karyotype (45%-60%) (Schlenk et al., 2008). Several 
mutations of the NPM1 gene exist in AML, but more than 90% harbour the so-called A, B and D 
mutations (Falini et al., 2007). NPM1 mutation dislocates the nuclear expressed wild-type protein 
into the cytoplasm and hence interferes with the ARF/p53 pathway and NF-κB. 
  
The favourable prognosis of AML with NPM1mut led to the hypothesis that immune responses 
may contribute to the positive outcome by specific lysis of residual leukaemic cells that bear the 
NPM1mut. Therefore, epitopes derived from the mutated regions of NPM1 were analyzed with 
regards to their ability to induce specific CD4+ and CD8+ T-cell responses (Greiner et al., 2012). 
Two HLA-A2 restricted epitopes, induced high frequencies of specific CD8+ T-cell responses in 
healthy volunteers  and AML patients (Hofmann et al., 2013).  
 
In AML with NPM1mut, the NPM1mut load can be used to detect MRD by real-time quantitative 
polymerase chain reaction and more than 200 NPM1mut/104 ABL copies or an increasing load 
over time indicates early relapse in the post-treatment phase (Kronke et al., 2011). Patients 
harbouring a low tumour burden represented by MRD without haematological relapse, could be 
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vaccinated to expand NPM1mut–specific CD8+ T-cells to prolong remission or even cure the 
disease. 
 
PASD1 
PASD1 was identified as a CTA in diffuse large B-cell lymphoma (Liggins et al., 2004) and 
AML (Guinn et al., 2005).  The gene maps to chromosome Xq28 and alternative splicing 
produces at least two variants, PASD1_v1 and PASD1_v2 (Liggins et al., 2004). PASD1 may be 
an important CTA for haematological malignancies as it is frequently expressed in myeloid 
leukaemia (Guinn et al., 2005).  There is evidence that CD4 and CD8 T cells can respond to 
PASD1 epitopes in patients with lymphoma (Ait-Tahar et al., 2009) and myeloid leukaemia 
(Hardwick et al., in press) while DNA vaccines targeting PASD1 epitopes have shown efficacy in 
HLA-A2 chimeric HHD mice (Joseph-Pietras et al., 2010)(Hardwick et al., in press). 
 
SSX2/SSX2IP  
The SSX family of genes are CTAs which include SSX2.  SSX2 is expressed in a range of 
leukaemia cell lines (Figure 2) as well as 50% of human melanomas, 25% of colon cancers, 30% 
of hepatocarcinomas and 20% of breast carcinomas (Tureci et al., 1996).  Synovial sarcomas are 
characterised by the t(X; 18) translocation which sees the fusion of SSX2 with the gene SYT on 
chromosome 18. SSX2 has been found to have a strong association with reduced survival in MM 
(p = 0.0001) (Taylor et al., 2005) and overexpression of SSX2 induces cell growth and prompts 
cell invasion by suppression of ERα and E-cadherin (Chen et al., 2012).     
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SSX2 interacting protein (SSX2IP) was identified by a yeast two-hybrid screening system as an 
associate of SSX2 (de Bruijn et al., 2002).  Elevated expression of SSX2IP at disease presentation 
was associated with improved survival (Guinn et al., 2009) in AML patients who lacked 
cytogenetic abnormalities while levels of SSX2IP expression in AML patients harboring a t(8;21) 
translocation were reduced (Guinn et al., 2007). Using microarray datasets, associations between 
SSX2IP and the genes involved in spindle checkpoints were found. A strong correlation between 
low-CDC20 expression, one of the substrate-targeting subunits of the anaphase-promoting 
complex and low SSX2IP expression in patients harbouring a t(8;21) translocation (P<0.0001) 
suggested that SSX2IP may also play a role in mitotic spindle failure in this group of patients. 
Indeed SSX2IP expression was increased in patients who have the t(15;17) translocation and 
found to be significantly associated with genes involved in the cell cycle.  
 
SUMMARY 
Results from completed clinical phase I/II trials in which LAAs in the form of peptides or administered 
via DC vaccination strategies are encouraging. Although none of the LAAs listed above fulfil all 
criteria for an ideal target antigen, clinical efficacy as well as immunogenicity can be influenced by the 
optimal regimen. Careful consideration of vaccination intervals, use and choice of an adjuvant and 
dosage remain to be optimised in many studies. In the post-treatment/remission phase, when a low 
tumour burden is achieved through chemotherapy and/or allogeneic HSCT, immunotherapy appears to 
be a promising tool to remove residual disease and support a longer-lasting remission of the leukaemia 
with the potential to lead to cures. 
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Table 1. Characteristics of the “ideal” target antigen as applied to myeloid leukaemias (based on 
criteria developed by Cheever et al. 2009) 
 
Characteristics of the “ideal” 
target antigen  
Examples of antigens 
fitting this criteria 
References 
(a)   Induce clinical effects 
 
WT1 
 
 
RHAMM 
G250 
Aurora kinase A & B 
 
NPM1 mutation 
Rezvani et al., 2008 
Oka et al., 2004 
Keilholz et al., 2009 
Greiner et al., 2010 
Santoni et al., 2012 
Arkenau et al., 2012 
Dennis et al., 2012 
Hofmann et al., 2013 
 (b) Immunogenic  
 
 
PRAME 
RHAMM 
WT1 
MUC1 
PASD1 
Li et al., 2006 
Greiner et al., 2005 
Chaise et al., 2008 
Brossart et al., 2001 
Ait-Tahar et al., 2009 
Joseph-Petras et al., 2010 
Hardwick et al., in press 
(c) Critical role in cell differentiation 
and proliferation of the malignant 
cells or characterize the malignant 
cell  
PRAME 
WT1 
Aurora kinase A & B 
HAGE 
MUC1 
SSX2IP 
Tanaka et al., 2011 
Yamagami et al., 1996 
Mancini et al., 2012 
Linley et al., 2012 
Kawano et al., 2007 
Guinn et al., 2007 
(d) Expression restricted to 
malignant cells 
G250 
 
Greiner et al., 2006 
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(e) Expression in all malignant cells   
(f) Expression in malignant stem 
cells 
NPM1 mutation 
WT1 
Falini et al., 2007 
Keiholz et al., 2009 
(g) High number of patients bearing 
antigen-positive cells 
WT1 
NPM1 mutation 
PASD1 
SSX2IP 
Inoue et al, 1997 
Falini et al., 2007 
Guinn et al., 2005 
Guinn et al., 2005 
(h) Includes multiple antigenic 
epitopes 
WT1 
Aurora kinase A & B 
NPM1 mutation 
 
PASD1 
Chaise et al., 2008 
Schneider et al., 2012 
Greiner et al., 2012 
Hofmann et al., 2013 
Ait-Tahar et al., 2009 
Hardwick et al., in press 
(i) Expressed on the cell surface SSX2IP Denniss et al., 2007 
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Table 2. Active Phase I and II clinical trials targeting WT1 in the myeloid leukaemias 
No. Phase Purpose Cancer type 
Principal 
Investigator 
Status 
Date to be 
completed: 
Identifier 
(ClinicalTrials
.gov) 
1 I, II 
To evaluate the safety and the efficacy 
of combined treatment strategy: 
Recombinant WT1 -A10 + AS01B 
Antigen-Specific Cancer 
Immunotherapeutic (ASCI) combined 
with regulatory T cell depletion. 
WT1-positive AML 
Institute 
Jules Bordet 
Active 12/2014 NCT01513109 
2 I 
To evaluate the safety and efficacy of 
treatment with WT1-sensitized T cells. 
WT1-positive residual or 
relapsed leukaemia after 
allogeneic 
hematopoietic 
progenitor cell 
transplantation. 
R. O'Reilly Active 02/2013 NCT00620633 
3 II 
To evaluate the safety and efficacy of 
treatment with p.DOM-epitope DNA 
vaccination in patients with WT1-
positive CML and AML. 
WT1-positive CML, 
ALL, APL  and AML 
K. Rezvani Active 08/2012 NCT01334060 
4 I 
To evaluate the safety and efficacy of 
treatment with WT1 peptide vaccine in 
combination with Montanide ISA-51 and 
GM-CSF. 
WT1-positive AML, 
CML, ALL, MDS, B cell 
malignancies. 
M. Morse Active 06/2014 NCT00672152 
5 II 
To evaluate the safety and efficacy of 
GSK2302024A antigen-specific cancer 
immunotherapeutic combined With 
Standard Neoadjuvant Treatment. 
WT1-positive primary 
invasive breast cancer 
Pharmacy/ 
Industry 
Active 12/2013 NCT01220128 
6 II To evaluate the safety, immunogenicity 
and antitumour activity of WT2725. 
WT1-positive 
advanced solid 
malignancies  
Pharmacy/ 
Industry 
Active 09/2013 NCT01621542 
7 I, II 
To determine the safety, effectiveness, 
immune response and side effects of 
giving WT1 peptide-pulsed DCs and 
donor white blood cells to patients. 
WT1-positive AML, 
ALL, CML,MDS, NHL 
A. Wayne Active 11/2015 NCT00923910 
8 I, II 
To evaluate the safety and efficacy of 
WT1 TCR-transduced T cells.  
WT1-positive AML and 
CML 
E. Morris Active 04/2016 NCT01621724 
9 II 
To evaluate the safety and efficacy of 
WT1-vaccine Montanide + GM-CSF 
WT1-positive 
malignant pleural 
mesothelioma 
L. Krug Active 12/2014 NCT01265433 
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Figure 1: Schematic presentation of the need of immunotherapy in the treatment of AML. 
At the time of diagnosis, the load of leukemic blasts (yellow circles) as well as of leukaemic stem 
cells (red circles, MRD minimal residual disease as detected by WT1 and/or NPM1mut 
expression) is high and minimises the space available to normal haematopoietic cells (blue 
circles) in the bone marrow. After chemotherapy cycles, the MRD burden decreases as well as 
the burden of leukaemic blasts but often quiescent or chemoresistant leukaemic stem cells are 
not eliminated. Immunotherapeutic approaches have the potential to target LAAs expressed in 
and on leukaemic stem cells such that a LAA-specific vaccine could boost LAA-specific cytotoxic 
T-cells and lead to a long-lasting remission.  
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Figure 2. SSX2 expression in human leukaemia cell lines. Leukaemia cell lines were spotted at 5 x 10
6
 
cells per ml in PBS and air dried. Cells were fixed in cold methanol, permeabilised with 0.25% saponin 
20min (with 0.05% saponin in all subsequent buffers). Slides were washed 3 x in TBS and then incubated 
with 40µl of primary mouse rabbit anti-human SSX2 antibody (clone 4d10) from Abcam (1/200) was 
incubated with the cells overnight at 4
o
C. Slides were washed 3 x in TBS and then incubated with 40µl of 
goat anti-rabbit:AF488, diluted 1/1000 (Life Technologies) was incubated with the cells for 1hr and 
visualised following the addition of Vectamount with DAPI (Vector Labs). Nuclei were stained with 
DAPI (blue). Images were collected with an Olympus CKX inverted microscope with reflected 
fluorescence system with Olympus CellB software. Blue and green images (TIFF) were transferred to 
Adobe Photoshop CS5 merged and contrast stretched to use the whole grey scale. Jurkats is a human T 
cell leukaemia cell line, the white bar shows a 100µm scale bar) while HL60, VLB, U937, P39 and NB4 
are myeloid leukaemia cell lines. Intracellular staining with SSX2 is predominantly nuclear with some 
cytoplasmic except U937 (mostly cytoplasmic) and NB4 (strong nuclear and cytoplasmic staining). 
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Appendix II   SEREX Primary Immunoscreening 
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Date of 
experiment 
and Plate No.  
SERUM ID 
Plaques 
cored out 
and label 
Total 
No. of 
plaqu
es 
Plaques confirmation - 
date of Secondary SEREX 
screening 
Date of  
isolating 
positive 
plaques  
No. Of isolated 
plaques 
29.1.2013    1 
CC005 
1:2000 
310113-1-1 
4116 
negative (22/5/13) (CC005) / / 
310113-1-2 negative (22/5/13) (CC005) / / 
29.1.2013    2 
CC005 
1:2000 
0 3716 / / / 
29.1.2013    3 
CC005 
1:2000 
0 3948 / / / 
29.1.2013    4 
CC005 
1:2000 
310113-4-1 4452       
29.1.2013    5 
CC005 
1:2000 
310113-5-1 
3516 
negative (22/5/13) (CC005) / / 
310113-5-2 negative (22/5/13) (CC005) / / 
29.1.2013    6 
CC005 
1:2000 
0 3736 / / / 
29.1.2013    7 
CC005 
1:2000 
310113-7-1 3656 negative (22/5/13) (CC005) / / 
29.1.2013    8 
CC005 
1:2000 
0 3452 / / / 
              
06.2.2013    1 
CC014 
1:200 
060213-1-1 3924       
06.2.2013    2 
CC014 
1:200 
060213-2-1 
3072 
UOB-COL-1 (19/02/13) 
20/02/13 
3x(CC005)                
3x(CC014) 
21/06/13 
negative with CC014 
negative with CC005 
negative with CC010 
060213-2-2 
negative (27/06/13) (CC005) 
negative (27/06/13) (CC010) 
negative (27/06/13) (CC014) 
negative (13/07/13) (CC014) 
/ / 
06.2.2013    3 
CC014 
1:200 
060213-3-1 
3248 
negative (27/06/13) (CC005) 
negative (27/06/13) (CC010) 
negative (27/06/13) (CC014) 
negative (13/07/13) (CC014) 
/ / 
060213-3-2 negative (27/06/13) (CC014)      
06.2.2013    4 
CC014 
1:200 
0 3724 / / / 
06.2.2013    5 
CC014 
1:200 
0 4124 / / / 
06.2.2013    6 
CC014 
1:200 
060213-6-1 2916       
              
12.2.2013   1 
CC014 
1:200 
0 3452 / / / 
184 
 
12.2.2013   2 
CC014 
1:200 
130213-2-1 3140       
12.2.2013   3 
CC014 
1:200 
130213-3-1 
3332 
      
130213-3-2 negative (07/03/13) (CC014) / / 
12.2.2013    4  
CC014 
1:200 
130213-4-1 
3656 
negative (21/06/13) (CC005) 
negative (21/06/13) (CC010) 
negative (21/06/13) (CC014) 
/ /  
130213-4-2 negative (28/02/13) (CC014) / / 
130213-4-3       
130213-4-4       
130213-4-5 negative (07/03/13) (CC014) / / 
130213-4-6       
12.2.2013    5 
CC014 
1:200 
130213-5-1 3852 negative (07/03/13) (CC014) / / 
              
18.2.2013   1 
CC005 
1:200 
0 TMTC / / / 
18.2.2013   2 
CC005 
1:200 
190213-2-1 
4300 
      
190213-2-2       
190213-2-3       
190213-2-4       
18.2.2013   3 
CC005 
1:200 
190213-3-1 3956 
negative (21/03/13) (CC005)   / / 
UOB-COL-8  (CC005) (7/4/13) 07/04/13 8x(CC005) 
18.2.2013   4 
CC005 
1:200 
190213-4-1 4844       
18.2.2013   5 
CC014 
1:200 
190213-5-1 4128 UOB-COL-2  (28/02/13) 07/03/13 3x(CC014) 
18.2.2013   6 
CC014 
1:200 
190213-6-1  
4404 
negative (07/03/13) (CC014) / / 
190213-6-2       
              
26.2.2013    1 
CC014 
1:200 
260213-1-1 4256       
26.2.2013    2 
CC014 
1:200 
0 4276 / / / 
26.2.2013    3 
CC014 
1:200 
260213-3-1 
4152 
negative (21/03/13) (CC014) / / 
260213-3-2 
negative (06/07/13) (CC005) 
negative (06/07/13) (CC010) 
negative (06/07/13) (CC014) 
negative (13/07/13) (CC014) 
/ / 
260213-3-3 
negative (27/06/13) (CC005) 
negative (27/06/13) (CC010) 
negative (27/06/13) (CC014) 
negative (13/07/13) (CC014) 
/ / 
26.2.2013    4 
CC005 
1:200 
260213-4-1 
4300 
      
260213-4-2       
260213-4-3       
185 
 
26.2.2013    5 
CC005 
1:200 
260213-5-1 
4132 
negative (27/06/13) (CC005) 
negative (27/06/13) (CC010) 
negative (27/06/13) (CC014) 
negative (19/07/13) (CC005) 
/ / 
260213-5-2 
negative (21/06/13) (CC014) 
negative (21/06/13) (CC005) 
negative (21/06/13) (CC010) 
  / / 
260213-5-3       
26.2.2013   6 
CC005 
1:200 
260213-6-1 
4040 
      
260213-6-2       
260213-6-3 
negative (06/07/13) (CC005) 
negative (06/07/13) (CC010) 
negative (06/07/13) (CC014) 
negative (19/07/13) (CC005) 
/ / 
260213-6-4       
260213-6-5       
260213-6-6       
              
5.3.2013   1 
CC005 
1:200 
050313-1-1 4892 negative (22/5/13) (CC005) / / 
5.3.2013   2 
CC005 
1:200 
050313-2-1 4584 negative (22/5/13) (CC005) / / 
5.3.2013   3 
CC005 
1:200 
050313-3-1 
4132 
negative (22/5/13) (CC005) / / 
050313-3-2 
negative (06/07/13) (CC005) 
negative (06/07/13) (CC014) 
negative (06/07/13) (CC010) 
negative (13/07/13) (CC014)  
/ / 
050313-3-3 
negative (21/03/13) (CC005) 
negative (14/06/13) (CC005) 
negative (14/06/13) (CC010) 
/ / 
050313-3-4 negative (11/04/13) (CC014) / / 
050313-3-5 
negative (07/04/13) (CC005) 
negative (11/04/13) (CC014) 
negative (21/06/13) (CC010)  
/ / 
050313-3-6 negative (11/04/13) (CC014) / / 
5.3.2013    4 
CC014 
1:200 
050313-4-1 
4336 
negative (11/04/13) (CC005) / / 
050313-4-2 
negative (27/06/13) (CC005) 
negative (27/06/13) (CC010) 
negative (27/06/13) (CC014) 
negative (19/07/13) (CC005) 
/ / 
050313-4-3 
negative (21/03/13) (CC005) 
negative (07/04/13) (CC014) 
/ / 
050313-4-4       
050313-4-5 UOB-COL-14 (14/06/13) 
14/06/13 3x(CC005) 
14/06/13 negative with CC010 
186 
 
050313-4-6 
negative (01/05/13) (CC005) 
negative (01/05/13) (CC010) 
negative (16/06/13) (CC005) 
negative (14/06/13) (CC010) 
/ / 
050313-4-7 
negative (21/03/13) (CC005) 
negative (07/04/13) (CC014) 
/ / 
050313-4-8 
negative (11/04/13) (CC005) 
negative (21/06/13) (CC005) 
negative (21/06/13) (CC010) 
negative (21/06/13) (CC014) 
/ / 
5.3.2013    5 
CC014 
1:200 
050313-5-1 
5252 
      
050313-5-2 UOB-COL-15 (14/6/13) 
14/06/13 3x(CC005) 
14/06/13 negative with CC010 
050313-5-3 UOB-COL-11 (11/4/13) 11/04/13 5x(CC005) 
050313-5-4 
negative (21/03/13) (CC005) 
negative (07/04/13) (CC014) 
/ / 
050313-5-5 UOB-COL-3 (14/03/13) 
14/03/13 3x(CC005) 
27/04/13 4x(CC005) 
27/04/13 negative with CC014 
5.3.2013    6 
CC014 
1:200 
050313-6-1 
4136 
UOB-COL-4 (14/03/13) 
21/03/13 
07/04/13 
29/04/13  
29/04/13 
3x(CC005)                     
3x(CC014)                 
4x(CC005)                 
negative with CC014 
050313-6-2       
050313-6-3 negative (14/03/13) (CC005) / / 
050313-6-4 negative (14/03/13) (CC005) / / 
050313-6-5       
050313-6-6 UOB-COL-6 (14/03/13) 
21/03/13 
07/04/13 
3x(CC005)            
3x(CC014) 
050313-6-7 UOB-COL-12 (11/4/13) 11/04/13 5x(CC005) 
050313-6-8 UOB-COL-5 (21/03/13) 
21/03/13 3x(CC005) 
07/04/13 negative with CC014 
29/04/13 3x(CC014) 
29/04/13 5x(CC005) 
050313-6-9 UOB-COL-10 (11/4/2013) 11/04/13 5x(CC005) 
050313-6-
10 
negative (11/04/13) (CC005) / / 
5.3.2013    7 
CC014 
1:200 
050313-7-1 
4976 
UOB-COL-9 (11/04/13) 11/04/13 5x(CC005) 
050313-7-2 
negative (06/07/13) (CC005) 
negative (06/07/13) (CC014) 
negative (06/07/13) (CC010) 
negative (13/07/13) (CC005)  
/ / 
050313-7-3 
negative (06/07/13) (CC005) 
negative (06/07/13) (CC014) 
negative (06/07/13) (CC010)  
/ / 
050313-7-4 
negative (14/06/13) (CC005) 
negative (14/06/13) (CC010) 
/ / 
187 
 
050313-7-5 
negative (07/04/13) (CC014) / / 
UOB-COL-13 (11/04/13) 11/04/13 5x(CC005) 
050313-7-6 UOB-COL-7 (14/03/13) 21/03/13 3x(CC005) 
050313-7-7       
050313-7-8 
negative (21/06/13) (CC014) 
negative (21/06/13) (CC005) 
negative (21/06/13) (CC010) 
negative (13/07/13) (CC005) 
/ / 
              
12.3.2013    1 
CC005 
1:200 
130313-1-1 3856       
12.3.2013    2 
CC014 
1:200 
130313-2-1 
4124 
negative (21/03/13) (CC014) 
negative (01/05/13) (CC005) 
negative (01/05/13) (CC010) 
negative (14/06/13) (CC005) 
negative (14/06/13) (CC010)  
/ / 
130313-2-2 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
/ / 
130313-2-3 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
/ / 
130313-2-4 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
/ / 
130313-2-5 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
/ / 
130313-2-6 negative (11/04/13) (CC014) / / 
130313-2-7 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
/ / 
130313-2-8 negative (11/04/13) (CC014) / / 
12.3.2013    3 
CC014 
1:200 
130313-3-1 
3940 
negative (11/04/13) (CC014) / / 
130313-3-2 negative (11/04/13) (CC014) / / 
130313-3-3 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
negative (01/05/13) (CC010) 
/ / 
130313-3-4 
negative (11/04/13) (CC014) 
negative (29/04/13) (CC005) 
/ / 
12.3.2013    4 
CC005 
1:200 
0 4444 / / / 
              
19.3.2013   1 
CC014 
1:200 
200313-1-1 
4144 
negative (15/05/13) (CC014) / / 
200313-1-2 
negative (21/06/13) (CC014) 
negative (21/06/13) (CC005) 
negative (21/06/13) (CC010) 
/ / 
19.3.2013   2 
CC014 
1:200 
200313-2-1 4552 negative (15/05/13) (CC014)     
19.3.2013   3 
CC014 
1:200 
0 4340 / / / 
19.3.2013   4 
CC014 
1:200 
200313-4-1 
4620 
negative (15/05/13) (CC014) / / 
200313-4-2 negative (15/05/13) (CC014) / / 
188 
 
              
25.3.2013   1 
CC005 
1:200 
0 3756 / / / 
25.3.2013   2 
CC005 
1:200 
0 3564 / / / 
25.3.2013   3 
CC005 
1:200 
250313-3-1 
4040 
negative (03/04/13) (CC005) / / 
250313-3-2 negative (03/04/13) (CC005) / / 
25.3.2013   4 
CC005 
1:200 
0 3796 / / / 
25.3.2013   5 
CC005 
1:200 
0 3844 / / / 
25.3.2013   6 
CC014 
1:200 
0 4520 / / / 
25.3.2013   7 
CC014 
1:200 
0 4800 / / / 
25.3.2013   8 
CC014 
1:200 
250313-8-1 
4044 
negative (03/04/13) (CC014) 
/ / 250313-8-2 negative (03/04/13) (CC014) 
250313-8-3 negative (03/04/13) (CC014) 
25.3.2013   9 
CC014 
1:200 
0 3852 / / / 
25.3.2013   
10 
CC014 
1:200 
0 3936 / / / 
              
28.3.2013   1 
CC005 
1:200 
0 4256 / / / 
28.3.2013   2 
CC005 
1:200 
290313-2-1 
3728 
negative (03/04/13) (CC005) / / 
290313-2-2 negative (03/04/13) (CC005) / / 
28.3.2013   3 
CC005 
1:200 
0 3932 / / / 
28.3.2013   4 
CC005 
1:200 
0 4440 / / / 
28.3.2013   5 
CC014 
1:200 
290313-5-1 4920 negative (03/04/13) (CC014) / / 
28.3.2013   6 
CC014 
1:200 
290313-6-1 4040 negative (03/04/13) (CC014) / / 
28.3.2013   7 
CC014 
1:200 
0 3852 / / / 
              
06.4.2013   1 
CC005 
1:200 
0 4440 / / / 
06.4.2013   2 
CC014 
1:200 
0 3724 / / / 
06.4.2013   3 
CC014 
1:200 
0 4844 / / / 
06.4.2013   4 
CC005 
1:200 
060413-4-1 
3644 
      
060413-4-2       
060413-4-3       
189 
 
060413-4-4       
06.4.2013   5 
CC005 
1:200 
060413-5-1 
3968 
      
060413-5-2       
060413-5-3       
060413-5-4       
060413-5-5       
              
29.4.2013   1 
CC005 
1:200 
0 3724 / / / 
29.4.2013   2 
CC005 
1:200 
0 3460 / / / 
29.4.2013   3 
CC005 
1:200 
0 3964 / / / 
29.4.2013   4 
CC014 
1:200 
0 2860 / / / 
29.4.2013   5 
CC014 
1:200 
0 5520 / / / 
29.4.2013   6 
CC014 
1:200 
0 5244 / / / 
              
02.5.2013   1 
CC005 
1:200 
0 4844 / / / 
02.5.2013   2 
CC005 
1:200 
0 4524 / / / 
02.5.2013   3 
CC005 
1:200 
030513-3-1 
4072 
negative (08/05/13) (CC005) / / 
030513-3-2 negative (08/05/13) (CC005) / / 
02.5.2013   4 
CC005 
1:200 
0 4880 / / / 
02.5.2013   5 
CC014 
1:200 
030513-5-1 5244 negative (08/05/13) (CC010) / / 
02.5.2013   6 
CC014 
1:200 
0 3944 / / / 
02.5.2013   7 
CC014 
1:200 
0 4052 / / / 
02.5.2013   8 
CC014 
1:200 
0 4660 / / / 
02.5.2013   9 
CC010 
1:200 
0 4852 / / / 
02.5.2013   
10 
CC010 
1:200 
0 4724 / / / 
              
06.5.2013   1 
CC005 
1:200 
0 3892 / / / 
06.5.2013   2 
CC005 
1:200 
0 4052 / / / 
06.5.2013   3 
CC005 
1:200 
0 4252 / / / 
06.5.2013   4 CC010 0 3872 / / / 
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1:200 
06.5.2013   5 
CC010 
1:200 
0 4804 / / / 
06.5.2013   6 
CC010 
1:200 
0 4644 / / / 
              
13.5.2013   1 
CC005 
1:200 
0 4052 / / / 
13.5.2013   2 
CC005 
1:200 
0 4844 / / / 
13.5.2013   3 
CC005 
1:200 
0 3964 / / / 
13.5.2013   4 
CC005 
1:200 
0 5204 / / / 
13.5.2013   5 
CC010 
1:200 
0 3884 / / / 
13.5.2013   6 
CC010 
1:200 
0 4344 / / / 
13.5.2013   7 
CC010 
1:200 
0 4844 / / / 
13.5.2013   8 
CC010 
1:200 
0 5164 / / / 
13.5.2013   9 
CC010 
1:200 
0 4644 / / / 
13.5.2013   
10 
CC010 
1:200 
0 4528 / / / 
13.5.2013   
11 
CC014 
1:200 
0 3960 / / / 
13.5.2013   
12 
CC014 
1:200 
0 3936 / / / 
13.5.2013   
13 
CC014 
1:200 
0 4576 / / / 
              
17.5.2013 1 
CC014 
1:200 
0 4524 / / / 
17.5.2013 2 
CC014 
1:200 
180513-2-1 
4264 
negative (22/05/13) (CC014) / / 
180513-2-2 negative (22/05/13) (CC014) / / 
180513-2-3 negative (22/05/13) (CC014) / / 
180513-2-4 negative (22/05/13) (CC014) / / 
17.5.2013 3 
CC005 
1:200 
180513-3-1 3992 negative (29/05/13) (CC005) / / 
17.5.2013 4 
CC005 
1:200 
0 4052 / / / 
17.5.2013 5 
CC005 
1:200 
180513-5-1 
3612 
negative (29/05/13) (CC005) / / 
180513-5-2 negative (29/05/13) (CC005) / / 
180513-5-3 negative (29/05/13) (CC005) / / 
17.5.2013   6 
CC005 
1:200 
0 4844 / / / 
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17.5.2013   7 
CC010 
1:200 
0 5204 / / / 
17.5.2013   8 
CC010 
1:200 
180513-8-1 
5156 
negative (22/05/13) (CC010) / / 
180513-8-2 negative (22/05/13) (CC010) / / 
180513-8-3 negative (22/05/13) (CC010) / / 
              
19.5.2103   1 
CC005 
1:200 
0 4480 / / / 
19.5.2103   2 
CC005 
1:200 
0 4292 / / / 
19.5.2103   3 
CC005 
1:200 
0 4740 / / / 
19.5.2103   4 
CC005 
1:200 
0 4852 / / / 
19.5.2103   5 
CC010 
1:200 
0 4264 / / / 
19.5.2103   6 
CC010 
1:200 
0 4336 / / / 
19.5.2103   7 
CC010 
1:200 
0 4852 / / / 
19.5.2103   8 
CC010 
1:200 
200513-8-1 
4768 
negative (29/05/13) (CC010) / / 
200513-8-2 negative (29/05/13) (CC010) / / 
19.5.2103   9 
CC010 
1:200 
0 4440 / / / 
19.5.2103   
10 
CC014 
1:200 
0 5220 / / / 
19.5.2103   
11 
CC014 
1:200 
0 5616 / / / 
              
27.5.2013   1 
CC005 
1:200 
0 5464 / / / 
27.5.2013   2 
CC005 
1:200 
0 5524 / / / 
27.5.2013   3 
CC005 
1:200 
0 5164 / / / 
27.5.2013   4 
CC010 
1:200 
0 5644 / / / 
27.5.2013   5 
CC010 
1:200 
0 5896 / / / 
27.5.2013   6 
CC010 
1:200 
0 5124 / / / 
27.5.2013   7 
CC014 
1:200 
0 5252 / / / 
27.5.2013   8 
CC014 
1:200 
0 5180 / / / 
27.5.2013   9 
CC014 
1:200 
0 4712 / / / 
27.5.2013   
10 
CC014 0 5776 / / / 
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1:200 
              
03.6.2013  1 
CC010 
1:200 
0 4964 / / / 
03.6.2013  2 
CC010 
1:200 
0 4704 / / / 
03.6.2013  3 
CC010 
1:200 
0 5652 / / / 
03.6.2013  4 
CC010 
1:200 
0 5684 / / / 
03.6.2013  5 
CC010 
1:200 
0 4692 / / / 
03.6.2013  6 
CC005 
1:200 
0 4864 / / / 
03.6.2013  7 
CC005 
1:200 
0 5152 / / / 
03.6.2013  8 
CC005 
1:200 
0 5432 / / / 
03.6.2013  9 
CC014 
1:200 
0 4904 / / / 
03.6.2013  10 
CC014 
1:200 
0 4392 / / / 
              
12.6.2013   1 
CC005 
1:200 
0 4736 / / / 
12.6.2013   2 
CC005 
1:200 
0 4844 / / / 
12.6.2013   3 
CC014 
1:200 
0 4380 / / / 
12.6.2013   4 
CC014 
1:200 
0 5204 / / / 
              
24.6.2013   1 
CC005 
1:200 
260613-1-1 5108 
  
  
24.6.2013   2 
CC005 
1:200 
260613-2-1 
5604 
negative (24/07/13) (CC005) / / 
260613-2-2 negative (24/07/13) (CC005) / / 
24.6.2013   3 
CC005 
1:200 
260613-3-1 5248 negative (24/07/13) (CC005) / / 
24.6.2013   4 
CC014 
1:200 
0 5196 /  /  / 
24.6.2013   5 
CC010 
1:200 
0 5444 /  /  / 
24.6.2013   6 
CC010 
1:200 
0 5084 /  /  / 
              
01.7.2013   1 
CC005 
1:200 
0 5204 / / / 
01.7.2013   2 CC005 0 4448 / / / 
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1:200 
01.7.2013   3 
CC005 
1:200 
030713-3-1 
4924 
negative (24/07/13) (CC005) / / 
030713-3-2 negative (24/07/13) (CC005) / / 
01.7.2013   4 
CC005 
1:200 
0 4880 / / / 
01.7.2013   5 
CC014 
1:200 
030713-5-1 5244 negative (24/07/13) (CC014) / / 
01.7.2013   6 
CC014 
1:200 
0 5288 / / / 
01.7.2013   7 
CC014 
1:200 
0 4660 / / / 
01.7.2013   8 
CC014 
1:200 
0 5608 / / / 
01.7.2013   9 
CC010 
1:200 
0 5244 / / / 
01.7.2013   
10 
CC010 
1:200 
0 5336 / / / 
  
10.7.2013   1 
CC014 
1:200 
0 4844 / / / 
10.7.2013   2 
CC014 
1:200 
120713-2-1 
4852 
negative (24/07/13) (CC014) / / 
120713-2-2 negative (24/07/13) (CC014) / / 
10.7.2013   3 
CC005 
1:200 
0 5272 / / / 
10.7.2013   4 
CC005 
1:200 
0 4224 / / / 
10.7.2013 5 
CC005 
1:200 
120713-5-1 
5068 
negative (24/07/13) (CC005) / / 
120713-5-2 negative (24/07/13) (CC005) / / 
120713-5-3 negative (24/07/13) (CC005) / / 
10.7.2013   6 
CC005 
1:200 
0 5124 / / / 
10.7.2013   7 
CC010 
1:200 
0 5284 / / / 
10.7.2013   8 
CC010 
1:200 
120713-8-1 
4956 
negative (31/07/13) (CC010) / / 
120713-8-2 negative (31/07/13) (CC010) / / 
120713-8-3 negative (31/07/13) (CC010) / / 
10.7.2013   9 
CC010 
1:200 
0 4884 / / / 
10.7.2013   
10 
CC010 
1:200 
0 4452 / / / 
  
17.7.2103   1 
CC005 
1:200 
0 4492 / / / 
17.7.2103   2 
CC005 
1:200 
0 5248 / / / 
17.7.2103   3 
CC005 
1:200 
0 4404 / / / 
17.7.2103   4 CC005 0 4348 / / / 
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1:200 
17.7.2103   5 
CC010 
1:200 
0 4852 / / / 
17.7.2103   6 
CC010 
1:200 
0 4416 / / / 
17.7.2103   7 
CC010 
1:200 
0 4816 / / / 
17.7.2103   8 
CC010 
1:200 
190713-8-1 
4956 
negative (31/07/13) (CC010) / / 
190713-8-2 negative (31/07/13) (CC010) / / 
17.7.2103   9 
CC010 
1:200 
0 5204 / / / 
17.7.2103   
10 
CC014 
1:200 
0 5220 / / / 
17.7.2103   
11 
CC014 
1:200 
0 5244 / / / 
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